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1.1 RNA importance and functions 
1.1.1 Comparison of DNA and RNA  
RNA and DNA are large biomolecules, which together with proteins, lipids and carbohydrates are 
essential for all known forms of life. Nucleic acids are polymers and consist of four different monomers, 
which are called nucleotides. Each nucleotide is composed of a phosphate group, a sugar ring and one 
of the four nucleobases: guanine (G), adenine (A), cytosine (C) and uracil (U) (RNA) or thymine (T) 
(DNA). The bases have either purine based structures (A and G) or pyrimidine based structures (U, C 
and T). The sugar ring is a 2'-deoxyribose for DNA and a ribose for RNA (Figure 1.1, left panel). The 
presence of the 2'-hydroxyl group differentiates RNA from DNA and makes the first more prone to self-
cleavage through in-line nucleophilic attack on the neighbouring 3ʹ-phosphate group. Additionally, it is 
also responsible for their structural difference, as it will be discussed below (Figure 1.2) and enables 
RNA to have catalytic activity (e.g. Group II introns). Neighbouring nucleotides are covalently linked 
with each other through phosphate groups linking the 5ʹ-end of one sugar to the 3ʹ-end of the next 
resulting in the formation of a highly negatively charged backbone (strand) with a well-defined 
directionality (5ʹ- to 3ʹ-direction). Both DNA and RNA strands have a hydroxyl group on the sugar 
moiety at the 3ʹ-end and a terminal phosphate group at the 5ʹ-end. This strand constitutes the primary 
structure of nucleic acids. The secondary structure of nucleic acids is the double-stranded arrangement, 
which is the result of hybridization of their complementary strands in an antiparallel way. The bases are 
forming hydrogen bonds with each other by the establishment of Watson-Crick base-pairs (canonical 
base-pairing) where guanine pairs with cytosine through three hydrogen bonds and thymine/uracil pairs 
with adenine through two hydrogen bonds. Besides the Watson-Crick base-pairs other base-pairing 
schemes are also encountered in RNA like the Hoogsteen base-pairing and G-U wobbles1,2 (Figure 1.1, 
right panel). Apart from the formation of hydrogen bonds the π-π interactions between the stacked 
aromatic rings of neighbouring nucleobases play the most important role in the duplex stability3.  
17 
 
 
Figure 1.1: Left panel: An illustration of an RNA strand. The purines (A, G) are coloured in blue and the 
pyrimidines (C, U) in magenta. The phosphate backbone and the ribose are marked with a purple oval and a red 
square respectively. Right panel: Watson-Crick base pairs of A-U and G-C (top), a G-U wobble base pair and a 
guanine base with indicated the Hoogsten and Watson-Crick sites (bottom).  
 
Duplex nucleic acids can adopt various conformations (e.g. A-, B- and  
Z-form) with DNA being usually found in B-form and RNA in A-form 
(Figure 1.3, left panel)4–6. A comparison of some parameters for A- and  
B-helical forms are summarized in Table 1.1. Both helices are right-handed 
and the choice between the two conformations depends mostly on the sugar 
pucker conformation. More specifically the 2ʹ-OH group of ribose is forcing 
the RNA sugar into a C3ʹ endo conformation while in B-form DNA the sugar 
is found a C2ʹ endo arrangement (Figure 1.2). The A-form RNA has a deep 
and narrow major groove and wide and shallow minor groove while DNA 
grooves are of a similar depth. Despite their similarities on a chemical 
base, the two nucleic acids have important differences concerning their 
secondary structures. DNA is found usually in a double-stranded helical 
B-form. RNA is transcribed as a single strand but it folds in a complex 
three-dimensional structure in order to minimize its overall energy. Because of this it can adopt different 
Figure 1.2: The sugar pucker 
conformations of deoxyribose 
(C2ʹ-endo) and ribose sugars 
(C3ʹ-endo).  
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secondary structures including hairpins, internal/terminal loops, bulges, and junctions7 (Figure 1.3, right 
panel). These non-helical regions are stabilized by stacking interactions and hydrogen bonds and 
provide potential binding sites for proteins or other molecules. Additionally, they contribute to the 
formation of tertiary interactions which are crucial for RNA folding8.  
  
Figure 1.3: Left panel: Illustration of B-form DNA helix and A-form RNA helix. The figures were prepared using 
Maestro Schrödinger Version 10.5.014 based on the PDB files 1BNA9 and 1RNA10 respectively. Right panel: 
Schematic representation of RNA secondary structural elements. 
 
Table 1.1: Some parameters for the A-helical and the B-helical form of nucleic acids3,11 
 A-helical form B-helical form 
Helix Sense Right handed Right handed 
Average base pairs / turn 10.7 10 
Rotation / base pair 33.6° 35.9° 
Pitch / turn of helix 24.6 Å 33.2 Å 
Rise / base pair along axis 2.3 Å 3.32 Å 
Propeller twist +18° +16° 
Glycosyl angle Anti Anti 
Sugar pucker C3ʹ-endo C2ʹ-endo 
Diameter 26 Å 20 Å 
 
1.1.2 The importance of RNA structure 
According to the central dogma of molecular biology, DNA contains all the information necessary to 
build up an organism. The three main types of RNA namely messenger RNA (mRNA), transfer RNA 
(tRNA) and ribosomal RNA (rRNA) convert this information into a protein sequence. During the last 
decades, it was found that RNA is more than an intermediate between DNA and proteins, having many 
more essential functions. More specifically, a great variety of non-coding RNAs have been discovered 
and were found to be involved in very important biological functions12. For example, ribozymes are 
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catalytically active RNAs, which are able to perform catalysis without the presence of a protein12 (e.g. 
group II introns which can undergo self-splicing13–15) and riboswitches were found to be important for 
gene regulation16. Critical to its functions are the specific three-dimensional structures that RNA can 
adopt7. While DNA is typically helical, RNA folds into complicated structures, which resemble the 
ones from proteins. For instance, in eukaryotes, RNA based processes like splicing and mRNA 
maturation are performed from a complex RNA-protein molecular machine with complex tertiary 
structures called spliceosome17. Targeting and disturbing these structures is a way to interfere with RNA 
function.  
1.1.3 RNA and metal ion interactions  
The structural complexity of RNA cannot be achieved in the absence of metal ions. Monovalent and 
divalent cations are needed for the stabilization of secondary and tertiary RNA structures. Metal ions 
have been found to be important for both RNA folding and function18. They primarily serve as charge 
screeners of the negatively charged phosphate backbone. Upon RNA folding the phosphate groups of 
the backbone are coming closer further intensifying the negative charge and creating unspecific or 
specific binding pockets for metal ions19–21. The monovalent ions are usually bound to RNA for charge 
neutralization and enable the formation of the secondary structures while the divalent ones stabilize the 
tertiary structure22. Two very important metal ions are K(I) and Mg(II). The first is the most abundant 
intracellular monovalent ion (140 mM)23 and is bound to RNA for charge neutralization and pre-
organization of the RNA structure. However, it has been reported that ribosomal RNA unfolds upon 
reduction of K(I) suggesting that its role it is not limited only to charge screening24. Mg(II) is the most 
important divalent metal ion in RNA folding and catalysis. It is crucial for folding the RNA into its 
complex and functional tertiary structures25. Mg(II) is also considered an RNA cofactor for catalytically 
active RNAs (e.g. group II introns)14,26. For example in the two-metal-ion mechanism, which has been 
proposed for the prosphoryl transfer reactions catalysed by the group I and group II introns, Mg(II) ions 
both activate the attacking nucleophile and stabilize the leaving group19.  
Various methods have been used for the investigation of the interactions between metal ions and 
RNAs27,28, including biochemical (e.g. hydrolytic cleavage experiments, nucleotide analogue 
interference mapping etc.) and spectroscopic techniques (NMR, EPR, X-ray crystallography etc.). 
Moreover, transition metal ions and lanthanides29 have been used for mapping RNA structures and 
identifying metal ion binding sites. In contrast to metal ion-RNA interactions, the data on metal 
complexes-RNA interactions are still very scarce30.  
1.1.4 Our model RNA: D1-27  
To gain insights into the binding of metal complexes to RNA, we decided to investigate the interaction 
of an important class of metal complexes, namely platinum(II) anticancer drugs, with RNA. For the 
current study, a model RNA system was needed and for this purpose a 27nt long RNA was employed. 
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This RNA is derived from the mitochondrial group II intron Sc.ai5γ from Saccharomyces cerevisiae (S. 
cerevisiae), baker’s yeast31 (Figure 1.4, left panel), and corresponds to the central part of domain 1, 
from which the name D1-27 comes (Figure 1.4, right panel). 
 
 
Figure 1.4: Left panel: Schematic representation of the secondary structure of the group II intron Sc.ai5γ from S. 
cerevisiae14 from which our model RNA (D1-27) derives. Right panel: The 3D structure of D1-27 and its 
secondary structure32. The internal loop is depicted in bold and the stacked adenines are highlighted in purple. 
The 3D figure was prepared using Maestro Schrödinger, Version 10.5.014. 
 
D1-27 has structural features which are common in many RNAs. More specifically, it contains an 
artificially inserted -UUCG- tetraloop and an 11nt asymmetric internal loop. The asymmetric 11nt 
internal loop of D1-27 (Figure 1.4, right panel, bold) contains a G-U wobble base-pair, three stacked 
adenines and a U-U mismatch33,34. The -UUCG- tetraloop was added to stabilize the whole construct33 
and the 5ʹ-end guanosines were added in order to increase the transcription yield35. In the context of the 
whole group II intron, the internal loop acts as a tetraloop receptor for the -GAAA- tetraloop36,37. In 
general the interactions between GNRA tetraloops (N = any nucleotide, R = purine) and their receptors 
represent an important RNA folding motif38. It is well known that the interactions of  
-GAAA- tetraloops with their receptors are necessary for the correct folding and function of various 
RNAs like the Group I and II introns and RNase P39. Upon tetraloop binding a conformational 
rearrangement of the receptor is observed34,40,41. This tetraloop receptor system represents a good model 
to study metal ion-RNA interactions38. Interestingly, it was shown that upon Mg(II) titration no 
structural changes were induced on the isolated tetraloop receptor34. The structure of the receptor 
docked to a -GAAA- tetraloop showed no difference in the presence of various cations and in this 
docked form the AA platform in the internal loop acts as binding site for monovalent metal ions 
[K(I)]39,42. Recently, NMR studies on metal ion binding to the undocked tetraloop receptor of D1-27 
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have revealed a general electrostatic interaction at the internal loop region upon addition of Cd(II), 
Mg(II) and cobalt(III)hexammine with all three metal ions exhibiting only slightly different behaviour43.  
In conclusion, the chosen RNA contains structural features widespread in many RNAs, thus 
representing a good model system to investigate structural preferences of drug interaction. Moreover, 
its NMR characterization in solution is available, making the NMR investigation of platinum(II)-RNA 
species easier32. Finally, knowing already the Mg(II) binding sites on this RNA construct, which based 
on a recent study are closely related to the platination sites44, we wanted to further investigate the 
platinum(II) binding using platinum(II) anticancer drugs.  
In addition to D1-27, three more RNA constructs were also used for this study (Figure 1.5). More 
specifically an analogue of D1-27 without the internal loop was used in order to study the influence of 
the internal loop on the platination sites and was named RNA 26 (Chapter 2, Paragraph 2.6 and Chapter 
3, Paragraph 3.3.3). To investigate preferential binding sites of platinum(II) complexes over different 
terminal loops, the -UUCG- terminal loop was replaced for the -GAAA- (Chapter 3, Paragraph 3.3.2), 
and this RNA was named D1-27GAAA. Finally, an analogue of D1-27 containing two terminal U-A  
base-pairs instead of the two G-C base pairs was used to study the effect of platination at the 5'-end GG. 
The latter construct was named RNAUU (Chapter 4, Paragraph 4.10).  
 
Figure 1.5: The secondary structures of all the RNA constructs used for this study. Starting from the original 
construct D1-27 other three D1-27 analogues were used. RNA 26 does not contain the internal loop, D1-27GAAA 
has a -GAAA- tetraloop instead of the -UUCG- and RNAUU has two U-A terminal base-pairs instead of two  
G-C base pairs.  
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1.2 Platinum(II) anticancer drugs 
1.2.1 The anticancer drug cisplatin 
In 1965 Rosenberg and co-workers reported the inhibition of cell division in Escherichia coli (E. coli) 
by electrolysis products from a platinum electrode45. The therapeutic potentials of whatever was causing 
this behaviour were enormous and follow-up studies revealed that the cis-[Pt(NH3)2Cl2] complex 
(cisplatin) could inhibit cell division of E. coli46. Upon the discovery of the biological activity of 
cisplatin, the medicinal inorganic chemistry as a discipline came to exist and vigorous research on how 
platinum(II) complexes are functional as anticancer drugs started47. Cisplatin was approved for clinical 
use from FDA in 1978. It is best known for the treatment of testicular cancer but it is also used for 
curing other cancers like lung, bladder, cervical and ovarian cancer48. It is believed that the anticancer 
activity is due to the covalent binding of cisplatin to nuclear DNA preferably at the N7 sites of two 
adjacent guanines. Despite its success, cisplatin has several limitations, like severe side-effects (nausea, 
vomiting, kidney and nervous system toxicity) and tumours can develop drug resistance49. Additionally, 
cisplatin was not effective in the treatment of two very common types of cancer, the colorectal and 
breast tumours50. Over forty years of research have been invested to develop cisplatin analogues with 
similar or improved clinical activity and reduced side-effects. From all the platinum-based drugs entered 
clinical trials only two gained international clinical approval and these are the second generation 
platinum anticancer drug carboplatin and the third-generation platinum anticancer drug oxaliplatin48 
(Figure 1.6). The term second and third generation refers to the development of the new platinum(II) 
complexes. For example in the second generation the ammine or chloride ligands were replaced by 
more stable chelating ligands (see carboplatin) and in the third generation both leaving and non-leaving 
groups were replaced (see oxaliplatin)51.  
 
Figure 1.6: Platinum(II) drugs which are in clinical use worldwide: Left: cisplatin; middle: carboplatin: right: 
oxaliplatin. 
 
1.2.2  Chemistry and development of platinum(II) complexes 
Cisplatin is a square-planar platinum(II) complex. It has two relatively exchange-inert ammine ligands 
and opposite to them two kinetically-labile chloride ligands in a cis geometry around the platinum(II) 
metal centre. This scaffold is characteristic for all platinum(II) anticancer drugs (Figure 1.6, left). Their 
biological activity depends on how fast their leaving groups can be substituted from water molecules 
23 
 
leading to the active form of the complex. Upon formation of the aquated platinum(II) complex they 
have the tendency to form kinetically-inert complexes with soft ligands. This class of ligands includes 
cyanato, thiocyanato, sulfido, thiolate, thiol, phosphine, ammines and imines groups52. For the 
development of new improved platinum(II) anticancer complexes structure-activity relationship rules 
were established upon screening of many platinum compounds53,54. These rules are summarized in the 
following: 
1. The compound should be neutral  
2. Two cis monodentate leaving groups with intermediate binding strength to platinum(II) 
are required 
3. The presence of amine ligands with cis configuration lead to active species 
4. The less the alkyl substituent on the amine ligands the better the activity 
Beside these structural requirements, platinum drugs, which will be considered for clinical approval, 
should further bring along: 
1. Activity in cisplatin resistant tumours or improved activity towards tumours responding 
to cisplatin 
2. Reduced toxicity and side-effects 
3. Improved physical properties like better water solubility 
Carboplatin belongs to the second generation platinum(II) anticancer drugs (Figure 1.6, middle); it has 
similar activity like cisplatin but reduced side effects. Its lower toxicity was connected to the slower 
hydrolysis of its cyclobutanedicarboxylate ligand. Additionally, its side effects are different compared 
to the ones of cisplatin48. Upon aquation it forms the same active species and the same DNA adducts as 
cisplatin and therefore is only clinically different to its parent compound. 
Oxaliplatin belongs to the third generation platinum(II) anticancer drugs 
(Figure 1.6, right). Compared to cisplatin it has a single bidendate ligand 
(1R,2R-cyclohexane-1,2-diamine) instead of the two ammine groups and the 
two chlorides are replaced by an oxalate group. It was approved for clinical 
use due its capability to treat cisplatin resistant tumours. The presence of the 
oxalate was found to be responsible for its reduced side effect compared to 
cisplatin55. Oxaliplatin is the platination agent that will be used in the 
current study and more details about its function, including comparison with cisplatin, will be discussed 
in chapter 2 (Paragraph 2.4).  
Another platinum(II) complex was also used in this thesis, namely kiteplatin (kitePt). Its chemical 
structure is shown in Figure 1.7. The in vivo and in vitro activity of kitePt was reported for the first time 
more than 20 years ago56 but in the last years its potency as possible anticancer drug has been revisited57. 
The interest in this compound resulted from its activity against cisplatin- and oxaliplatin-resistant 
Figure 1.7: Kiteplatin. 
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tumors57,58 as well as from its potential application against colorectal cancer56,57. Structurally it contains 
an isomeric form of the diammino DACH ligand of oxaliPt (cis-1,4-DACH) as non-leaving group, while 
its leaving groups are two chlorides similarly to cisPt. A special feature of the  
cis-1,4-DACH is the formation of a seven-membered chelate ring which results in a larger bite angle 
(97 °) compared to cisPt and oxaliPt, which might affect the mobility of the cis ligands59,60. Preliminary 
studies were performed in order to compare its behaviour with oxaliplatin and cisplatin and these will 
be discussed in chapter 3 (Paragraphs 3.6 - 3.10). 
1.2.3 Platinum(II) binding targets in cell: The example of cisplatin 
The suggested mechanism of action of cisplatin is shown in Figure 1.8. Cisplatin is administered 
intravenously into the bloodstream where the high chloride concentration (~100 mM) is preventing the 
displacement of its chloride ligands. Once in the bloodstream, studies have shown that after one day  
65 - 98 % platinum is bound to proteins found in the plasma. This might be connected to its deactivations 
and/or its side effects. Cisplatin can enter the cell either by passive diffusion61 or by active uptake 
through copper transporter proteins62 (Figure 1.8). Upon its entrance the lower intracellular chloride 
concentration (~ 4 mM) promotes the exchange of chloride ligands giving rise to the formation of 
positively charged monoaquated platinum complexes63 (Figure 1.8). Possible targets of this cationic 
platinum(II) complex are biomolecules which contain soft nucleophiles found in proteins and on RNA 
and DNA nucleobases. In proteins cysteine, methionine and histidine residues represent good 
platinum(II) targets while in DNA and RNA bases N7 position of both guanine and adenine, but also 
N1 of adenine and N3 of cytidine, can behave as platinum binding sites64. Cisplatin is considered to 
exert its anticancer activity upon covalent binding to nuclear DNA. In vitro studies have shown that the 
monoaquated complex is responsible for at least 98 % of the nuclear DNA platinum binding. At first, it 
usually reacts with a guanine base at the N7 position forming monofunctional adducts. Further aquation 
of the second chloride leads to rapid ring closure and formation of bifunctional Pt(II)-DNA adducts. 
These bifunctional adducts are usually bound to the N7 atoms of adjacent purine nucleotides with the 
1,2-Pt-GG adducts representing the 65 % and the 1,2-Pt-AG adducts the 25 % of the platinated species 
formed. The platinated DNA adducts are significantly distorted and can be recognised by DNA damage 
repair proteins. These proteins will either repair the platinated DNA or they will initiate apoptosis49. 
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Figure 1.8: Schematic representation of the suggested mechanism of action for cisplatin49. Upon entering the 
intracellular environment, cisplatin undergoes hydrolysis and the aquated species can bind to the nuclear DNA. 
Inability of repairing the platinated DNA could lead to apoptosis. 
 
1.2.4 Platinum(II)-DNA interactions 
In general, platinum(II)-DNA interactions are linked with the anticancer activity of cisplatin and 
platinum(II) drugs49. Cisplatin can bind to DNA only after hydrolysis of the first chloride which is the 
rate-limiting step for platinum binding65. The positively charged monoaquated cisplatin is probably first 
associated electrostatically with the negatively charged phosphate backbone of the DNA before forming 
a covalent bond with the nucleobases66. The preference for binding first at the N7 site of guanines was 
attributed to the fact that guanine is the most nucleophilic base. However, the basicity of the 
coordination site is not the main factor affecting the platinum(II) binding. Studies revealed that the 
preference for this site could be either due to the hydrogen bond formation of the ammine group of 
cisplatin with the O6 keto oxygen of the guanosine or the hydrogen bonding between the water molecule 
of the aquated cisplatin with the O6 keto oxygen of the guanosine. It has been reported that the first 
plays only a minor role while the latter is the main reason for the preference of cisplatin to guanine over 
adenine67. After the monofunctional adduct is formed closure of the ring (chelation) to form the 
bifunctional species can take place either directly from the monofunctional or it might involve aquation 
of the second chloride ligand49. Due to the very slow ligand exchange of the platinum(II) complexes 
their adduct formation is under kinetic rather than thermodynamic control. This hypothesis seems to be 
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accepted for the first platination step that leads to mono-adduct formation while the chelation step that 
leads to bi-adduct formation is suggested to be partially under thermodynamic rather than under kinetic 
control68. The major intrastrand bifunctional adducts formed can be either GG (65 %) or AG (25 %) 
(Figure 1.9, left). Other minor species formed include: 1) 1,3-GNG intrastrand adducts, with N being 
any of the nucleobases, 2) GG interstrand species, 3) G monofunctional adducts (X = water molecule 
or chloride) and 4) G-protein cross-linked species (Figure 1.9)64.  
 
 
Figure 1.9: Illustration of the possible cisplatin-DNA adducts. 
 
Crystal structures as well as NMR solution structures of platinated DNAs have been reported69–71. Upon 
binding of cisplatin to DNA the double helix is bended (32 ° - 35 °) towards the major groove, widening 
and flattening of the minor groove opposite the platinated adducts occur and a generalized distortion 
over 4-5 bases from the platination site was reported72. This distortion makes the phosphate groups of 
the backbone moving closer to the platinum site resulting in the formation of hydrogen bonding between 
a phosphate oxygen atom and the ammine ligand, which however does not play a role in the activity of 
cisplatin. Depending on the type of adducts formed (1,2-GG, 1,2-GA or 1,3-GNG) the DNA helix 
unwinds to a different degree (21 °, 13 ° and 23 ° in the case of 1,2-GG, 1,2-GA and 1,3-GNG adducts, 
respectively) but they all have the ability to bend DNA helix to the same extent. High-mobility group 
(HMG) domain proteins can recognise the DNA helix bending and unwinding. Their binding to the 
platinated nuclear DNA is believed to interfere with the removal and repair of the platinated site from 
the normal DNA repair proteins thus initiating apoptosis (cell death)73. The 1,2-GG intrastrand adduct 
is considered to play the major role in toxicity of cisplatin and it is specifically recognised by several 
proteins (HMGB1 and TATA-binding proteins)72. However, the importance of the minor adducts 
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should not be underestimated when describing the overall profile of cisplatin toxicity. Towards this 
direction it should be noted that cisplatin forms adducts also with the mitochondrial DNA, and this 
could contribute to its toxicity74. Moreover, cisplatin can interact with cellular targets other than DNA. 
In this regard, the interaction between proteins and platinum(II) drugs75 is also investigated, in an 
attempt to understand better their mechanism of action, which could lead to optimized drug 
development. Surprisingly, much less studied are the interactions of platinum(II) complexes with RNA, 
despite its biological importance30,76.  
The potency of RNA as possible drug target and more specifically as potential target for platinum(II) 
anticancer drugs will be discussed in the following paragraphs.  
 
1.3 RNA as possible target for platinum(II) drugs  
1.3.1 Targeting RNA with small molecules 
Apart from the early discovered mRNA, tRNA and rRNA which are the intermediate between DNA 
and proteins a large variety of new classes of non-coding RNAs exhibiting multiple functional roles in 
regulating cellular processes have been discovered in the last few decades12,77 (Paragraph 1.1.2). These 
findings greatly expanded the functions in which RNA is involved including regulation of transcription 
and translation, catalysis of protein synthesis and control of gene expression. RNA is very rich in non-
canonical structural elements (Paragraph 1.1.1) which are essential for the tertiary interactions leading 
to the correct RNA folding. RNA functions are very closely related with its structure and a promising, 
even if challenging, way to interfere with its functions is by targeting these structural elements. Indeed, 
the involvement of RNA in crucial cellular functions, together with the large variety of non-canonical 
structural features which could serve as specific binding sites, makes RNA a very interesting drug 
target78,79. Towards this direction the use of oligonucleotides as well as small organic molecules were 
employed for targeting RNAs79. Approaches which are used to modulate RNAs function are 1) antisense 
oligonucleotides which is an oligonucleotide-based approach where an RNA sequence is bound 
selectively80,81 and 2) small organic molecules which are employed for targeting specific structural 
elements78.  
In the last few years, a few small organic molecules have been developed which are able to target RNA 
and alter its functions. Some examples of these molecules are the following78,79: 1) a few classes of 
antibiotics (e.g. aminoglycosides and tetracyclines) known to exert their activity by targeting bacterial 
RNA82, 2) cyclic peptides which are able to target HIV-1 RNA83, 3) small molecules with the ability to 
modulate miRNAs functions84 and 4) small molecules which can target nucleotide repeats known to 
cause neuromuscular diseases85. Small molecules can bind in many sites within RNA, but in order to 
have an impact the binding to these sites should have a biological consequence (functional sites)84. 
Additionally, RNAs are expressed at low levels (except for rRNA) making the targeting of functional 
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RNA sites very challenging79. Despite the challenges of this approach, there are significant advantages 
of using small molecules for RNA targeting. Small molecules are often orally available and in case of 
toxicity synthesis of their derivatives could be enough to overcome this problem. Their most important 
benefit though is that they can recognise different RNA structures and not only sequences79.  
Among small molecules with biological importance are the platinum(II) anticancer drugs which are 
known to interact with DNA. Investigating their interactions with other biological targets, like RNA, is 
crucial for a more complete understanding of their biological activity. In this regard the following 
paragraphs are dedicated to the description of RNA as platinum(II) target including the influence of 
Pt(II)-RNA adducts on RNA based processes, as well as to a few examples of platinum(II) binding to 
RNA.  
1.3.2 RNA as target for platinum(II) drugs 
DNA is the target that is considered to be responsible for the biological activity of cisplatin49. However, 
as discussed above, cisplatin can also interact with other biological targets like RNA and proteins. 
Studying the interactions of platinum(II) drugs with molecules other than DNA is necessary in order to 
obtain a better picture of its biological activity76. RNA is chemically very similar to DNA, therefore 
cisplatin and its derivatives are expected to bind to RNA as well. Being already available in the cytosol 
it is very probable that platinum(II) drugs could easily bind to RNA. Indeed, recent studies using 
inductively coupled plasma mass spectrometry (ICP-MS) reported that after treatment of  
S. cerevisiae with cisplatin, platinum accumulates in total 4- to 20-fold more in total cellular RNA than 
in genomic DNA86. Additionally, in vitro studies suggested that RNA platination kinetically competes 
or is even preferred over DNA platination66,87. Consequently, Pt(II)-RNA interactions might play a role 
in cisplatin or platinum(II) drugs activity, in cell resistance and/or toxicity, and investigation of such 
interactions might be helpful towards better understanding of their activity76.  
1.3.3 Influence of platinum(II) compounds on RNA-based processes 
Early findings supported the hypothesis of RNA being a good platinum(II) drug target by showing that 
biologically important RNA processes are inhibited upon platinum(II) administration. An important 
step in RNAs lifecycle is the splicing, where the mature RNA is formed. Inhibition of splicing upon 
platination has been reported in the presence of cisplatin88. Similar behaviour was also found upon 
cisplatin treatment of the protein independent self-splicing Tetrahymena rRNA group I intron and it 
was related with the formation of interstrand cisplatin-RNA crosslinking89. For the efficient and correct 
translation of RNA into proteins, fully functional RNA molecules such as mRNA, tRNA and rRNA are 
important. Studies have suggested that the platination of precursor mRNAs (pre-mRNA) or rRNAs 
could interfere with translation. Indeed, in vitro studies have shown that upon cisplatin administration 
the synthesis of peptides was inhibited suggesting that is related with cisplatin interaction with mRNA90. 
The inhibition of translation was connected with the blockage of the initiation of translation91. More 
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recent findings on the level of translation revealed that cisplatin influences mRNA function and its 
effects on mRNA are more pronounced compared to oxaliplatin and carboplatin92. Several studies were 
devoted also to the investigation of the ribosomal RNA platination suggesting a potential ribotoxic role 
for platinum which could contribute to its general cytotoxicity86,93. Lastly, in vitro studies revealed that 
platinated RNA adducts can inhibit the function of important RNA processing enzymes such as 
endonucleases and exonucleases94.  
1.3.4 Examples of platinum(II) binding to RNA 
In the last few years, several examples of platinum(II)-RNA interactions have been reported30,76, some 
of which are summarized below. More specifically the examples are divided into two main categories. 
The first category includes platination of short RNA duplexes, and the second includes platination of 
structured RNAs such as tRNA, rRNA and spliceosomal RNA. In addition, the effect of platination on 
RNA silencing is briefly described.  
Upon platinum(II) binding to DNA and RNA duplexes their melting profiles are strongly influenced. 
To gain more information into this topic, Elmroth and co-workers measured the destabilization induced 
by cisplatin and oxaliplatin in two small RNA and DNA duplexes via UV/Vis. These duplexes 
contained as central platination site either -GG- or -GNG- (N = T or U). They showed that both platinum 
complexes cause destabilization (reduced melting temperatures) with the larger changes observed for 
the -GNG- containing duplexes, especially for the RNA species95. After these findings, small RNA 
duplexes were also used in studying the kinetics of monoaquated cisplatin binding using UV/Vis, and 
the influence of various parameters was examined. From this investigation it was concluded that 1) the 
monoaquated cisplatin, under physiological conditions, is able to discriminate between different RNA 
targets, 2) local structure variations (such as, the length of the duplex, the nature of the bases around a 
GG site and the presence of mismatches) can influence the duplex reactivity, and 3) the platination of 
short RNA duplexes with monoaquated cisplatin is favoured in the intracellular [presence of K(I)] rather 
than in the extracellular [presence of Na(I)] environment and that increased hydrophobicity of the 
environment can reduce reactivity96–98.  
Understanding how platinum(II) anticancer drugs can bind to structured RNAs is important in order to 
understand how platinum binding can affect biologically important RNA processes (Paragraph 1.3.3). 
Towards this direction Elmroth and co-workers studied the platination of a full length tRNAAla and of 
hairpin models of the anticodon loop and the acceptor stem with cisplatin [Figure 1.10, tRNAAla, MhAla 
(blue frame), acMhAla (green frame)], using biochemical assays in order to get information about 
sequence and structure specificity of platinum(II) binding. They reported that the replacement of a 
native G-U wobble with a G-C base pair (Figure 1.10, MhAla, blue frame, G-U wobble in red) inhibited 
the platination at this site and that the replacement of a natural -UGC- sequence in the terminal loop by 
-GGC- (Figure 1.10, acMhAla, green frame, -XGC- in red) increased the platination at this site. In 
addition to these findings, they found that the attachment of a 5ʹ-terminal phosphate group changes the 
30 
 
distribution of the observed platinated products (Figure 1.10, MhAla, phosphate group in red)99,100. 
Combined these results showed that platination takes place at GG sites when RNA is used as target, 
similarly to what was found with DNA, and suggest that small sequence variations and local structure 
could significantly influence the platinum binding.  
Another example of platinum binding to highly structured RNAs is the platination of a model system 
of the spliceosome. The spliceosome is a complex RNA-protein molecular machine, which removes 
introns from a transcribed pre-mRNA in the eukaryotes. Its catalytic core consists of the U2-U6 snRNA 
complex. A model system of this core was platinated with monoaquated cisplatin and formation of an 
intramolecular crosslink was observed in the internal loop (Figure 1.10, BBD RNA). The formation of 
this crosslink may influence RNA dynamics and function101.  
Platination of ribosomal RNA (rRNA) have also been reported and addition of cisplatin to  
S. cerevisiae in cellulo has shown significantly larger amounts of platinum in rRNA compared to 
mRNA86. Cisplatin has been utilized as chemical probe for identifying solvent exposed purine 
nucleotides in helix 24 of E. coli rRNA102. For this purpose, primer extension in order to detect platinum 
dependent stops of reverse transcription was employed. Two consecutive guanines located in a non-
Watson-Crick base paired region were platinated even if a competing GG sequence close-by was 
present (Figure 1.10, helix 24). Specific GG binding and changes in loops upon platination was also 
reported when two highly conserved E. coli hairpins from rRNA were platinated with cisplatin103. 
Platination of rRNA was also performed using amino acid-linked cisplatin derivatives. The size and the 
charge of the platinum complexes used resulted in different RNA platination profiles104. Moreover, 
recent in vivo studies have revealed that cisplatin accumulates in the sarcin-rich loop and at the peptidyl 
transferase centre of rRNA93 and that tRNA is also a possible cisplatin substrate.  
Finally, the effect of platination on siRNA silencing was also investigated. RNA silencing refers to gene 
silencing in which the gene expression is regulated by non-coding RNAs like miRNA and siRNA105. 
Elmroth and co-workers platinated siRNA with cisplatin and oxaliplatin and observed that even if the 
RNAs were still active upon platination, an overall decrease of silencing activity was found with this 
effect to be more pronounced with oxaliplatin87,106. 
A common characteristic of all the Pt(II)-RNA adducts mentioned in these examples is the binding of 
platinum(II) in non-Watson-Crick base paired regions and its high selectivity towards the GG sites. 
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Figure 1.10: Examples of platination of structured RNAs such as RNA hairpins derived from the 
tRNAAla 99,100 [(MhAla (blue frame) and acMhAla (green frame)], a purine-rich internal loop derived from 
the spliceosome101 (BBD RNA) and a region of the 16S rRNA102 (helix 24). The modifications inserted 
(G-U to G-C, in MhAla; the phosphate group and the -XGC- in acMhAla) as well as the guanines involved 
in platination are shown in red. 
 
1.3.5 Structural determination of platinum(II)-RNA adducts 
Shortly after the antitumor activity of cisplatin was discovered, few preliminary X-ray studies were 
performed aiming at identifying the possible platination sites in tRNAPhe107–109. However, the crystal 
structure resolution was rather low preventing a detailed analysis. Only very recently the first 2.6 Å 
resolution crystal structure of a platinated ribosome was reported44. Cisplatin was used as platination 
agent. Surprisingly out of the two thousand two hundred possible binding sites, only nine cisplatin-
modified sites were found. Three of the cisplatin units were observed at the N7 atoms of adenines (A790 
of the 16S rRNA and A1848, A2531 of the 23S the rRNA), five were located at the N7 atoms of 
guanines (G1300 of the 16S rRNA and G27, G425, G2220, G2221 of the 23S rRNA), and one platinum 
moiety was found bound at the N-terminus of the ribosomal protein L9. Out of all the affected 
nucleobases only G425 is found in a canonical G-C base pair while all the rest are located in non-
canonical regions (bulges, junctions, internal and hairpin loops), which are quite common in RNAs. 
The preference of platinum(II) binding to irregular RNA structures confirms what was also observed 
from previous studies on Pt(II)-RNA adducts, suggesting that the presence of not-regular RNA 
geometries may be used as a criterion for the prediction of possible platination sites. At the guanine 
platinated sites it was found that, the interaction was not limited to the N7 position but contacts were 
formed also between neighbouring phosphate groups and the amino groups of cisplatin. Highly folded 
RNAs result in having in close proximity the N7 atoms of guanines to the phosphates, which could 
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explain why cisplatin binding occurs in non-Watson-Crick geometries. Another criterion for predicting 
platinum reactivity towards a guanine could be its ability to coordinate Mg(II). Indeed, all five guanines 
coordinated to cisplatin did coordinate Mg(II) in the untreated ribosome. On the other hand, all 
platinated adenines are positioned immediately before a guanine in an AG-motif. In this motif, cisplatin 
is covalently bound to N7 of adenine while its amine group interacts with the O6 atom of the 
neighbouring guanine. All the AG platinated motifs showed a slight structural distortion in the untreated 
ribosome, and this is believed to be the cause for their platination. Moreover, they are located at the 
RNA-RNA and RNA-protein interfaces. Out of an overall of three hundred and forty three AG-sites 
only twelve could accommodate cisplatin and only three were actually platinated. This suggests that the 
surroundings, and not only the structure and accessibility of the N7 atoms, are important for platinum(II) 
reactivity. These findings offer a third criterion for predicting cisplatin reactivity, i.e. adenine could be 
a possible platination site if found within an AG-motif. Finally, during rapid soaking experiments it was 
found that only adenines were platinated suggesting that they react faster compared to guanines. In 
paragraph 1.3.3 it was mentioned that the presence of platinum(II) could inhibit protein synthesis. In 
the crystal structure of the platinated ribosome cisplatin moieties were bound in many functional centres 
of the ribosome such as the mRNA channel, the peptide exit channel, the GTPase activating centre and 
the bridge B7a between the two ribosomal subunits, which could justify the ability of cisplatin to inhibit 
protein synthesis44.  
1.3.6 Comparison of platinum(II)-DNA and platinum(II)-RNA adducts 
Since DNA is considered the main responsible for cisplatin anticancer activity, its interaction with 
platinum(II) drugs has been extensively studied. Platinum(II) drugs bind to the major groove of B-form 
DNA with simultaneous widening of the minor groove. These perturbations lead to a combination of 
A- and B-form around the platination site. More specifically the N7 sites of neighbouring purines are 
closer, the major groove becomes narrower, the minor groove wider and shallower, and the nucleotide 
at the 5ʹ to the platination site shows a C3ʹ-end conformation which is found in A-form helices. 
Additionally, a hydrogen bond between the O6 of a guanine and the ammine group of cisplatin is 
observed. These observations were done on B-form DNA, whereas crystal structures of Z-form DNA 
with cisplatin showed very little distortion of the helix while the O6-ammine hydrogen bond was still 
present110.  
The equivalent positions of cisplatin binding in DNA are significantly buried in the deep and narrow 
major groove of A-form RNA probably excluding the formation of the same type of platinum adducts. 
From the only one high-resolution crystal structure of the platinated ribosome available together with 
biochemical and spectroscopic studies on structured RNAs is concluded that platination is favoured in 
non-helical regions of RNA, and that cisplatin binds with high affinity at GG sites. Internal and terminal 
loops, bulged regions and mismatches are preferred over helical regions suggesting that the presence of 
distorted geometries is probably the cause and not the consequence of RNA platination44.  
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Interestingly, only few information are available on possible RNA platinum binding sites and even less 
on RNA structural distortions caused by platinum(II) binding. Towards a better understanding of  
Pt(II)-RNA interactions, the current study is dedicated to the isolation of a homogeneously platinated 
RNA aiming at investigating the structural preferences of platinum(II) binding as well as the effect of 
platinum(II) binding on RNA structure. 
 
1.4 Thesis outline and aims 
Platinum(II)-DNA interactions have been extensively studied since the anticancer activity of cisplatin 
was discovered (Paragraph 1.2.3 - 1.2.4). However, very little is known on the interaction of 
platinum(II) drugs with RNA. Understanding the interactions of platinum(II) anticancer drugs with 
other biologically relevant targets is important for a better understanding of their mechanism of actions 
as well as for the development of less toxic and more effective antitumor drugs (Paragraph 1.3.2 - 1.3.3). 
RNA is an important potential drug target considering the variety of biologically crucial RNA-
dependent processes and its crucial structure-function relationship (Paragraph 1.3). 
Towards this direction, the topic of this thesis was the investigation of the interaction between 
platinum(II) drugs and RNA. In particular, a homogeneously platinated RNA was prepared and 
characterized in detail using various biochemical and spectroscopic techniques, in order to study the 
effect of platinum(II) binding on RNA structure. For this study, a model RNA construct (D1-27) was 
employed and cisplatin and oxaliplatin were used as platination agents. The RNA construct chosen 
contains several structural features common in many RNAs, which allowed us investigating possible 
structural preferences of platinum binding (Paragraph 1.1.4). 
The first part of Chapter 2 is dedicated to the investigation of the platination reaction conditions which 
lead to a homogeneously platinated RNA (monoplatinated) using both cisplatin and oxaliplatin. For this 
investigation gel mobility shift assays and MALDI-MS analysis were utilized. The data collected 
showed that the use of oxaliplatin led to the formation of a homogeneous platinated species in higher 
yield than cisplatin. For this reason, oxaliplatin was used as platination agent in all the following 
investigation, and the isolated oxaliplatin-modified RNA adduct was carefully characterized. The latter 
migrates slowly in gels performed on platination mixtures, and gives rise to a well-defined upper band. 
In the second part of the chapter, the methods used for the isolation of the monoplatinated oxaliplatin-
RNA adduct as well as the use of dephosphorylated RNA as starting material for the platination 
reactions are described. 
In Chapter 3 the use of 1H-NMR time evolution experiments to study platination reactions is described. 
Indeed, changes in imino proton resonances upon platinum binding can give a quick indication of 
platinum binding sites. The experiments were used to 1) study the influence of the internal loop, the  
5ʹ-end phosphate group and the terminal tetraloop on the platination profile of D1-27 in the presence of 
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oxaliplatin, 2) screen the platination behaviour of oxaliplatin, cisplatin and kiteplatin towards D1-27 
and 3) investigate the role of Cl¯ in the platination reaction in the presence of cisplatin. Denaturing gels 
were also employed to compare the platination reactions of D1-27 with various platinum(II) complexes, 
and to evaluate the platination profiles using different salt conditions. Finally, the behaviour of 
oxaliplatin, cisplatin and kiteplatin towards plasmid DNA was also compared, using plasmid binding 
assays. 
Having optimized the reaction conditions for the platination of D1-27 with oxaliplatin (Chapter 2) and 
established that dephosphorylated RNA will be used in order to have a homogeneous starting RNA 
sample, time evolution NMR experiments were performed, which provided us with a first information 
on which nucleobases were mostly affected upon platination (Chapter 3). Therefore, the 
characterization of the homogeneously platinated dephosphorylated RNA sample, isolated from the 
upper band on gels performed on platination mixtures, was the next step, and it is described in Chapter 
4. Thermal melting studies were used to assess the stability of the RNA sample before and after 
platination, circular dichroism was used to probe the influence of platinum(II) on RNA structure, and 
enzymatic digestions of 32P-end labelled samples and HPLC analysis showed which nucleobases were 
affected upon platination. In the end 1D and 2D-NMR experiments were performed to further confirm 
the platinum(II) binding sites. In the very last part of the chapter a short characterization of the 
additional minor platinated RNA species formed using dephosphorylated RNA is also described. 
Finally, in Chapter 5 the experimental details for all the studies performed throughout this thesis are 
given.  
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2 Investigation of the platination reaction conditions 
and isolation of monoplatinated RNA 
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2.1 Aim 
In the first half of this chapter it will be described the evaluation of cisplatin (cisPt) and oxaliplatin 
(oxaliPt) as possible platination agents for D1-27. Gel mobility shift assays together with MALDI-MS 
analysis were employed for this purpose. The desired final product is a homogeneously monoplatinated 
RNA, in which the platination binding site can be unambiguously identified. In the second half, the 
methods used for the isolation of monoplatinated RNA samples as well as the use of dephosphorylated 
RNA (deph-RNA) for the platination reactions will be described.  
 
2.2 Introduction: Platination of RNA 
RNA has received a lot of attention in the last few years as possible platinum binding target in an attempt 
to study platinum interactions with biomolecules other than DNA, in order to better understand their 
mechanism of action and probably the origin of their side effects1,2. Additionally, the inhibition of 
important RNA-based processes like transcription3 and translation4 in the presence of platinum(II) has 
further supported the importance of RNA as platinum(II) drug target (Chapter 1, Paragraph 1.3). 
Towards this direction we were aiming at investigating the interaction of platinum(II) anticancer drugs 
with RNA. Considering that RNA platination may be sequence and structure dependent5, an RNA model 
was used (D1-27) (Figure 2.1) in which both structure and sequence dependency of platinum binding 
could be investigated (Chapter 1, Paragraph 1.1.4). This RNA derived from the mitochondrial group II 
intron ribozyme Sc.ai5γ from Saccharomyces cerevisiae, baker’s yeast6, and it has high content of 
guanines and adenines, which represent possible platinum binding sites7, but it also contains various 
structural motifs which are common in many RNAs. In these motifs are included the very stable  
-UUCG- terminal loop8, and an internal loop which in the context of the Group II intron is acting as a 
GAAA tetraloop-receptor9 (Chapter 1, Paragraph 1.1.4). The presence of these biologically relevant 
structural motifs will allow us to investigate possible structural preference of the platination. 
Additionally, its NMR three dimensional structure in solution is known10, thus making easier the NMR 
characterization of its platinated species. Lastly, NMR studies on Mg(II), Cd(II) and Co(III)hexammine 
binding to this specific RNA were recently reported11 which gave us evidences about the sites which 
can accommodate divalent metal ions. After the recently reported crystal structure of cisplatin-ribosome 
which is suggesting that the Mg(II) binding sites could also represent possible platinum(II) binding 
sites12 (Chapter 1, Paragraph 1.3.5), knowing where Mg(II) binds in our construct may give us a first 
indication of the possible platination sites.  
 
The characterization of the Pt(II)-RNA adducts was performed with various biochemical methods and 
spectroscopic techniques. Gel mobility shift assays are widely used for the evaluation of the platination 
reactions with both RNA and DNA. For example, it was reported that the reaction of RNA or DNA with 
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platinum(II) complexes results in products which could migrate either slower or faster compared to 
unplatinated RNA5,13,14 or DNA15,16 when analyzed by denaturing PolyAcrylamide Gel Electrophoresis 
(dPAGE). Slower migration of the platinated species could be either due to their higher molecular 
weight or to the reduced overall negative charge of the nucleic acid upon binding of the platinum 
complex. Contrarily, faster migration could be caused by the formation of intrastrand cross-linking13,15. 
Moreover, least distorted Pt(II)-RNA adducts could be formed, with similar migration as the 
unplatinated RNA. In the current study, the presence of one or more new bands was used as indication 
of actual platination. The intensity of the new band was used to evaluate the platination efficiency. The 
higher the intensity, the higher the amount of platinated species formed. From the ratio of the intensity 
of the new band and the band corresponding to the unreacted RNA, a first evaluation of the reaction 
speed could be done. The faster the reaction was, the less intense was the band corresponding to the 
unreacted RNA, and new band(s) appeared on the gel, depending on the different RNA species formed. 
In order to get information about the platinated RNA species migrating in the gel bands, the gel pieces 
were cut and the Pt(II)-RNA species were isolated (Chapter 5, Paragraph 5.4) and characterized with 
MALDI-MS. From the mass spectra we could get information about the number and the identity of the 
formed species (Paragraph 2.7). The RNA with one platinum moiety will be called monoplatinated and 
the RNA sample with two platinum moieties diplatinated. The expected and measured m/z for each 
species (monoplatinated, diplatinated etc.) are given in Appendix 1. 
The optimization of the platination reaction conditions that will be described below has as a target to 
obtain a homogeneously platinated RNA sample in reasonable yield, which will be used later on for 
further characterization. More specifically, we investigated the presence of a preferential binding site. 
The RNA molecule chosen for this study offers several platination sites (Figure 2.1), and only the 
presence of a strong preferential platinum binding site would indeed ideally lead to the formation of a 
single monoplatinated RNA species. The investigation of the platination reaction conditions involved 
optimization of parameters like RNA and platinum concentration, temperature, time of incubation and 
reaction buffer.  
 
Figure 2.1: The secondary structure of D1-27. In red are denoted the guanines, which could be possible 
platination sites. 
 
The platination reactions were performed at pH 6 – 6.5. Indeed, on the one hand, RNA stability 
decreases at alkaline pH17, therefore staying within this range we avoided RNA degradation. On the 
other hand, aquation rates and species, and binding of cisplatin and oxaliplatin depend on pH and ionic 
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environment18,19. For example, in the case of monoaquated cisplatin and its derivatives the pKa of the 
monoaquated species is between 6 to 7 and therefore under the pH conditions used here the formation 
of the less reactive hydroxyl species is avoided20–24 (Figure 2.2). For oxaliplatin the pKa for the oxalate 
monodentate complex (ring-opening) was estimated at 7.2 and therefore within this pH range the use 
of the intact complex is assured19. 
 
 
Figure 2.2: Cisplatin speciation in aqueous solutions20.  
 
2.3 Platination reactions of D1-27 with cisplatin 
The first platinum(II) complex used for platination studies was cisplatin, both in its non-activated and 
its activated form, as monoaquo complex (Figure 2.3). The aquation / activation of cisPt is described in 
detail in the experimental part (Chapter 5, Paragraph 5.2.4).  
 
Figure 2.3: Activation of cisplatin and formation of the monoaquated complex. 
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2.3.1 Platinum concentration dependent experiments at 25 °C 
Preliminary data on the interaction of D1-27 with cisPt were collected by the master student Dania 
Marthaler25. These data showed that 1 equivalent (eq) of cisPt was enough to give rise to the formation 
of a new slower migrating band which though was very low in intensity. Trying to increase the intensity 
of the band and consequently the platination yield an excess of platinum complex (5 eq and 10 eq) as 
well as the activated monoaquated cisPt were used. Higher reaction rates are expected by increasing the 
concentration either of RNA or platination agent, since more molecules are available to react. This 
would in turn lead to the formation of a higher amount of platinated species, then contributing to 
increasing the platination yield. The use of monoaquated cisPt instead of its parent compound was also 
expected to increase the platination rate. It is indeed known that activated platinum(II) complexes react 
faster compared to their parent compounds7. At first, 1 eq, 5 eq and 10 eq of cisPt and monoaquated 
cisPt were reacted with 0.1 mM D1-27 in 60 mM KClO4 / 10μM EDTA for 5 days at 25 °C (Figure 
2.4). No second band was observed on the gel in the case of 1 eq of cisPt and monoaquated cisPt, while 
for 5 eq and 10 eq a not defined band (smear) was observed for both platinum complexes. Smear is 
formed when there are differently multiplatinated species which are not properly separated in a gel to 
give a compact band. For 10 eq of cisPt and monoaquated cisPt additionally to the formation of a smeary 
band there was also not unreacted RNA left. That indicates that the reaction with 10 eq of platinum(II) 
complex proceeded faster compared to the reaction with 5 eq. Comparing the behaviour of the two 
platinum(II) complexes using 10 eq it is also worth noting that the smeary band observed in the case of 
the reaction performed with monoaquated cisPt migrated slower compared to the one with cisPt. This 
slower migration may be indicative of the presence of higher content of different multiplatinated RNA 
species suggesting faster reaction rate. This is in accordance with what is reported in the literature about 
the speed of the activated and non-activated platinum(II) complexes7,18. 
Figure 2.4: 18 % denaturing PAGE for the platinum 
concentration dependent experiments at 25 °C. 1 eq,  
5 eq and 10 eq of cisPt and monoaquated cisPt were 
tested in 60 mM KClO4 / 10 μM EDTA for 5 days. 
Both lanes correspond to the repetition of the same 
reaction. The gel was run at room temperature.  
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2.3.2 Platinum concentration dependent experiments at 37 °C 
At 25 °C there was no formation of a well-defined second band. So similar experiments, as above, were 
performed at higher temperature (37 °C) attempting to enhance the formation of platinated RNA 
species, which were homogeneous enough to form a compact band. Now only monoaquated cisPt was 
used considering that it reacts faster than cisPt7,18. 1 eq, 5 eq and 10 eq of monoaquated cisPt were 
reacted with 0.1 mM D1-27, for 5 days in 60 mM KClO4 / 10 μM EDTA and in MOPS buffer (Figure 
2.5). MOPS buffer is widely used for platination reactions5. Also in this case, no second band was 
observed on the gel when the reaction was performed in the presence of 1 eq of monoaquated cisplatin. 
Conversely, the use of 5 eq and 10 eq of monoaquated cisplatin led to the formation of smeary bands 
on the gel (Figure 2.5). There was no significant difference in the behaviour of the reactions in MOPS 
and in KClO4 / EDTA solution (Figure 2.5) but for the slower migrating smeary band that is observed 
when 10 eq of monoaquated cisPt are used in the presence of MOPS. This suggests that the content of 
platinum per RNA was higher in the presence of MOPS, likely due to higher platination speed. 
Interestingly, in the presence of 5 eq of monoaquated cisplatin in KClO4 / EDTA, the band 
corresponding to unreacted RNA is stronger at 25 °C (Figure 2.4) than at 37°C (Figure 2.5), suggesting 
that the reaction at this temperature proceeded faster, as expected. Unfortunately, the platination 
reactions performed so far at 25 °C and 37 °C, whatever the reaction conditions and the platinum 
complex used, did not result in the formation of a clear second band.  
 
Figure 2.5: 18 % denaturing PAGE for the platinum concentration dependent experiments at 37 °C. 1 eq, 5 eq 
and 10 eq of monoaquated cisPt were tested in 60 mM KClO4 / 10 μM EDTA and in MOPS buffer. Both lanes 
correspond to the repetition of the same reaction. The gel was run at room temperature.  
 
The behaviour was different when instead of 60 mM KClO4 / 10 μM EDTA, double distilled water 
(ddH2O) was used. When 5 eq, 10 eq and 15 eq of monoaquated cisPt were reacted with 0.1 mM  
D1-27 at 37 °C for 15 h in ddH2O, there was formation of a second band in the case of 5 eq (Figure 2.6, 
blue frame). In the other two cases, not defined bands were observed, indicative of a mixture of multiple 
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platinated RNAs. As already commented above, the slower the migration of these bands, the higher 
their platinum content (Figure 2.6). In the platination reaction in ddH2O the incubation time was 
significantly reduced (15 h), because folding and stability of D1-27 are expected to be lower in the 
absence of monovalent metal ions, and the platination sites are likely to be better accessible, thus leading 
to easier and faster platination (Chapter 4, Paragraph 4.4 - 4.5). 
 
Figure 2.6: 18 % denaturing PAGE for the platinum concentration dependent experiments at 37 °C. 5 eq, 10 eq 
and 15 eq of monoaquated cisPt were tested in ddH2O. Both lanes for each reaction correspond to the repetition 
of the same reaction. The gel was run at room temperature. 
 
2.3.3 Platinum concentration dependent experiments at 50 °C 
In the previous paragraphs it was shown that at 25 °C and 37 °C there was not formation of a clear 
second band and there were only smeary bands when 60 mM KClO4 / 10 μM EDTA or MOPS buffer 
were used. The next temperature tested was 50 °C. This corresponds to the first melting temperature of 
D1-27 (Tm1 = 53.8 ± 2.1 °C). The melting temperature profile of D1-27 shows two transitions, which 
may be attributed to the denaturing of the first and the second part of the construct, respectively (Chapter 
4, Paragraph 4.4). At 50 °C partial denaturing of the first part of the construct is expected26,27, thus 
making possible binding sites more accessible. The reactions were performed in both 60 mM KClO4 / 
10 μM EDTA and in ddH2O (Figure 2.7). Thermal melting studies show that D1-27 stability increases 
upon addition of potassium ions. Moreover, CD spectra recorded in the presence of increasing 
potassium(I) concentration suggest that the fraction of folded RNA increases upon potassium(I) 
addition (Chapter 4, Paragraph 4.4 - 4.5). Since faster reaction is expected at higher temperature, 
especially in water, the reaction time was reduced from 5 days to 15 h and cisplatin was used instead of 
the monoaquated derivative.  
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Figure 2.7: 18 % denaturing PAGE for the platinum concentration dependent experiments at 50 °C. 1 eq, 5 eq 
10 eq and 15 eq of cisPt were tested in 60 mM KClO4 / 10 μM EDTA and in ddH2O. Both lanes correspond to the 
repetition of the same reaction. The gel was run at room temperature.  
 
Both in the presence and in the absence of monovalent ions, a new slower migrating band was observed 
in the gel when the reaction was performed using 1 eq of cisPt and 0.1 mM D1-27 at 50 °C (Figure 2.7, 
blue frame). This band was more pronounced in the reaction with ddH2O. With  
5 eq -15 eq there were only undefined bands which by increasing the platinum concentration were 
migrating slower (Figure 2.7). Comparing the reaction of 5 eq of cisPt with RNA in 60 mM KClO4 /  
10 μM EDTA and in ddH2O, formation of a new slower migrating band was observed in both cases 
(Figure 2.7, red frame). The difference was that for the reaction in ddH2O there was no unreacted RNA 
left suggesting that the platination reaction was faster. This was not surprising, since in the absence of 
monovalent ions D1-27 is expected to be less stable, making the platination sites more available. 
Moreover, the absence of cations which could compete with platinum for RNA binding is expected to 
favour platination13. Based on the collected results until now, the best picture was obtained using 5 eq 
of cisPt in ddH2O, at which the formation of a new band and no band for unreacted RNA was observed. 
Consequently, less than 5 eq had to be tested in order to investigate when the new band appears. 
The next set of experiments included the platination of 0.1 mM D1-27 with 0.5, 1, 2, 3, 4 and 5 eq of 
monoaquated cisPt, at 50 °C, for 15 h in ddH2O (Figure 2.8). Monoaquated cisPt was used instead of 
cisPt attempting to further increase the platination yield in the presence of less equivalents of platination 
agent. In the following gel (Figure 2.8) is depicted the formation of the upper band with increasing 
platinum concentration (blue frame). The upper bands corresponding to the reactions performed in the 
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presence of 2 to 5 eq were intense enough to be cut (Figure 2.8, blue frame). The platinated RNA species 
were isolated from the gel pieces and purified (Chapter 5, Paragraph 5.4). Due to low recovery of the 
samples corresponding to the reactions performed with 2 eq and 3 eq of cisPt only the upper bands 
obtained in the case of 4 eq and 5 eq were characterized with MALDI-MS. The MS spectrum of the 
two samples combined showed that they contained mixture of multiplatinated RNA species 
(monoplatinated, diplatinated, triplatinated and tetraplatinated RNA) (Appendix 1, A 1.1). Summing 
up, these experiments showed that the platination of D1-27 with 4 and 5 eq of monoaquated cisPt at  
50 °C, for 15 h in ddH2O on the one hand resulted in the formation of a well-defined new band but on 
the other hand the reaction was fast enough to lead to the formation of multiplatinated species. 
 
Figure 2.8: 18 % denaturing PAGE for the platinum concentration dependent experiments at 50 °C. 
0.5 eq -5 eq of monoaquated cisPt were tested in ddH2O. Both lanes correspond to the repetition of the same 
reaction. The gel was run at room temperature. 
 
2.3.4 Time and temperature dependent experiments in the presence of 1 eq and 2 eq of 
monoaquated cisplatin in ddH2O 
The experiments commented in paragraph 2.3.3 showed that the use of 4 eq or 5 eq of monoaquated 
cisPt led to multiplatinated species. Consequently, 1 and 2 eq of monoaquated cisPt were tested, with 
0.1 mM D1-27, at 25, 37 and 50 °C for 15 h, 1 day and 2 days in ddH2O (Figures 2.9 and 2.10). At  
25 °C using 1 eq of monoaquated cisPt the band corresponding to unreacted D1-27 was almost intact 
and a faint smear close to this band was observed (Figure 2.9, right). That suggests that the formation 
of platinated RNA species was slow and the species formed were not separated sufficiently on the gel. 
However, formation of species which were not significantly distorted and therefore had mobility similar 
to the unreacted RNA could also be the reason for the observed behaviour14. On the contrary, at 37 °C 
and 50 °C, using 1 eq of monoaquated cisPt there was formation of a second slower migrating band 
which was better defined (Figure 2.9, centre and left). These gel bands were cut and the platinated RNA 
samples were isolated and characterized with MALDI-MS. The upper bands corresponding to the 
reactions performed at 37 °C contained unreacted RNA and monoplatinated species (Appendix 1,  
A 1.2), while the corresponding upper bands at 50 °C contained a mixture of unreacted, monoplatinated 
and diplatinated RNA with the monoplatinated being the major species (Appendix 1, A 1.3). 
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Figure 2.9: 15 % denaturing PAGE for time and temperature dependent experiments for 1 eq of monoaquated 
cisplatin. Reaction of 1 eq monoaquated cisPt was tested at 25 °C, 37 °C and 50 °C in ddH2O. The reaction time 
varied from 15 h to 1 day and 2 days. The gel was run at room temperature.  
 
A similar behaviour was observed when the reaction was repeated at 25 °C in the presence of 
2 eq of monoaquated cisplatin (Figure 2.10, right). At 37 °C and 50 °C using 2 eq of monoaquated cisPt 
the behaviour was also similar to 1 eq but the bands seem to be slightly more intense, suggesting that 
higher amount of platinated RNA was formed (Figure 2.10, middle, left). At 50 °C there was less 
unreacted RNA and the new band was more intense compared to the new band at 37 °C, indicating that 
the reaction was faster (Figure 2.10, middle, left). The platinated RNA from the new upper bands at  
50 °C and 37 °C were isolated and characterized with MALDI-MS. They both contained a mixture of 
mostly monoplatinated and, to a lesser extent, diplatinated as well as triplatinated and tetraplatinated 
RNA (Appendix A 1.4 - A 1.5). By increasing the temperature, the reaction was faster and more 
platinated species were formed; the upper bands were better defined but they all contained a mixture of 
monoplatinated and diplatinated RNA. The presence of a better-defined second band could be the result 
of the formation of more similarly platinated RNA species possibly suggesting the existence of a 
preferable platination site.  
Putting together the results from the abovementioned comparison using 1 eq and 2 eq of platinum 
complex, the upper bands which did not contain multiplatinated RNA resulted from the reaction of  
1 eq of monoaquated cisPt with 0.1 mM D1-27 at 37 °C (Figure 2.9, middle) and these were the 
conditions chosen. The platinated RNA species from the upper bands in all cases were mixed in order 
to have enough sample to be characterized by MALDI-MS. Therefore, a safe conclusion about the time 
dependency could not be done.  
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Figure 2.10: 15 % denaturing PAGE for time and temperature dependent experiments for 2 eq of monoaquated 
cisplatin. Reaction of 2 eq of monoaquated cisPt was tested at 25 °C, 37 °C and 50 °C in ddH2O. The reaction 
time varied from 15 h to 1 day and 2 days. The gel was run at room temperature. 
 
2.3.5 RNA concentration dependent experiments  
Based on the results commented in paragraph 2.3.4, the platination reactions were repeated using 1 eq 
of monoaquated cisPt in the presence of different concentration of D1-27, namely 0.1 mM, 0.25 mM 
and 0.5 mM (Figure 2.11). The reaction mixtures were incubated at 37 °C and the reaction was allowed 
to proceed for 2 days. For all three RNA concentrations new slower migrating bands (upper bands) 
were observed in the gel, together with a band corresponding to unreacted RNA and undefined faster 
migrating bands. All bands were similar in intensity suggesting that the platination reaction proceeded 
comparably for all the three tested RNA concentrations. Interestingly, this time two upper bands were 
visible on the gel, and they could be analysed separately. Indeed, for the reaction performed in the 
presence of 0.5 mM D1-27, enough sample could be recovered from the gel and analysed by  
MALDI-MS. Interestingly, the faster migrating upper band seems to contain a mixture of 
monoplatinated and diplatinated RNA, with the monoplatinated RNA being the major species, whereas 
the slower migrating upper band seems to contain monoplatinated and diplatinated RNA but in this case 
the diplatinated RNA was the major specie (Appendix 1, A 1.6 - A 1.7). Considering that with all 
different concentrations tested, the bands appeared were similar (intensity and number of the bands), 
the lower RNA concentration was chosen as the working concentration (0.1 mM). The quality of this 
gel was good enough to allow the quantification of the bands with the use of the software ImageJ 1.50i. 
With this software, the relative band area is calculated and from the comparison of the band area of the 
two bands, a percentage for each is given. Considering that the upper bands correspond to the platinated 
RNA species, this percentage can be used as an indication of the platination yield. The gel bands from 
the reaction using 0.5 mM were the better-defined ones and were analysed with ImageJ 1.50i. The 
platination yield in this case was found to be around 25 %.  
 
 
56 
 
 
Figure 2.11: 15 % denaturing PAGE for RNA concentration dependent experiments. 0.1 mM, 0.25 mM and  
0.5 mM D1-27 were tested with 1 eq of monoaquated cisPt at 37 °C for 2 days in ddH2O. Both lanes for  
0.25 mM correspond to the repetition of the same reaction. The gel was run at room temperature. The presence 
of two slower migrating bands as well as several faster migrating bands was observed here for the first time. 
 
2.3.6 Time dependent experiments 
All the experiments commented above showed that a good combination of experimental conditions in 
order to get mostly monoplatinated D1-27 with cisPt was: 1 eq monoaquated cisPt, 0.1 mM D1-27,  
37 °C, incubation for 2 days in ddH2O. Aiming at improving the platination yield, different incubation 
times were tested with the same reaction conditions. Namely, the incubation time was increased from 
2 days to 3 days and 4 days. The gel obtained from these reactions (Figure 2.12) was similar to the one 
obtained for 2 days incubation (Figure 2.11), showing two main bands. The upper band contained the 
platinated D1-27 and the other band corresponded to unreacted D1-27. However, despite the increased 
incubation time, the platination yield did not improve (23 % for both 3 days and 4 days). MALDI-MS 
characterization of the platinated D1-27 recovered from the upper band corresponding to 4 days 
incubation showed that the main species were the diplatinated ones (Appendix 1, A 1.8). These data 
suggest that the increased incubation time, instead of leading to a higher number of monoplatinated 
species, favoured multiplatination. This behaviour suggests lack of strong binding preference of cisPt 
for a platination site, and advices against the use of long incubation time. Therefore, 2 days were kept 
as the optimal incubation time for the platination reactions of monoaquated cisPt with D1-27. Similarly 
to the previous experiment, (Figure 2.11) a faster migrating undefined band was also observed, but 
unfortunately, the identity of the species giving rise to this band could not be identified due to very low 
recovery from the gel. 
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Figure 2.12: 15 % denaturing PAGE for time dependent experiments. D1-27 was incubated with 1 eq of 
monoaquated cisPt at 37 °C for 3 and 4 days in ddH2O. All lanes for 4 days of incubation correspond to the 
repetition of the same reaction. The gel was run at room temperature.  
 
2.3.7 Conclusions for cisplatin platination reactions 
For the platination of D1-27 with monoaquated cisPt the platination conditions which allowed the best 
separation of the Pt(II)-RNA adducts on the gel and the highest platination yield with the least possible 
multiplatinated species formed were: 1 eq of monoaquated cisPt, 0.1 mM D1-27, 37 °C,  
2 days incubation in ddH2O (Figure 2.13). The maximum platination yield achieved using these reaction 
conditions was around 25 %. Several problems were encountered while investigating the platination 
reactions involving D1-27 and cisPt. First, the platinated D1-27 species isolated from the upper band 
were not homogeneous. From their MALDI-MS characterization it was found that the newly formed 
slower migrating band contained a mixture of monoplatinated and diplatinated D1-27 with the 
monoplatinated being the major species. The formation of a mixture of differently platinated RNAs 
migrating together in the newly formed band was also reported in the literature13. Second, the platination 
yield was always rather low (25 %). Any attempt to increase the platination yield resulted in the 
formation of more multiplatinated species (Figures 2.11 and 2.12). This behaviour may be related to 
the lack of a preferential binding site for cisplatin, together with the presence of similarly accessible 
platination sites within D1-27, which resulted in the formation of multiplatinated RNA species. Having 
as a target to obtain high amount of homogeneous Pt(II)-D1-27 sample for studying the possible 
sequence and / or structural preferences of platinum(II) complexes, the use of cisPt was not ideal. The 
next platinum(II) complex to be tested was oxaliplatin (oxaliPt).   
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Pt-RNA species (upper band) Predicted mass (m/z) Experimental mass (m/z) 
D1-27 – {HPO3}
 a 8768 8769 
D1-27 8848 8847 
Monoplatinated D1-27 – 2 {HPO3} 8917 8917 
Monoplatinated D1-27 – {HPO3}
 8997 8996 
Monoplatinated D1-27 9076 9076 
Diplatinated D1-27 – {HPO3} 9226 9227 
Diplatinated D1-27 9306 9303 
a.{HPO3}: Its molecular mass (80) corresponds to the loss of a phosphate group
28. 
Figure 2.13: 15 % denaturing PAGE for the platination reaction of D1-27 with cisPt, using the following 
experimental conditions: 0.1 mM D1-27 incubated with 1 eq of monoaquated cisPt at 37 °C for 2 days in ddH2O. 
The gel was run at room temperature. A characteristic mass spectrum of the platinated species isolated from the 
upper band is depicted on the right. 
 
In the mass spectrum of the platinated D1-27 with cisPt (Figure 2.13) in addition to the peaks 
corresponding to monoplatinated and diplatinated RNA there are also peaks for the monoplatinated and 
diplatinated RNA with different number of phosphate groups. The RNA used (D1-27) after transcription 
is expected to have a triphosphate group at the 5ʹ-end. However, the presence of Mg(II) in the 
transcription mixture enhances the hydrolysis of the triphosphate leading to a mixture of RNA 
molecules having triphosphate and diphosphate groups at the 5ʹ-end (Figure 2.14). Therefore, a mixture 
of platinated RNAs containing three or two phosphate groups was observed. Additionally, cleavage of 
phosphate ester bonds have been reported during the ionization procedure of  
MALDI-MS28,29. These molecules are differing by 80 Da and the phosphate group lost will be noted as 
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{HPO3}. The behaviour of the RNA during the MALDI-MS measurements will be further discussed in 
paragraph 2.7. 
 
 
Figure 2.14: Representation of the hydrolysis of the 5ʹ-end triphosphate, which leads to the presence of RNAs 
with different number of phosphate groups 
 
2.4 Platination reactions of D1-27 with oxaliplatin 
OxaliPt {[Pt (oxalato) (1R, 2R-cyclohexane-1,2-diamine)]} is a third-generation platinum(II) complex, 
which was developed in order to show less side effects and better cytotoxicity compared to cisPt7,30–32. 
OxaliPt is not side effect free but it shows activity against cisPt resistant cancers32. CisPt is believed to 
exert its anticancer activity by covalent binding to nuclear DNA. Upon platinum binding the induced 
DNA distortion and its inability to be fixed is leading to apoptosis. The main cisPt-DNA adducts formed 
consist of 1,2-d(GG) and 1,2-d(AG)7 (Chapter 1, Paragraph 1.2.3). The exact mechanism of action of 
oxaliPt is not clear and is mostly extrapolated from the understanding of the cisPt one. Compared to 
cisPt, oxaliPt has a 1,2-diaminocyclohexane (DACH) as non-leaving group instead of ammine groups 
and an oxalate ligand as leaving group instead of chlorides32 (Figure 2.15, left). The different reactivity 
observed for oxaliPt may be attributed to its different non-leaving group, DACH31,33. The sterical 
hindrance introduced by the bulky DACH moiety leads to significant conformational changes between 
the cisPt and oxaliPt DNA adducts34. It is hypothesized that these conformational differences result in 
discrimination from the various DNA repair proteins which could explain their differences in 
reactivity34,35. It was shown that the same type of adducts at similar abundance are formed upon DNA 
platination with both cisplatin and oxaliplatin32 but oxaliPt has been also found to form additional 
adducts involving adenine when reacting with RNA36. Considering that, upon platination of D1-27 with 
oxaliPt the formation of platinated species at adenine sites was also expected. CisPt reacts with DNA 
upon hydrolysis which leads to the formation of the monoaquated complex7,32. However, the active 
form of oxaliPt is considered to be its diaquated complex31,37. The exact route by which the diaquated 
complex is formed is complicated and not completely understood, but it is suggested that, following 
oxalate ring opening, the dichloride complex [Pt(DACH)Cl2] is first formed. This dichloride complex 
is hydrolysed, similarly to cisPt, to the monoaquated and finally diaquated active form37–40. The 
hydrolysis of oxaliPt to its active form is longer compared to the cisPt, therefore slower reaction with 
DNA / RNA is expected. This is probably explaining the fewer oxaliPt-DNA adducts formed compared 
to cisPt when the reactions is performed under the same conditions37. Therefore, the combination of the 
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slower kinetics of oxaliPt together with its increased bulkiness compared to cisPt, could lead to the 
formation of homogeneous Pt(II)-RNA adducts considering that less platinum moieties could be 
accommodated per RNA. In principle, these characteristics of oxaliPt make it a better candidate for the 
current study. The optimization of the experimental conditions, which would lead to the formation of 
homogeneously platinated D1-27 species, was performed using gel mobility shift assays and the newly 
formed species were analysed by MALDI-MS, similarly to the procedure explained for cisPt.  
 
 
Figure 2.15: Chemical structure of oxaliplatin (left) and secondary structure of D1-27 (right). In red are denoted 
the guanines, which could be possible platination sites. 
 
2.4.1 Oxaliplatin concentration, temperature and time dependent experiments  
Based on the procedure followed in the case of cisPt, similar experiments were performed for the 
investigation of the platination conditions with oxaliPt. At first, 1 eq, 5 eq and 10 eq of oxaliplatin were 
reacted with 0.1 mM D1-27. The mixtures were incubated for 15 h, 1 day and 2 days at 25 °C, 
37 °C and 50 °C in ddH2O. The reaction of D1-27 with 1 eq of oxaliPt at 25 °C and 37 °C, independently 
of the reaction time, showed intense bands for the unreacted RNA as well as a smeary band very close 
to the band of the unreacted RNA (Figure 2.16).  
 
Figure 2.16: 15 % denaturing PAGE for time, platinum concentration and temperature dependent experiments 
of oxaliPt in ddH2O. 1 eq and 5 eq of oxaliPt were incubated with 0.1 mM D1-27 for 16 h, 1 day and 2 days, at  
25 °C, 37 °C and 50 °C in ddH2O. The gel was run at room temperature.  
 
The formation of smeary bands suggests that similarly platinated RNAs are formed, which cannot be 
sufficiently separated on the gel. At 50 °C, with increasing incubation time, the band corresponding to 
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the unreacted RNA becomes weaker and the smeary band is more extended. The decrease of the amount 
of unreacted RNA at 50 °C indicates higher reaction speed compared to the other two temperatures. 
However, the presence of an extended smear suggests that several differently platinated species were 
formed which could not be separated. 
With 5 eq of oxaliPt at 25 °C after 16 h there was a not well-defined band which was poorly separated 
from the band of the unreacted RNA. However, after 1 day of incubation there was formation of a more 
compact second band on the gel whose intensity was further increased after 2 days of incubation (Figure 
2.16, blue frame). The upper band corresponding to the reaction performed for 2 days was cut and 
analysed via MALDI-MS. The mass spectrum showed that the major species was the monoplatinated 
D1-27 while there were minor peaks corresponding to diplatinated D1-27 and unreacted D1-27 
(Appendix 1, A 1.9). The presence of unreacted D1-27 in the sample isolated from the upper band may 
be due to not sufficient separation on the gel and could be eliminated with optimization of the gel 
running conditions (see below). On this gel, these two bands were intact enough to allow their 
quantification with the use of ImageJ 1.50i. From the comparison of the band area, it was found that the 
upper band and therefore the platination yield was around 50 %. An intense band for the unreacted  
D1-27 was observed for all three reaction times investigated, but in the case of the reactions performed 
for 16 hours and 1 day, quantification was not possible due to their not sufficient separation from the 
upper band (Figure 2.16). At 37 °C after 16 h of incubation, there was a clear second band and a band 
for the unreacted RNA while after 1 day and 2 days there was only one band and no unreacted RNA 
left. The content of the upper band corresponding to the reactions performed for 16 h was analysed by 
MALDI–MS. Τhe spectrum showed the presence of a mixture of monoplatinated and diplatinated RNA 
(Appendix 1, A 1.10). Under all the incubation times tested, 5 eq of oxaliplatin at 50 °C resulted in a 
very slow migrating undefined smeary band, indicative of a mixture of multiplatinated RNA species. 
The longer the incubation time the slower the band was migrating, suggesting higher degree of 
multiplatination (Figure 2.16).  
The use of 10 eq of oxaliPt at 25 °C resulted in the formation of a second well-separated band only after 
1 day and 2 days of incubation while the band of the unreacted RNA was still visible. At 37 °C and  
50 °C there were only undefined smeary bands and no band for unreacted RNA indicating that the 
reaction proceeded very fast. The smeary bands formed migrate slower at 50 °C suggesting that there 
were more platinum moieties per RNA (Figure 2.17). 
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Figure 2.17: 15 % denaturing PAGE for time, platinum concentration and temperature dependent experiments 
of oxaliPt in ddH2O. 10 eq of oxaliPt were incubated with 0.1 mM D1-27 for 16 h, 1 day and 2 days at 25 °C, 
37 °C and 50 °C in ddH2O. The gel was run at room temperature.  
 
Summing up, the most promising results were obtained by using 5 eq of oxaliPt, incubating for 2 days 
with 0.1 mM D1-27 at 25 °C in ddH2O (Figure 2.16, blue frame). Under these conditions, the platination 
yield was almost 50 % and the upper slower migrating band contained mostly monoplatinated RNA. 
However, a small amount of diplatinated RNA was also formed, which could be possibly eliminated 
with further optimization of the reaction conditions.  
 
2.4.2 RNA concentration and time dependent experiments 
In order to reduce the amount of diplatinated RNA, the reaction time was reduced to 1 day. Moreover, 
different RNA concentrations were tested (0.1 mM, 0.25 mM and 0.5 mM) in order to increase the 
amount of platinated sample formed which then could be used for further characterization. Incubation 
for 1 day with 0.1 mM D1-27 resulted in bands with similar intensity as observed before  
(Figure 2.18). With 0.25 mM and 0.5 mM D1-27 for 1 day of incubation upper bands with similar 
intensity were observed (Figure 2.18). The overall different migration of the bands obtained using  
0.5 mM D1-27 was due to mishandling of the gel during the gel pocket preparation. The MALDI-MS 
spectrum of the upper band obtained using 0.25 mM D1-27 for 1 day reaction showed that it consisted 
mostly of monoplatinated RNA but a small amount of diplatinated RNA was still present  
(Appendix A 1.11). Therefore, even at reduced incubation time the diplatinated RNA species were 
already formed. Despite the presence of a small amount of diplatinated species, 0.25 mM D1-27 and  
1 day of incubation were kept as the conditions of choice. Due to very low recovery it was not possible 
to characterize the species from the upper band obtained using 0.5 mM D1-27. 
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Figure 2.18: 15 % denaturing PAGE for RNA concentration and time dependent experiments. 5 eq of oxaliPt 
were incubated with 0.1 mM, 0.25 mM and 0.50 mM D1-27 for 1 day at 25 °C in ddH2O. The gel was run at room 
temperature.  
 
2.4.3 Influence of salt concentration on platination reaction efficiency  
All the experiments performed during the optimization procedure with oxaliPt were carried out in 
ddH2O. The reason for that was that during the corresponding reactions with cisPt, it was found that the 
replacement of 60 mM KClO4 solution for ddH2O resulted in the formation of a clear second band 
(Paragraph 2.3.3, Figure 2.7). As discussed before, in the absence of monovalent cations the RNA does 
not have its compact secondary structure, and the possible platination sites are more exposed, which 
leads to the enhancement of the platination reaction (Chapter 4, Paragraph 4.4). Also in the case of 
oxaliplatin a second clear band is observed when the reaction is performed in water. However, the mass 
spectrum of the sample isolated from the upper band showed that it contained a mixture of mono- and 
diplatinated RNA. In the attempt of reducing the amount of diplatinated species, ddH2O was replaced 
with 60 mM KClO4, to reduce platination kinetics and possibly favour a single platination site. For these 
reactions 5 eq and 10 eq of oxaliPt were used and the incubation times tested were 1 day and 2 days at 
25 °C using 0.25 mM D1-27.  
By reacting 5 eq of oxaliPt with 0.25 mM D1-27 for 1 day in 60 mM KClO4 the formation of a smear, 
migrating very close to the band of the unreacted RNA, was observed. That shows that the few 
platinated RNA species formed were not separated on the gel (Figure 2.19). No clear upper band was 
observed, suggesting that the platination yield was reduced. In the presence of 5 eq (2 days) and 10 eq 
(1 day) of oxaliPt a second well-defined band was visible on the gel, in both cases. The MS 
characterization of the platinated RNAs extracted from these upper bands showed that they consisted 
of a mixture of multiplatinated RNAs (Appendix 1, A 1.12- 1.13). The formation of multiplatinated 
species may be attributed to longer platination time and increased platinum concentration. Upon 
reaction of 10 eq of oxaliPt for 2 days, the band corresponding to the unreacted RNA was significantly 
reduced, showing that the reaction proceeded faster, and a slower migrating band was well visible on 
the gel. As expected, the content of the upper bands was a mixture of multiplatinated RNAs (Appendix 
1, A 1.14). Summing up, the use of 5 eq oxaliPt incubating for 2 days and 10 eq of oxaliPt incubating 
for 1 and 2 days, all lead to the formation of a second band on the gel but all bands contained a mixture 
of multiplatinated RNAs. However, no clear upper band was observed on the gel when the reaction was 
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performed with 5 eq of oxaliPt for 1 day. Therefore, the use of 60 mM KClO4 does not seem to be ideal 
for the formation of measurable amount of a homogeneously platinated RNA. 
 
Figure 2.19: 15 % denaturing PAGE for RNA concentration and time dependent experiments. 5 eq and 10 eq of 
oxaliPt were incubated with 0.25 mM D1-27, for 1 day and 2 days, at 25 °C in 60 mM KClO4. All four lanes 
correspond to the repetition of the same reaction. The gel was run at room temperature.  
 
In addition to improving the platination yield, much effort was put in order to have a better gel 
separation between the bands of the unreacted and the platinated RNA. Better separation could be 
achieved by reducing the speed at which the gel was running. A way to do that was to run the gels at 
lower power and for longer time. Towards this direction, longer gel plates were used and the electric 
power was reduced to 1-2 W from 5-8 W used before. By increasing the length of the plates and by 
reducing the electric power the two bands on the gel were more compact but still very close to each 
other (Figure 2.19). Another way that could further improve the separation was to run the gel at 4 °C 
instead of room temperature and use higher percentage of denaturing gel solution, like 20 % instead of 
15 %. The lower temperature, similarly to the lower electric power and longer gel plates, would lead to 
longer running time. The higher gel solution percentage is expected to favour more compact and better 
resolved gel bands, thus improving the separation41. The reaction was then repeated (5 eq of oxaliplatin, 
0.25 mM D1-27, 1 day of incubation at 25 °C) both in ddH2O and in 60 mM KClO4 and the gel was run 
at 4 °C, using 20 % denaturing gel solution (instead of 15 %). This significantly improved the separation 
of the two bands (Figure 2.20). The good quality of this gel allows for a few important comments. 
Firstly the platination yield is higher in the presence of ddH2O (35 %) than in the presence of KClO4 
(16 %), as previously observed for cisPt (Paragraph 2.3.3). Additionally, the platination yield of the 
reaction in ddH2O seemed to be reduced with respect to the previous experiments (35 % vs 50 %, 
compare Figure 2.20 with Figure 2.16). Of course, the platination yield is not related to the improved 
separation, but now, because of that the yield could be evaluated more precisely. Finally, the 5th lane of 
each reaction shows only one band corresponding to the platinated D1-27, thus suggesting that 100 % 
platination was achieved (Figure 2.20, blue boxes). The reaction mixture for these two platination 
reactions was prepared in different Eppendorf tubes and the pH was measured only in one of them, 
whose content was loaded on the 5th lane of the gel. Similar behaviour was observed also in a previous 
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gel (Figure 2.19, blue boxes). These bands were cut and the platinated RNA species were isolated and 
analysed with MALDI-MS. They contained a mixture of monoplatinated and diplatinated RNA 
(Appendix 1, A 1.15).  
 
 
Figure 2.20: 20 % denaturing PAGE for platination reactions in ddH2O and in 120 mM KClO4. 5 eq of oxaliPt 
were incubated with 0.25 mM D1-27 for 1 day at 25 °C. All five lanes correspond to the repetition of the same 
reaction. The gel was run at 4 °C.  
 
A pH electrode (Minitrode glass electrode from Hamilton) contains saturated solution of KCl, which is 
released in very small amount through the membrane in the measured samples. Consequently, traces of 
KCl are expected to be present in the samples in which the pH was measured. The final volume of the 
reaction mixtures loaded in the above commented gel was 10 μL. To investigate the effect of KCl 
concentration, the reaction was repeated using larger volumes (10 μL, 20 μL, 30 μL, 40 μL). The pH 
electrode was dipped in all samples to check the pH, the reactions were allowed to proceed for 1 days 
and the reaction mixtures were then loaded on the gel (Figure 2.21). Interestingly, the strongest effect 
on platination yield is observed when the reaction is performed in 10 μL final volume, compared to the 
other volumes tested. Even if a faint band corresponding to unreacted RNA was still visible (Figure 
2.21), while only one band corresponding to the platinated RNA was observed in the previous gels 
(Figure 2.19 - 2.20), the platination yield was around 68 %, which is considerably higher than in all 
previous cases. When the reaction was performed in larger volumes, around 40 % platination yield was 
obtained. Assuming that the same amount of KCl is released by the pH electrode each time, the data 
commented above suggest that the final concentration of KCl, expected to be higher in the smaller 
volume samples, has a strong influence on the platination yield.  
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Figure 2.21: 20 % denaturing PAGE for the investigation of the influence of the volume on the platination 
reaction. Increasing volumes of platination reactions were used: 10 μL, 20 μL, 30 μL and 40 μL. Both lanes for 
the 10 μL volume, as well as all four lanes for the rest, correspond to the repetition of the same reaction. The gel 
was run at 4 °C.  
 
Having established that the presence of KCl in the platination reaction increases the platination yield 
and that this behaviour seems to depend on KCl concentration, the next platination reactions were 
performed in 60 mM KCl as well as in 60 mM KClO4 in the presence of 5 mM KCl (Figure 2.22). In 
the first case, high platination yield was observed (60 %), similarly to what reported above (Figure 2.21) 
while the presence of 5 mM KCl in the reaction mixture did not improve the platination yield, which 
remained rather low (25 %).  
 
Figure 2.22: 20 % denaturing PAGE for the investigation of the influence of KCl. The platination reactions were 
performed in 60 mM KCl (left) and in 60 mM KClO4 / 5 mM KCl (right). Both lanes correspond to the repetition 
of the same reaction. The gel was run at 4 °C.  
 
Since it was found that 60 mM of KCl could enhance the platination (Figure 2.22), increased amounts 
of Cl¯ were tested. More specifically 60 mM, 80 mM, 120 mM and 200 mM of KCl were used (Figure 
2.23). The reaction performed in the presence of 60 mM KCl behaved as expected, reaching almost  
70 % platination yield. Similar platination yield was obtained in the presence of 80 mM and 120 mM 
KCl, while significantly higher platination yield (85 %) was observed with 200 mM KCl. The platinated 
species from the upper bands corresponding to the reactions performed in the presence of 80 mM,  
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120 mM and 200 mM KCl were isolated and analysed with MALDI-MS (Appendix 1, A 1.16 - A 1.18), 
while in all the other cases the amounts collected were not sufficient for any characterization. The major 
platinated species in all samples was monoplatinated RNA, but diplatinated RNA was also present. 
Despite the presence of diplatinated RNA in the samples, 120 mM KCl was chosen as the salt 
concentration to be used for the platination reactions. The lower salt concentrations were not chosen 
because of the lower platination yield and the higher, even if the yield was better, due to higher content 
of diplatinated species. The mass spectra of the platinated species resulting from the reactions 
commented above suggest that the relative intensity of the diplatinated RNA increase with the increase 
of the KCl concentration used (Appendix 1, A 1.16 - A 1.18). Aiming at reducing the amount of 
diplatinated RNA species, the reaction was repeated for shorter time, e.g. only for 15 h, in the presence 
of 120 mM KCl (Figure 2.24). However, the platination yield was lower and similar amount of 
diplatinated RNA was formed. The evaluation of the amount of the diplatinated RNA formed when the 
reaction was carried out for 15 h and 1 day was performed via HPLC (Paragraph 2.8.1).  
 
 
Figure 2.23: 20 % denaturing PAGE for the investigation of the influence of different KCl concentrations. The 
platination reactions were performed in the presence of 60 mM, 80 mM, 120 mM and 200 mM KCl. Both lanes 
for each condition correspond to the repetition of the same reaction. The gel was run at 4 °C.  
 
 
Figure 2.24: 20 % denaturing PAGE for the time dependency of the platination reaction of D1-27 with 5 eq of 
oxaliPt, at 25 °C in 120 mM KCl. Both lanes correspond to the repetition of the same reaction. The gel was run 
at 4 °C.  
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By replacing ClO4¯ with Cl¯ in the platination reaction a noticeable increase of the platination yield 
was observed. Platination reactions of cisPt take place in chloride free medium in order to avoid the 
replacement of water molecules of the activated cisPt with chloride which slows down the reaction42. 
In our study, all the reactions with cisPt were performed indeed in chloride free medium but it was 
found that, in the case of oxaliPt, the presence of the Cl¯ enhanced the platination reaction. More 
particularly the higher the concentration of Cl¯ the higher the yield was (Figure 2.23). A possible 
explanation for this behaviour relays on the fact that the oxalate group of oxaliPt is lost in the presence 
of Cl¯40,43. The mechanism of action of cisPt is well-established7,32,44,45 but it is unclear the way oxaliPt 
reacts and the mechanism of action proposed is mostly deduced from the one of cisPt44,45. Latest findings 
suggest that oxaliPt rapidly reacts with Cl¯ forming a ring opened intermediate ([Pt(DACH)Cl(ox)]) 
which is then converted to [Pt(DACH)Cl2]. The last one could be then hydrolysed to its monoaquated 
and diaquated complex. The diaquated species is supposed to be the most active one40,46 (Figure 2.25). 
This could explain the behaviour observed in our study where upon KCl addition the platination yield 
increased. Most probably the presence of Cl¯  leads to the formation of [Pt(DACH)Cl2]. This complex, 
after replacement of the Cl¯ ligands, forms aquated complexes, which are known to be more reactive 
compared to the parent compound47. However, the complete mechanism of action of oxaliplatin is more 
complicated than that. For example, it has been reported that the oxalate ligand can be detached also in 
aqueous solution leading to the formation of the aquated platinum complexes37,46,48,49. Additionally, 
computational studies have shown that under neutral conditions the oxalate ring-opening is the rate-
determining step49. Summing up, the increased platination yield observed in our study is most probably 
related to oxaliPt degradation in the presence of KCl. Interestingly, the use of NaCl to increase the speed 
of the formation of active species in reactions containing oxaliplatin was already reported in the 
literature50.  
 
Figure 2.25: Proposed reaction mechanism for the activation of oxaliplatin in the presence of chloride40. 
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2.4.4 Conclusion for the oxaliplatin platination reactions 
The experiments commented above showed that the reaction of 5 eq of oxaliplatin with 0.25 mM  
D1-27, in the presence of 120 mM KCl, for 1 day at 25 °C led to the formation of platinated species 
responsible for a well-defined upper band in the gels. The platination yield was about 50 %, and mass 
spectra confirmed that the platinated species consisted mainly of monoplatinated RNA. During the 
investigation of the platination conditions it was found that the presence of Cl¯ was beneficial for the 
increase of the platination yield. The quality of the gels was significantly improved by running the gel 
at lower temperature (4 °C) and increasing the percentage of the gel solution from 15 % to 20 %. 
Because of the better gel band separation, unreacted RNA was not anymore present in the samples 
isolated from the upper band. However, the upper band always contained a small amount of diplatinated 
RNA together with monoplatinated RNA species. Effort was put to separate the diplatinated RNA 
species from the monoplatinated ones using HPLC, and this will be described in detail in the next part 
of this chapter (Paragraph 2.8). In Figure 2.26, it is depicted an example gel obtained for the platination 
reaction of oxaliPt with D1-27 using the experimental conditions mentioned above. Upon platination a 
slower migrating band, containing platinated RNA was formed. All the three bands on the gel were cut 
and the RNA samples were characterized with MALDI-MS. The band corresponding to the control 
(Figure 2.26, blue frame) consisted, as expected, of unreacted RNA. The extra peaks on its MS spectrum 
(Figure 2.26, blue line spectrum) correspond to RNAs with different number of phosphate groups at the 
5ʹ-end, which results from the hydrolysis of the phosphate groups during in vitro transcription 
(Paragraph 2.3.7, Figure 2.14). The behaviour of the RNA during the MS measurement will be 
discussed in detail in the next part of this chapter (Paragraph 2.7). The upper band (Figure 2.26, red line 
spectrum) contains monoplatinated and diplatinated D1-27, with the monoplatinated one being the 
major specie. The extra peaks are due to platinated D1-27 containing different number of phosphate 
groups. Finally, the lower band (Figure 2.26, green line), which was expected to contain only unreacted 
RNA, consisted mainly of unreacted RNA, but minor peaks were present in the mass spectrum, which 
could be attributed to monoplatinated and diplatinated RNA species. The presence of platinated RNA 
species in both upper and lower band was also reported upon RNA platination with cisPt, and it was 
justified as secondary products which were created from slower platination reactions once the main 
platination sites were occupied13. Only the platinated species contained in the upper band, which 
corresponds to the major species, was further characterized. Unfortunately, the Pt(II)-RNA adducts 
found in the lower band were always in little amount and migrate together with unreacted RNA. 
Consequently, no further characterization on these species was performed.  
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Figure 2.26: 20 % denaturing PAGE for the platination reaction of D1-27 with oxaliPt, using the optimal 
experimental conditions found for oxaliPt. These conditions are: 0.25 mM D1-27 incubated with 5 eq of oxaliPt 
at 25 °C for 1 day in 120 mM KCl solution. The gel was run at 4 °C. Characteristic mass spectra from the control, 
upper and lower bands are depicted (Appendix 1, A 1.19 - A 1.21).  
 
2.5 Comparison of cisPt and oxaliPt platination reactions – Conclusions 
Sections 2.3 and 2.4 described the optimization of the platination conditions carried out in order to  
1) obtain a well-defined and well-separated upper band on the gel, which would likely corresponds to 
single monoplatinated species, and to 2) obtain the highest platination yield, with the lowest number of 
multiplatinated products. In the case of cisplatin, the best separation between unreacted and platinated 
species and the highest platination yield was obtained by reacting 0.1 mM of D1-27 with  
1 eq of monoaquated cisPt for 2 days at 37 °C in ddH2O, while in the case of oxaliplatin by reacting 
0.25 mM of D1-27 with 5 eq of oxaliPt, in the presence of 120 mM KCl, for 1 day at 25 °C. The 
platination yield in the case of cisPt was about 20 – 25 % while for oxaliPt was varying between 50 and 
60 %. The first advantage of oxaliPt over cisPt was the higher platination yield achieved. Additionally, 
the slower migrating band appearing upon platination in the case of cisPt was always less defined 
compared to the one from the reaction with oxaliPt. This not well-defined band may be due to the 
absence of a preferential binding site or to the fact that, upon platination of a preferable site, other 
slower platination reactions are taking place at other sites, giving rise to products, which are not well-
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separated on the gel. This behaviour could be related to both faster kinetics compared to oxaliPt as well 
as to the lack for a strong preferential binding site. The platinum(II) complexes are bound to DNA upon 
hydrolysis of their leaving group7,45,49. Cisplatin leaving groups are the two chloride ligands while for 
oxaliplatin is the oxalate ligand7,30. The chlorides of cisPt are good leaving groups and are faster 
substituted by water molecules compared to the oxalate group of oxaliPt7,49. Additionally, as discussed 
before (Paragraph 2.4.3) the formation of the active oxaliPt species is not really well understood but it 
is supposed to be more complicated compared to cisPt given that more steps are required before the 
formation of the aquated species31,37–40,43,46,48,49. Therefore, cisPt is expected to react faster compared to 
oxaliPt. The Pt(II)-RNA species formed with oxaliPt are more bulky compared to the adducts with 
cisPt32,34,35 meaning that, in principle, less platinum moieties could be accommodated per RNA in the 
case of oxaliPt compared to cisPt. It has been suggested that the different non-leaving groups contribute 
to the different anticancer activity of the two platinum drugs7,32,45,49. The more compact bands formed 
upon RNA platination with oxaliPt suggest that similar Pt(II)-RNA species were formed, which could 
indicate the existence of a preferential binding site for oxaliplatin. To get a better picture about the 
different behaviour of the two platinum(II) complexes, platination of RNA was performed with both 
complexes, using the experimental conditions which led to the formation of a well-separated upper band 
on the gel in the case of oxaliPt (Figure 2.27, conditions commented in Paragraph 2.4.4). Interestingly, 
under these conditions, only a dispersed smeary band was visible in the case of cisPt, suggesting the 
formation of many differently multiplatinated RNA species. This behaviour may be due to the faster 
kinetics of cisPt as well as the lack of a specific binding site, which would prevent the formation of a 
homogeneously platinated RNA sample.  
For all these reasons, this work focuses on oxaliplatin as RNA platination agent, and the discussion 
about the methods used for the isolation of monoplatinated RNA, in the next part of this chapter 
(2.7 - 2.9), as well as the characterization of the Pt(II)-RNA adducts, that will be described in chapter 4 
will all be referred to the platinated RNA species formed upon RNA reaction with oxaliPt. 
 
Figure 2.27: 15 % denaturing PAGE for the platination reaction of D1-27 with 
oxaliPt (lane A) and cisPt (lane B) using the optimal conditions found for 
oxaliPt. (0.25 mM D1-27 incubated with 5 eq of oxaliPt at 25 °C for 1 day in 
120 mM KCl solution). C=control. The gel was run at room temperature.  
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2.6 Platination of RNA 26 with oxaliplatin 
Once oxaliPt was chosen as an appropriate platination agent for our study and the platination reaction 
conditions which could lead to well separated and homogeneous Pt(II)-RNA adducts were found using 
D1-27, the next step was to study the influence of structural RNA features on the platination reaction. 
For that reason, a 26nt long RNA construct (RNA 26) was used (Figure 2.28, right). RNA 26 is the 
analogue of D1-27 without the internal loop. Internal loops are structural motifs which can be found in 
many RNAs and are important for RNAs functions and folding51,52. D1-27 contains an asymmetric loop, 
with three stacked adenines capped by a U-U mismatch and a G-U wobble base pair53 (Chapter 1, 
Paragraph 1.1.4). The aim of the platination of RNA 26 was to obtain information on the influence of 
this internal loop on the platination sites.  
 
Figure 2.28: Secondary structures of D1-27 (left) and RNA 26 (right). 
 
The platination of RNA 26 was performed using 5 eq of oxaliPt, 0.25 mM RNA, and incubation for  
1 day at 25 °C in 120 mM KCl. The gel picture corresponding to this platination reaction was different 
compared to what observed in the case of D1-27. Indeed, no well-defined slower migrating band was 
observed. However, the band corresponding to Pt(II)-RNA 26 was cut, and the platinated RNA species 
were isolated and analysed with MALDI–MS. They consisted of monoplatinated RNA species and 
unreacted RNA (Appendix 1, A 1.22). In this case, contrarily to what observed in the case of D1-27, no 
diplatinated RNA species were formed. The absence of a second well-defined band in the case of RNA 
26 may be due to different distortion of the two constructs upon platination, and therefore different 
migration on the gel. However, it should be noted that RNA 26 migrates much faster than expected in 
the denaturing PAGE. Indeed, the two RNAs differ only by one nucleotide, and much lower separation 
in their migration was to be expected. The faster migration of RNA 26 indicates that probably it was 
not fully denatured under our working conditions, and this may also influence the gel migration of the 
corresponding platinated species.  
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In order to be able to expand the comparison of the two RNAs and get information on the platinum 
binding sites, their platinated adducts must be characterized. The use of RNA 26 as RNA target for 
oxaliPt will be discussed in chapter 3 (Paragraph 3.3.3).  
 
 
Figure 2.29: 20 % denaturing PAGE for the platination reaction of deph-D1-27 and deph-RNA 26 with oxaliPt, 
using the optimal experimental conditions found for oxaliPt. These conditions are: 0.25 mM RNA incubated with 
5 eq of oxaliPt at 25 °C for 1 day in 120 mM KCl solution. The gel was run at 4 °C. 
 
2.7 Matrix-assisted laser desorption ionization (MALDI-MS) for the 
characterization of the platinated RNA 
As described in the previous paragraphs, upon platination a new slower migrating band was observed 
on the gel (Paragraphs 2.3 - 2.4). The platinated RNA species were extracted from the gel pieces and 
MALDI-MS was used for their identification. Application of MS-based techniques such as MALDI and 
ESI are widely used to acquire information about the sequence and fragmentation of oligonucleotides54 
as well as metal-DNA55 and metal-RNA interactions56. In MALDI mass spectrometry singly charged 
oligonucleotide ions are formed. In the positive-ion mode, protonated ions of the form (M+H)+ are 
formed while in the negative ion-mode the corresponding deprotonated ions are formed (M ̶ H)¯. Unlike 
MALDI, with ESI a range of multiply charged ions of the form (M+nH)n+ or (M ̶ nH)n¯ are produced, 
depending on whether the positive or negative ion-mode is used. This tendency to form multiply 
charged ions, increases the complexity of ESI spectra compared to MALDI spectra. Additionally, the 
ESI instrumentation is more complex making the MALDI-based approach more favourable57. MALDI-
MS can be used in general for the characterization of oligonucleotides and nucleic acids58. It has been 
used for the analysis of RNA cleavage54, for the identification of RNA modifications59, as well as for 
the characterization of metallated DNA and RNA. For example, it was employed for the 
characterization of platinum(II)-RNA13,56,60,61 and platinum(II)-DNA complexes2,58,62,63. Literature data 
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on the interaction of nucleic acids with metal complexes other that platinum(II) compounds, like Ru(II) 
and Rh(III) complexes, are also available55,64.  
In MALDI-MS in order to improve the spectra quality factors like sample preparation, matrices, 
matrices additives, laser wavelength as well as laser power should be taken into consideration. For our 
study, the sample preparation had a key role. RNA has the tendency to form Na(I) and K(I) adducts; for 
this reason it is important to eliminate residual cations during the sample preparation procedure57. This 
is normally achieved by desalting the samples. The desalting was performed either by NAP columns or 
electroelution (Chapter 5, Paragraphs 5.1.2.3 - 5.1.2.4). Additionally to this, C18 reverse-phase pipette 
tips such as ZipTips were used. An important source of cations during the preparation of the platinated 
RNAs was the "crush and soak" buffer. This buffer was used in order to extract the RNA samples from 
the gels. It consisted of 250 mM NaOAc, 10 mM MOPS and 1 mM EDTA. Using this buffer, despite 
the desalting step, the quality of the mass spectra was low due to the presence of numerous Na(I) adducts 
(Figure 2.30, left). To overcome this problem, NaOAc was replaced by NH4OAc at the same 
concentration. The ammonium salts of the oligonucleotides can easier lose ammonia after proton loss 
during the desorption process resulting in homogeneous oligonucleotide ions28. With the use of the new 
buffer, the quality of the mass spectra was improved (Figure 2.30, right).  
 
Figure 2.30: Mass spectra of samples that were isolated with the use of NaOAc (left) and NH4OAc (right).  
 
The RNA and Pt(II)-RNA samples were analysed in the negative-ion mode with THAP  
(2,3,4-trihydroxyacetophenone) as matrix. A typical mass spectrum of D1-27 is given in Figure 2.31. 
In addition to the peak corresponding to D1-27 (m/z = 8848), peaks for the RNA with different number 
of phosphate groups were also observed (m/z = 8766 and m/z = 8694) (Table 2.1). As it was previously 
mentioned, the RNA used was transcribed in vitro and upon transcription there was a triphosphate group 
at the 5ʹ-end. Under the experimental conditions of the transcription, hydrolysis of the phosphate group 
could take place (Figure 2.14). The hydrolysis of the phosphates occurs by SN2 mechanism and is 
dependent on Mg(II) ions. The presence of RNA molecules containing different number of phosphates 
is confirmed by analytical denaturing gels run on freshly transcribed RNA (Figure 2.31). The 
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appearance of more than one band on the gels resulted from the longer running time (2 days instead of 
1 day) used. Additionally to this, it is known that the phosphate ester bonds of the triphosphate could 
be cleaved during the ionization process of MS measurement leading also to the formation of RNA 
species with different number of phosphate groups28.  
 
Figure 2.31: 20 % denaturing PAGE corresponding to D1-27 (left) and a characteristic mass spectra of D1-27 
(right). The gel was run for 2 days at 4 °C. In Table 2.1 are given the expected and measured m/z values for this 
sample. 
Table 2.1 
RNA species Expected m/z Measured m/z 
D1-27 8848 8848 
D1-27  ̶  {HPO3} 8768 8766 
D1-27  ̶  2{HPO3} 8688 8694 
D1-27  ̶  CMP 8542 8542 
 
Besides these peaks, a peak corresponding to D1-27 missing a cytidine monophosphate (m/z = 8542) 
unit was often observed in the mass spectra. The fragmentation of RNA during MS measurements is 
well established28,29. The possible fragmentation sites in oligonucleotides are given in Figure 2.32. 
There are four possible sites along the phosphodiester backbone, denoted as w, x, y, z when the fragment 
ion contains the 3ʹ terminus. The number in subscript gives the number of bases from the termini. The 
C indicates the cytosine. In the case of D1-27 the x1 fragment was observed, which corresponds to the 
loss of 305 Da. 
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Figure 2.32: Possible fragmentation sites in oligonucleotides and nomenclature 
proposed by McLuckey et al65.  
 
 
 
 
In the case of oxaliPt, an increase in mass by 309 or 618 Da is expected upon coordination of one or 
two Pt(DACH) moieties respectively, accompanied by the loss of the oxalate ligand. Due to the presence 
of a triphosphate group at the 5ʹ-end of D1-27, additional peaks, which corresponded to monoplatinated 
and diplatinated RNAs with different number of phosphate groups at their 5ʹ-end could also be observed 
(Figure 2.33). For example in the case of monoplatinated D1-27, peaks corresponding to [RNA + 1Pt – 
1{HPO3}] (m/z = 9070), [RNA + 1Pt – 2{HPO3}] (m/z = 8999) could be observed additionally to the 
major peak for the [RNA + 1Pt] (m/z = 9151) species (Figure 2.34). Unfortunately, the isotopic pattern 
of platinum is not observed in the MS spectra, the reason for that being the use of the linear ionization 
mode which shows reduced resolution compared to the reflectron mode58. The experimental masses 
obtained were in accordance with the predicted masses. For small oligonucleotides, typical errors are 
between 0.03 % - 0.05 % while for larger oligonucleotides the mass errors could reach 0.3 %. Therefore, 
the measurement errors observed here (< 0.1 %) were all within the limit58. 
 
Figure 2.33: Schematic representation of an A-form RNA with different number of 5'-phosphate groups together 
with possible monoplatinated species formed. α, β, γ indicate the three phosphates in the triphosphate group. 
Cartoons prepared with ChemDraw Pro 13.0. 
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Figure 2.34: A characteristic mass spectrum of platinated D1-27 with oxaliPt. In Table 2.2 are given the expected 
and measured m/z values for this sample.  
Table 2.2 
Pt-RNA species Expected m/z Measured m/z 
Monoplatinated D1-27 9157 9151 
Monoplatinated D1-27   ̶ {HPO3} 9077 9070 
Monoplatinated D1-27   ̶ 2{HPO3} 8998 8999 
Diplatinated D1-27 9467 9459 
Diplatinated D1-27  ̶  {HPO3} 9387 9379 
 
2.8 Isolation of the monoplatinated RNA 
As commented in section 2.4, when the platination was performed in the presence of 5 eq of oxaliPt, in 
120 mM KCl at 25 °C for 1 day, a slower migrating band was observed on the gels. This band was cut 
and the platinated RNA was isolated and characterized with MALDI–MS. The MS measurements 
showed that under these reaction conditions the predominant species was the monoplatinated RNA; 
however, there were always additional lower-intensity peaks corresponding to diplatinated RNA 
(Figure 2.34). It was not possible to avoid the formation of the diplatinated species nor to separate them 
from the monoplatinated ones via denaturing PAGE. For this reason, we explored the use of High 
Performance Liquid Chromatography (HPLC) for the separation of our various platinated RNA 
species66. HPLC has been widely used to assess the purity of oligonucleotides67, to separate differently 
platinated DNA species68 as well as to perform kinetic measurements of platination reactions68,69. 
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2.8.1 Ion-Pair Reversed Phase HPLC (IP RP HPLC) 
IP RP HPLC is a well-recognized method for the analysis of RNA66. It is used for the separation of 
different RNA species, quantification and purification. Ion-pairing agents are large ionic molecules 
which have a charge which is opposite of the sample of interest. These reagents are added in small 
concentrations to the mobile phase; their hydrophobic region associates with the non-polar stationary 
phase while the charged region interacts with the sample of interest. This interaction affects the affinity 
of the sample for the stationary phase leading to higher resolution67. Since we work with RNA, which 
is negatively charged, the positively charged triethylammonium acetate (TEAA) (buffer A) was used 
as ion-pairing agent. The negatively charged RNA backbone is ion paired with the triethylammonium 
ions resulting in the separation of the charged species according to their charged state. The molecules 
are released from the stationary phase by increasing the amount of a nonpolar solvent. For our study 
acetonitrile was used (buffer B). The order of elution depends mostly on: 1) the charge of the 
oligonucleotide: the retention time increased proportionally to the number of charges in the 
oligonucleotide, 2) the length of alkyl chain in the ion-pairing reagent: extended retention is the result 
of increased hydrophobicity in the ion-pairing reagent, 3) the proportion of the organic solvent in the 
mobile phase: the retention time is decreased while the concentration of organic solvent is increased67. 
By using HPLC we were aiming at separating the monoplatinated from the diplatinated D1-27. In order 
to do that, it was necessary to first establish a method, which could give rise to a single well-resolved 
peak for D1-27 alone. For that reason, different stationary phases and gradients of buffer B were tested. 
All the columns used contained C18 bonded phase packing. C18 columns are mostly used in studies of 
RNA platination5,69. The first method for testing them was method 1 (Chapter 5, Paragraph 5.5.3_ 
Method 1) and the columns tested were:  
RP cross-linked poly(styrene-co-divinylbenzene) polymer PRP® –h1 column (5 μm, 
4.6 x 250 mm) from Hamilton 
RP Ultraphere® (5 μm, 4.6 x 250 mm) from Beckman & Coultier 
Macherey-Nagel Nucleodur column, Gravity column (5 μm, 4 x 250 mm) 
RP X-Bridge column (3.5 μm, 4.6 x 150 mm) from Waters 
D1-27 was dissolved in ddH2O and a 0.4 nmol sample was injected. In the case of column 1, a low 
resolution peak corresponding to D1-27 was eluted at 19.7 min while by using column 2 a very small 
broad peak was observed at 19.4 min. The RNA peak was better when column 3 was used, but it was 
still too broad and asymmetric (Figure 2.35). 
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Figure 2.35: HPLC traces obtained for D1-27 using column 1 (left), column 2 (middle) and column 3 (right). 
Method 1, Flow rate: 1 mL / min, Buffer A: 23 mM TEAA, pH 7, Buffer B: Acetonitrile. 
 
The best result was achieved by using column 4. A well resolved but tailing peak appeared after  
21 min (Figure 2.36, left). The difference in retention time observed for the four different C18 columns 
may be attributed to differences in silica support or to the stationary phase chemistry67. The best 
performance was obtained with column 4, which was then used for the rest of the study. The shape of 
the peak was improved by increasing the gradient slope as well as by changing the TEAA concentration 
from 23 mM to 100 mM (Chapter 5, Paragraph 5.5.3_ Method 2) (Figure 2.36, right).  
 
Figure 2.36: HPLC traces obtained for D1-27 with column 4 using method 1 (left) and method 2 (right). Left 
chromatogram: Method 1, Flow rate: 0.5 mL / min, Buffer A: 23 mM TEAA, pH 7, Buffer B: Acetonitrile; Right 
chromatogram: Method 2, Flow rate: 0.5 mL / min, Buffer A: 100 mM TEAA, pH 7, Buffer B: Acetonitrile. 
 
Upon platination of D1-27 with oxaliPt (5 eq of platinum(II) complex, 0.25 mM RNA, 120 mM KCl, 
1 day at 25 °C) the sample was purified with a denaturing gel and the upper band was cut. The platinated 
RNA species were isolated from the band and injected in the HPLC machine (method 2) giving the red 
chromatogram in Figure 2.37. An RNA sample was injected separately and the chromatograms were 
overlaid. As shown in Figure 2.37 the retention time of the RNA and the Pt(II)-RNA species are very 
close, even if the two peaks correspond to two different species. The shorter retention time for RNA in 
Figure 2.37 compared to Figure 2.36 (10.8 vs 14 min) was due to the fact that a higher flow rate was 
used (1 mL / min vs 0.5 mL / min). Interestingly, the platinated RNA had shorter retention time 
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compared to the unreacted one. It is known that with the use of IP RP HPLC by increasing the gradient 
of the organic solvent, the smaller fragments are eluting first from the column. Here the platinated 
molecules were eluted first independently of their higher molecular weight. Similar behaviour was 
reported also by Papsai et al5 when using similar experimental conditions. This is likely because the 
mechanism by which the RNA samples are separated is more complicated, and does not simply rely on 
mass differences. Instead, more variables, like the overall charge as well as structural conformation, 
have to be taken into consideration. For instance, it is known that dsRNA elute faster compared to 
dsDNA species. Due to the different structural conformation that they adopt (A-form for RNA and  
B-form for DNA) the hydrophobicity of RNA is decreased compared to DNA and therefore RNA elutes 
first70.  
 
Figure 2.37: Chromatograms of D1-27 (black) 
and platinated D1-27 (red). Method 2, Flow rate: 
1 mL / min, Buffer A: 100 mM TEAA, pH 7, Buffer 
B: Acetonitrile.  
 
 
 
From MALDI-MS analysis of the sample before injection, it was known that it consisted of a mixture 
of monoplatinated and diplatinated RNA (Figure 2.34), with the monoplatinated species being the main 
one. With the use of HPLC we were aiming at separating and quantifying these two species.  
 
  
Figure 2.38: Chromatogram of the platinated D1-27 (left) and the MALDI mass spectrum (right) of the sample 
collected between 10.6 and 10.8 minutes, corresponding to the main peak in the chromatogram. Method 2, Flow 
rate: 1 mL / min, Buffer A: 100 mM TEAA, pH 7, Buffer B: Acetonitrile.  
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First, the attribution of the peaks appearing in the chromatogram had to take place. The main peak, 
which was thought to contain the monoplatinated RNA, was collected (from 10.6 to 10.8 min, Figure 
2.38) and analysed by MALDI-MS. A mixture of monoplatinated and diplatinated RNA was again the 
result of the MALDI-MS characterization (Figure 2.38, right). This result suggests that the two species 
eluted together and they were not separated. To solve this problem, the gradient used had to be further 
optimized in order to achieve a better separation of the two species. Towards this direction, the slope of 
the gradient was decreased. This had as a result to increase the peak resolution71 and a shoulder 
corresponding to the diplatinated RNA species appeared (Figure 2.39, black line). To confirm that the 
shoulder corresponds to diplatinated RNA, the platination reaction was repeated using 10 eq of oxaliPt 
instead of 5 eq, and it was allowed to proceed for 2 days instead of 1, which leads to the formation of 
more diplatinated RNA species (Appendix 1, A 1.23). The presence of increased amount of diplatinated 
RNA resulted in the increase of its peak on the chromatogram. Indeed, the intensity of the shoulder 
besides the main peak increased, confirming its attribution to the diplatinated species (Appendix 1, A 
1.24). Different gradients were tested to obtain the best separation between monoplatinated and 
diplatinated species: the smaller the slope used, the more pronounced the shoulder was (Figure 2.39). 
The method used in the case of the blue chromatogram (Figure 2.39) led to a better separated peak for 
the diplatinated species, and was then chosen for the following experiments (Method 5). 
 
Figure 2.39: Method optimization for the separation of monoplatinated and diplatinated D1-27. The gradient 
slope is decreasing from the left to the right. Black line: Method 3, Red line: Method 4, Blue line: Method 5, Flow 
rate: 1 mL / min, Buffer A: 100 mM TEAA, pH 7, Buffer B: Acetonitrile.  
 
A new platinated sample was prepared and it was injected in the HPLC machine using this new method 
(Method 5). The chromatogram obtained is shown in Figure 2.40. The main peak was collected and 
analyzed via MALDI-MS (Figure 2.40, right). The mass spectrum showed that the collected sample 
contained only monoplatinated RNA (m/z = 9154) (Figure 2.40). The procedure was repeated in order 
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to collect higher amounts of monoplatinated RNA for further studies but the result was unfortunately 
not reproducible, and a small amount of diplatinated species was always present in the collected 
samples. The chromatograms of the mixture was used to quantify the two platinated species. From that, 
it was found that the diplatinated species corresponded the 12 % of the sample while the monoplatinated 
one was the 88 %. The quantification of the platinated RNA species was however not very precise due 
to the presence of Pt(II)-RNA adducts with different number of phosphate groups, which are all 
expected to have different retention time. The way that we approached and solved this problem will be 
discussed in paragraph 2.9. Finally, considering that this amount of diplatinated RNA was the smallest 
possible that we could achieve, this mixture was used for further characterization (Chapter 4).  
 
Figure 2.40: Experimental procedure followed for the isolation of monoplatinated D1-27. From the left to the 
right are depicted the gel corresponding to the platination reaction, the HPLC chromatogram of the platinated 
RNA species isolated from the upper band (blue frame) and the mass spectrum corresponding to the species 
responsible for the main peak in the chromatogram. Method gradient 5, Flow rate: 1 mL / min, Buffer A: 
100 mM TEAA, pH 7, Buffer B: Acetonitrile. The higher platination yield observed with respect to the previous 
gels is because of the use of 200 mM KCl instead of 120 mM.  
 
2.8.2 Use of IP RP HPLC for sample isolation and purification 
By using denaturing PAGE the separation of the unreacted from the platinated species was successful 
but no separation between monoplatinated and diplatinated RNA was ever achieved. Since 
IP RP HPLC can be successfully used to separate various platinated species (see above), we evaluated 
the possibility of substituting dPAGE separation with HPLC separation. The platination reaction was 
performed following the experimental conditions commented above (5 eq of platinum, 0.25 mM RNA, 
120 mM KCl, 1 day at 25 °C) and then, instead of using denaturing PAGE, the reaction mixture was 
directly injected in the HPLC machine. The chromatogram obtained this time corresponds to the whole 
platination reaction mixture, and therefore two main peaks were observed (one for the unreacted and 
one for the platinated RNA, Figure 2.41, black line). Since the aim was to collect the platinated RNA, 
the retention times of the two peaks had to be further separated. Indeed, by using the methods explored 
until now, the retention times of the RNA and the Pt(II)-RNA species were very close (Figure 2.37), 
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making difficult the collection of only platinated RNA species. The optimization of the method took 
place by changing the slope of the gradient. More specifically, by decreasing the slope, better separation 
of the unreacted from the platinated RNA was achieved (Figure 2.41). The method chosen corresponds 
to the red chromatogram (Method 7) in which the main peak (15.6 min), which corresponds to the 
platinated RNA, was well-separated from the peak corresponding to the unreacted RNA (17.4 min) 
(Figure 2.41).  
 
Figure 2.41: Chromatograms corresponding to 
two different methods tested to optimize the 
separation of the peaks of platinated and 
unreacted RNA. The gradient slope is decreasing 
from the left to the right. Black line: Method 6, 
Flow rate: 1 mL / min, Buffer A: 100 mM TEAA, 
pH 7, Buffer B: Acetonitrile. Red line: Method 7, 
Flow rate: 1 mL / min, Buffer A: 100 mM TEAA, 
pH 7, Buffer B: Acetonitrile. Both 
chromatograms in Figure 2.41 correspond to the 
same sample and the different peak shape is due 
to the use of a different gradient slope.  
 
Having a good HPLC method, which allowed a better separation of the untreated from the platinated 
RNA (Figure 2.41, red line), the platination reaction mixture was prepared and injected once 
immediately after the start of the reaction (Figure 2.42, upper panel, left) and once after 1 day of 
incubation (Figure 2.42, upper panel, right). The comparison between the two chromatograms obtained 
at the beginning and at the end of the platination reaction confirmed the attribution of the peak at 17.4 
min to the unreacted RNA. This was indeed the main peak at the beginning of the reaction, which after 
1 day of incubation was reduced, whereas the intensity of the peak at 15.6 min increased, confirming 
its attribution to the platinated RNA. The area below the peaks denoted with a circle and with a square 
(Figure 2.42, upper panel, right) were collected and analysed with MALDI-MS. The mass spectrum of 
the sample corresponding to the main peak (yellow circle, Figure 2.42, lower panel, left) showed as 
major species the monoplatinated RNA [(m/z = 9156: (D1-27 + 1Pt), m/z = 9075: (D1-27 + 1Pt – 
1{HPO3})], in addition to a smaller peak corresponding to diplatinated species [(m/z = 9383: (D1-27 + 
2Pt – 1{HPO3}), m/z = 9463: (D1-27 + 1Pt)]. On the contrary, the mass spectrum of the sample 
corresponding to the peaks denoted with a square in the chromatogram (Figure 2.42, lower panel, right) 
shows a mixture of monoplatinated and diplatinated RNA species with similar intensity.  
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Figure 2.42: Upper panels: Chromatograms from the direct injection of the platination reaction mixture in the 
beginning of the reaction (left) and after 1 day of incubation (right). An improved gradient (method 7) was 
employed to better separate the unreacted from the platinated RNA. The peak under the circle and the square 
were collected and analysed with MALDI-MS. Lower panels: The MALDI-MS spectra of the collected peaks.  
 
Interestingly, even if the gradient used in this case (Figure 2.41, red line, method 7) was less steep 
compared to the one used while attempting to separate monoplatinated from diplatinated RNA (Figure 
2.39, blue line), it was still not possible to separate the diplatinated RNA from the monoplatinated one. 
Additionally, mass spectra showed that both collected samples contained a mixture of mono- and 
diplatinated RNAs. A reason for this behaviour could be the heterogeneity of D1-27 due to the presence 
of a different number of phosphate groups at the 5´-end. Indeed, the RNA samples in aqueous solution 
consist mostly of the species with the triphosphate, but RNA species with two or only one phosphate 
group at the 5ʹ-end are present (Paragraph 2.7, Figure 2.33). Upon platination there is formation of 
platinated species with three, two or one phosphate group and all of them, due to different overall 
negative charge, interact with the stationary phase of the column differently and therefore are eluted at 
different times. According to the information from MS data, the main peak observed in the 
chromatogram corresponds to a sample containing mostly the monoplatinated species with  
5ʹ-triphosphate (Figure 2.42). Indeed, the mass spectrum shows a main peak corresponding to the 
monoplatinated specie with 5ʹ-triphosphate together with a peak with lower intensity, corresponding to 
diplatinated species with 5ʹ-triphosphate. Additionally to these peaks, lower intensity peaks were 
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observed, corresponding to monoplatinated and diplatinated species with two phosphate groups at the 
5ʹ-end. The different number of the phosphate groups may then be the reason why it was not possible 
to separate the monoplatinated from the diplatinated RNA with IP RP HPLC (Paragraph 2.8.1). 
Summing up, the use of HPLC as an alternative way to separate the platinated RNA species from the 
unreacted ones, instead of denaturing PAGE, was explored. With this approach, the separation of the 
monoplatinated from the diplatinated RNAs was also attempted. However, due to the heterogeneity of 
the RNA used and, consequently, of the platinated RNA species formed, the separation of the differently 
platinated RNA species was not feasible. Since there was no advantage in using HPLC instead of 
dPAGE for sample separation, the latter was used for the rest of this study. 
 
2.9 Use of dephosphorylated RNA for platination reactions 
The data above suggest that the heterogeneity due to the presence of different number of phosphate 
groups per RNA could be the reason for not separating the monoplatinated from the diplatinated RNA. 
In the direction of obtaining a homogeneous RNA sample, D1-27 was dephosphorylated before being 
used for the platination reactions. The large scale RNA dephosphorylation is described in detail in the 
experimental part (Chapter 5, Paragraph 5.1.4). Upon dephosphorylation, 1D 31P-NMR experiments, 
MALDI-MS and HPLC analysis were performed in order to evaluate the quality of the sample (Figure 
2.43). The 31P-NMR spectrum shows that upon dephosphorylation the three peaks corresponding to α, 
β and γ phosphate are not present anymore (Figure 2.43, left). The MALDI-MS spectrum of the 
dephosphorylated RNA (deph-RNA) has a peak with m/z = 8612 that corresponds to the deph-D1-27. 
The other peak with m/z = 8307 corresponds to deph-D1-27 without the CMP from the 3ʹ- end (Figure 
2.43, middle). As mentioned before this could be either due to fragmentation during the ionization 
process (Paragraph 2.7) or possibly due to malfunction of the T7 polymerase during the in vitro 
transcription. Finally, the HPLC chromatogram shows only one peak that corresponds to deph-D1-27, 
unlike the chromatogram of triphosphate-D1-27 (triph-D1-27), where peaks for all the species with 
different number of phosphates were observed (Figure 2.43, right). The chromatogram in Figure 2.43 
corresponding to triph-D1-27 (black line, right) is different compared to the one showed above, which 
has only one peak and not four (Figure 2.37). The difference observed is because different methods 
were used in each case. The gradient slope that was used for the sample whose chromatogram is reported 
in Figure 2.37 was steeper compared to the one used in the case of Figure 2.43 (Method 7), and no 
separation of the various RNAs with different phosphate groups was achieved.  
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Figure 2.43: Characterization of deph-D1-27 with 31P-NMR (left), MALDI-MS (middle) and HPLC (right). The 
black line corresponds to triph-D1-27 and the red to dephosphorylated one.  
 
The platination of deph-RNA with oxaliPt was performed using 5 eq of oxaliplatin, 0.25 mM RNA, 
1 day of incubation at 25 °C in 120 mM KCl. Interestingly the gel picture obtained upon platination of 
deph-D1-27 is different from the gel picture obtained in the case of triph-D1-27 (Figure 2.44). More 
specifically when triph-D1-27 was platinated two main bands were visible on the gel and from the 
MALDI-MS analysis the one corresponded to the mixture of monoplatinated and diplatinated RNA 
(upper band) and the second corresponded to a mixture of mostly unreacted RNA as well as 
monoplatinated and diplatinated species (lower band) (Figure 2.26). Upon dephosphorylation three 
main bands were observed and named as upper, middle and lower band (Figure 2.44).  
 
Figure 2.44: 20% denaturing PAGE (19:1 gel solution) for the platination reaction of triph-D1-27 (left) and 
deph-D1-27 (right) with oxaliPt. In the same colours are indicated the bands which had similar MS spectra. The 
gel was run at 4 °C. 
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The three bands were cut and the samples were isolated and characterized via MALDI-MS (Figure 2.45, 
lower panel). The mass spectra showed that the upper band consisted of a mixture of monoplatinated 
(m/z = 8917) and diplatinated deph-RNA (m/z = 9225) (like the upper band obtained in the case of 
triph-RNA) (Figure 2.45, lower panel, left); the middle band was a mixture of unreacted (m/z = 8612), 
monoplatinated (m/z = 8919) and diplatinated deph-RNA species (m/z = 9226) (like the lower band 
obtained in the case of triph-RNA) (Figure 2.45, lower panel, middle) and the lower band contained 
species with the same molecular weight as the upper band, but in different ratio (Figure 2.45, lower 
panel, right). In the lower band the intensity of the peak for the diplatinated deph-RNA (m/z = 9226) 
was higher compared to the sample extracted from the upper band (See Appendix 1,  
A 1.25 - A 1.27). Analysis of the samples from all three bands was performed also via HPLC (Figure 
2.45, upper panels). 
 
 
Figure 2.45: Upper panels: HPLC traces of the platinated species extracted from the upper (green), middle 
(black) and lower (red) band of the denaturing gel. The method 7 was used. Lower panels: MALDI-MS spectra 
of the samples extracted from the three bands (colour code as above). 
 
In the case of the upper band, a main peak was observed at 16.3 min, which was assigned to the 
monoplatinated deph-D1-27, whereas the smaller peak at 15.9 min was assigned to diplatinated  
deph-RNA (Figure 2.45, upper panel, left). This attribution was confirmed by mass spectra recorded on 
the isolated samples, collected at 15.9 and 16.3 minutes (Figure 2.46). The sample eluting at  
15.9 min consisted of monoplatinated (m/z= 8992) and diplatinated deph-RNA (m/z= 9200), with the 
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latter being the major species (Figure 2.46, left), whereas the sample eluting at 16.3 min consisted 
almost completely of monoplatinated deph-RNA (m/z= 8890) and only a minor peak was attributed to 
diplatinated species (m/z= 9202) (Figure 2.46, right). Given that the two peaks can be confidently 
attributed to monoplatinated (16.3 min) and diplatinated (15.9 min) deph-D1-27, their integration was 
used to roughly quantify the two RNA species. The peak integration was performed automatically by 
the HPLC software (Chromeleon 7.1) and it was found that the sample consisted of 84 % of 
monoplatinated and 16 % of diplatinated deph-RNA. 
 
Figure 2.46: The MALDI-MS spectra of the sample collected from the peak at 15.9 min (left) and 16.3 min (right).  
 
The HPLC chromatogram of the middle band had a main peak for the unreacted RNA (19.2 min) and 
some minor peaks which could be attributed to monoplatinated and diplatinated RNA (Figure 2.45, 
upper panel, middle), based on the assignments commented above. The chromatogram of the lower 
band (Figure 2.45, upper panel, right) was more crowded compared to the one from the upper band even 
if their mass spectra were similar. This could be due to either the lower concentration of the sample (the 
HPLC trace of the sample has indeed similar intensity as the impurities), or to the fact that this sample 
consisted of a mixture of RNA species platinated at different sites. The two main peaks at 16 min and 
16.9 min, based on the assignment of the peaks from the upper band (Figure 2.45, upper panel, left) and 
considering the ratio of the products from the mass spectrum, can be attributed to diplatinated and 
monoplatinated RNA respectively. The peaks between 18 and 24 minutes can be considered as 
impurities (the same peaks were present also in the chromatogram of the sample from the upper band). 
Further assignment of the peaks was not performed.  
Concluding, upon platination of deph-D1-27 there was formation of three bands, two of which 
contained monoplatinated and diplatinated species. The main platinated species migrating in the upper 
band was further characterized, and compared with the corresponding one obtained when the platination 
was performed with triph-RNA (Chapter 4). However, to understand the origin of the newly appeared 
band (lower), the platinated species from the lower band was also characterized using various 
techniques, as described in detail at the end of chapter 4. 
89 
 
2.10 Conclusions 
In the first part of the chapter, the reasons why this study was conducted using oxaliplatin as platination 
agent have been discussed. Upon platination, a slower migrating band (upper) was formed and from 
MALDI-MS characterization it was found that it contained a mixture of monoplatinated and 
diplatinated RNA, with the first being the major species. Since no separation between the two species 
was achieved using denaturing PAGE, the use of HPLC was attempted. At first, the appropriate 
stationary phase as well as a method which would allow to obtain well resolved peaks for both RNA 
and platinated RNA were found. Once the HPLC method was optimized, the platinated samples 
extracted from the gel were analysed by HPLC. Unfortunately, despite the optimization, the retention 
time of the mono- and diplatinated RNA were very close, and no successful separation was obtained. 
Next, the use of HPLC for the isolation and purification of the platinated RNAs instead of dPAGE was 
attempted. The platination mixture was directly HPLC injected after the end of the reaction. However, 
no advantage with respect to dPAGE separation was obtained, and all the samples were then purified 
and isolated using denaturing gels. Unfortunately, isolation of pure monoplatinated RNA was not 
possible, likely because of the heterogeneity of the reaction mixture. However, HPLC could be used to 
quantify the diplatinated species (12 %). The heterogeneity observed was the result of the use of RNA 
samples with triphosphate and diphosphate groups at the 5ʹ-end (Figure 2.33), which led to the 
formation of platinated RNA species with different number of phosphate groups (Figure 2.33). In order 
to have a homogeneous starting material for our studies, D1-27 was dephosphorylated before being 
used for platination. The platination of deph-D1-27 resulted in a gel with three bands (Figure 2.44). In 
addition to the slower migrating band observed also in the previous case, a new faster migrating band 
(lower), which consisted of monoplatinated and diplatinated RNA, appeared. By using deph-RNA the 
chromatogram of the platinated RNA species from the upper band was improved (Figure 2.45, left, 
green line) and two main peaks were observed corresponding to monoplatinated and diplatinated RNA. 
Now, contrary to what previously observed, a more homogeneously platinated sample could be isolated 
(Figure 2.46, right), which corresponds to the species eluting at 16.3 min (Figure 2.45, left, up). 
However, this result is preliminary, and further optimization is likely required if the method is to be 
used to obtain large amount of homogeneous sample. Consequently, in all cases the main species that 
will be characterized contain monoplatinated RNA (88 %), but also a small percentage of diplatinated 
RNA (12 %) is present. Chapter 4 is dedicated to the characterization of the platinated species which 
were isolated from the upper band of denaturing gels run on reaction mixtures performed with both 
triph- and deph-D1-27. 
In the next chapter, time evolution NMR experiments will be employed as a way to directly follow the 
platination reactions and get a first indication about which nucleobases are affected upon platination.  
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3 Screening of platination reactions with the use of 
time evolution NMR experiments, PAGE and 
plasmid binding assays  
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3.1 Aim 
The main topic of this chapter is the use of time evolution NMR experiments as a way to directly 
monitoring the platination reactions, which will provide us with a first indication of the possible 
platination sites. In chapter 2 the experimental conditions that allowed to obtain homogeneous 
monoplatinated species (Paragraph 2.5) by reacting D1-27 with oxaliplatin were described. We here 
followed the same platination reactions directly into the NMR tube. The effect of changing platinum 
concentration was also investigated. Towards this direction, time evolution 1H-NMR experiments were 
used to study the interaction of oxaliplatin with different RNA constructs, namely an RNA construct 
without the internal loop (RNA 26), an RNA construct with a different tetraloop  
(D1-27GAAA) and dephosphorylated D1-27 (deph-D1-27). The behaviour of different platination agents, 
namely oxaliplatin, cisplatin and kiteplatin, towards D1-27, was compared via both NMR experiments 
and gel mobility shift assays. Finally, gel mobility shift assays were also used to obtain information 
about the role of Cl¯ and K(I) ions in the platination reactions. Further comparison of the behaviour of 
these three platinum complexes took place by screening of their reaction kinetics with DNA plasmids 
using plasmid binding assays.  
 
3.2 Introduction 
A quick and easy way to detect RNA-platinum(II) interactions is to record time evolution NMR 
experiments and to follow the changes induced in the imino proton region upon platinum(II) addition. 
Figure 3.1 shows the four common RNA nucleobases with the imino protons NH1 of guanine (G) and 
NH3 of uracil (U) indicated in red. Adenine (A) and cytidine (C) do not have imino protons. In free 
bases the imino protons are in fast exchange with the solvent and can therefore not be detected by NMR 
under normal ambient conditions. However, when these protons are involved in stable hydrogen 
bonding the exchange rate slows down and the resonances can be observed in the 1H chemical shift 
range of 10 - 15 ppm1.  
 
Figure 3.1: Structure of the four common bases of RNA, with imino protons in red. Numbering is indicated only 
for guanine and uracil.  
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In folded RNAs stable hydrogen bonds are typically found in double helical regions due to canonical 
base pairing (Figure 3.2, top). However, also loop or bulge regions can have an extensive hydrogen 
bonding network mainly caused by non-canonical base pairing1,2. Consequently, changes in chemical 
shifts and /or intensity of imino resonances upon addition of the platinum reagent can be indicative for 
platination or platinum-induced structural changes3,4. Unfortunately, it is very hard and often even not 
possible to distinguish between direct platination and structural changes induced by close-by platination 
using 1D 1H-NMR experiments. Another drawback of this method is that the imino proton resonances 
are also easily affected by changes in temperature or pH1,2. However, despite these drawbacks, looking 
at the changes of the imino proton resonances is a good qualitative method to identify regions affected 
by interaction with small molecules5 and/ or by platination. In our case, the combination of these data 
with complementary approaches allowed the identification of the platination site(s) (Chapter 4). 
In Figure 3.2 the 1H-NMR imino proton region of D1-27 is depicted at 4 °C (top, red line) and 25 °C 
(bottom, blue line) and all imino proton assignments are indicated6. For the imino proton resonances of 
the nucleobases found in stable base-pairing like U10, U24, G18, G8. G1, G16 and G2 strong peaks are 
observed between 12 and 15 ppm while the imino proton resonances of the nucleobases involved in the 
G-U wobble and -UUCG- tetraloop (U5, G23, U12) were found in the 9 - 12 ppm range. In general, 
lowering the temperature leads to stronger hydrogen bonding and accordingly to a decrease of the imino 
proton exchange rate. Therefore, the resonances at 4 °C have slightly increased overall intensities 
compared to 25 °C. The low intensity of G1NH1 at 25 °C is due to weak hydrogen bond close to  
5ʹ-end7. Similar behaviour was observed also for G23NH1, U5NH3 (G-U wobble) and U12NH3 
(terminal -UUCG- loop) due to their location in non-Watson-Crick regions, and therefore they will not 
be commented during the description of the time evolution NMR experiments. As the optimal 
platination reaction temperature was found to be 25 °C (Chapter 2, Paragraph 2.4.4) all time evolution 
NMR experiments were recorded at this temperature. 
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Figure 3.2: Stack plot of the imino proton region of 1H-NMR spectra of D1-27 at 25 °C (blue line) and 4 °C (red 
line). Top left: Canonical base-pairing between G-C and U-A, Top right: Secondary structure of D1-27. (120 mM 
KCl, pH 6, 600 MHz) 
 
3.3 Time evolution NMR experiments: Oxaliplatin 
OxaliPt (chemical structure on the right) was found to be the most 
appropriate platination agent for this study (Chapter 2, Paragraph 2.5) 
and therefore time evolution NMR experiments were performed to 
follow its platination reaction in the attempt to identify which 
nucleobases are affected upon platination. For these experiments, the experimental conditions used were 
the ones, which were found to favour the maximum platination yield, with the minimum amount of 
diplatinated RNA, i.e. 5 eq of oxaliplatin, 0.25 mM RNA, 1 day of incubation at 25 °C in the presence 
of 120 mM KCl (Chapter 5, Paragraph 5.9). However, for the time evolution NMR experiments lower 
RNA concentration was used. 0.1 mM RNA results in the formation of the same platination adducts 
like 0.25 mM and therefore it was the concentration used for all the time evolution NMR experiments. 
After studying the behaviour of D1-27 in the presence of 5 eq of oxaliplatin, its reaction with different 
amount of platinum(II) complex was also briefly investigated. Then, several RNA constructs (Chapter 
1, Paragraph 1.1.4) were employed in order to study the influence of different structural features on the 
platinum binding sites. At the end, the platination of deph-D1-27 was followed in order to investigate 
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the role of the 5ʹ-end triphosphate group in platinum binding specificity. For all these last reactions, 
5 eq of oxaliplatin were used and the experimental procedure is described in chapter 5 (Paragraph 5.9). 
3.3.1 Investigation of platinum(II) binding sites for the platination of D1-27 with oxaliplatin 
All the reactants were mixed in an NMR tube according to the experimental conditions mentioned 
above. 1D 1H-NMR spectra, focusing on the imino proton region, were recorded before and after the 
addition of oxaliPt every 1 hour for 22 hours (Figure 3.3). The first spectrum (Figure 3.3, blue line) 
corresponds to D1-27 prior the addition of oxaliPt. The overall pattern of the imino proton region after 
22 h of reaction was very similar to the one of the non-platinated sample, but for changes in intensity 
for some peaks. Interestingly, no chemical shift changes were observed (Figure 3.3). To evaluate more 
easily the changes induced upon platination a plot of the percentage of the intensity of each resonance 
over time is shown in Figure 3.3 and the percentage of the intensity decrease for each peak is given in 
Table 3.1. The imino proton resonances of G2, G8 and U25 seem to be the most affected by platination. 
Indeed, after 10 h, their intensity was already significantly decreased, and at the end of the reaction 
(after 22 h) it was reduced by around one half (Figure 3.3, green and red dotted frames, Table 3.1). 
Interestingly, a new peak appeared close to the resonance of G8 (Figure 3.3, green dotted frame). 
Significant intensity reduction was observed also for U10/U24 (Figure 3.3) but given their resonance 
overlap no safe conclusion could be done and they will generally not be considered for the discussion. 
The imino proton resonances of G16 and G18 were only moderately affected while the lowest decrease 
of intensity was observed for the G15 imino proton resonance (Figure 3.3, black dotted frame, Table 
3.1).  
Table 3.1: The percentage of the intensity decrease of the imino 
proton resonances at the end of the time evolution NMR 
experiment for the platination reaction of D1-27 with 5 eq of 
oxaliPt. 
G2 and U25 are found in the first helical part of D1-27 while 
G8 is located in the beginning of the second one and is very 
close to the internal loop (Figure 3.3, top, right). Since 
guanines are possible platination targets, considering the 
significant decrease of the intensity of the imino proton 
resonances of G2 and G8, they could represent possible 
platination sites. On the other hand, the changes of the imino 
proton resonance of U25 could be linked to local structural distortions provoked by close-by platination. 
Taking into consideration that the most abundant Pt(II)-RNA/DNA adducts observed are the 1,2-GG8, 
if platination occurred at G2, G1 would be most likely also involved in platination. Unfortunately the 
G1 imino proton resonance is very weak at this temperature7 therefore it was not possible to obtain any 
information about its behaviour in these conditions. In the case of G8 the possible platination patterns 
Resonance Intensity decrease (%) 
U25 59.9 
G2 58.8 
G8 54.6 
G18 21.3 
G16 19.7 
G15 10.3 
U10/U24 41.5 
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could be either G8-G18 or G8-G23 interstrand cross-links. However, the first scenario is excluded by 
the fact that G18NH1 is only moderately affected by platination. The second is also not very probable, 
first due to the large distance between the two nucleobases and second due to the presence of the stacked 
adenines in the internal loop (Chapter 1, Paragraph 1.1.4) which most probably prohibits the formation 
of a cross-link. However, monodentate interaction at G8 could not be excluded based on these data 
only, and further data will be needed to exclude direct G8 platination (Chapter 4). The intensity of G15 
was almost stable over time suggesting that the terminal loop remained unaffected upon platination 
(Figure 3.3, black dotted frame). 
Figure 3.3: Time evolution 1H-NMR experiments for the platination of D1-27 with oxaliPt (left panel). Right Top: 
Secondary structure of D1-27, Right Bottom: Plot of the percentage of the intensity of the imino proton resonances 
over time. (5 eq of oxaliPt, 0.1 mM RNA, 25 °C, 120 mM KCl, pH 6, 600 MHz) 
 
The same experiment was performed using 1 eq and 20 eq of oxaliPt (Figure 3.4). Only little changes 
are observed in the spectra using 1 eq of oxaliPt, with only a slight decrease for the imino proton 
resonances of G2, G8 and U25, in line with the results commented above (Figure 3.3, green and red 
dotted frames). Using 20 eq of oxaliPt, the imino proton resonances of G2, G8 and U25 almost disappear 
within the first 10 h suggesting preferential interaction at these sites, but afterwards all resonances 
exhibited a strong broadening indicating that non-specific, generalized interaction took place (Figure 
3.4, right panel, green and red dotted frames). Because of the high platinum(II) excess the reaction 
proceeded faster and after the preferential binding sites were occupied, within the first  
10 h, platination also took place in all possible sites. This led to a strong overall decrease of the intensity 
or complete disappearance of the imino proton resonances in the spectrum, likely indicating the 
presence of multiplatinated species (Figure 3.4, right panel). The latter was also confirmed by running 
small scale platination in the presence of 1, 5 and 10 eq of oxaliplatin (Chapter 2, Paragraph 2.4.1), 
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using the same experimental conditions used here. Gels run on the platination mixtures showed that, 
with increasing platinum(II) concentration, the gel bands moved from non-defined / non-separated to 
the formation of a well-defined and better separated gel band which contained mostly monoplatinated 
RNA. At 10 eq of oxaliplatin the band corresponding to unreacted RNA was reduced in intensity, 
indicating faster platination rates while the new well-defined new band formed (upper) contained higher 
amount of diplatinated RNA species (Chapter 2, Paragraph 2.4.1, Figures 2.16 - 2.17). 
 
Figure 3.4: Comparison of the time evolution NMR experiments for the platination of D1-27 with 1 eq and  
20 eq of oxaliPt. Right Top: Secondary structure of D1-27. In the dotted frames are the resonances, which are 
commented in the text. (1 eq and 20 eq of oxaliPt, 0.1 mM RNA, 25 °C, 120 mM KCl, pH 6, 600 MHz)  
 
Figure 3.5: Plot of the percentage of the intensity 
of G2 and G8 imino proton resonances over time 
for 1 eq, 5 eq and 20 eq of oxaliPt. 
Figure 3.5 shows the decrease of the intensity 
percentage of the imino proton resonances of 
G2 and G8 in the three cases. As expected, 
concentration dependency of the reaction is 
observed, with faster platination in the 
presence of higher amount of oxaliplatin. 
Moreover, very interestingly, in all the three cases, G2 and G8 behave very similarly to each other. This 
may be due to contemporary platination of G2 and G8, without preferential binding, or to the fact that 
platination at only one binding site affects also the other nucleotide. This second hypothesis will be 
confirmed by combining these data with data obtained by NMR and different analytic techniques 
collected on isolated monoplatinated samples (Chapter 4). 
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Summing up, the time evolution NMR experiment for the platination reaction of oxaliPt with D1-27 
using the reaction conditions found for oxaliPt (Chapter 2, Paragraph 2.4.4) revealed that G2 and G8 
imino proton resonances were the most affected ones, suggesting interaction at these sites. All other 
resonances, especially the ones of the -UUCG- tetraloop did not show significant changes upon 
platination. Only in the presence of 20 eq of oxaliPt a substantial overall broadening of all resonances 
was observed suggesting non-specific interaction. 
3.3.2 Influence of the terminal tetraloop on platination (-UUCG- vs -GAAA- tetraloop)  
Upon platination of D1-27, the imino proton resonance of G15 in the -UUCG- tetraloop remained 
mostly unaffected but this could be expected taking into consideration the high stability (more compact 
structure) of this tetraloop9. To investigate whether this behaviour was related to this specific tetraloop, 
the -UUCG- was replaced for a -GAAA- one. The new RNA used was named  
D1-27GAAA (Figure 3.6, right panel, top). The -GAAA- tetraloop belongs to the group of GNRAs 
(N=any nucleotide, R=purines) tetraloops, which are the most abundant tetraloop sequences in some 
catalytic RNAs as well as in rRNAs10. The -GAAA- tetraloop is thermodynamically less stable and can 
accommodate more substitutions compared to the -UUCG- one. Additionally this tetraloop often makes 
long-range interactions to other RNA structural elements, with the most famous being the tetraloop 
receptors10 (Paragraph 1.1.4).  
Before running the platination reaction, its 1D 1H-NMR spectrum was assigned. Upon replacement of 
the -UUCG- for a -GAAA- tetraloop, changes were expected for G16NH1 resonance, the imino proton 
resonance of G15 should not be present anymore and a new peak for G12 from the -GAAA- tetraloop, 
should appear. Indeed, as shown in Figure 3.6, a new peak appeared at 10.5 ppm corresponding to 
G12NH1, while G16NH1 was upfield shifted with respect to the spectrum of D1-27. All the other 
resonances remained the same. The assignment was confirmed by a [1H,1H]-NOESY recorded at 4 °C. 
 
Figure 3.6: Left panel: Comparison of the imino proton region of 1H-NMR spectra of D1-27 (bottom) and  
D1-27GAAA (top). Right panel: Secondary structure of D1-27 (bottom) and D1-27GAAA (top). 
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The D1-27GAAA construct was platinated with oxaliPt under the same experimental conditions as above 
(Chapter 2, Paragraph 2.4.4) and the reaction was followed by time evolution 1H-NMR experiments 
(Figure 3.7). Similar to the previous experiment, upon platination of D1-27GAAA the imino proton 
resonances of G2, G8 (Figure 3.7, green and red dotted frames) and U25 showed the largest decrease 
in intensity (Figure 3.7, Table 3.2). The imino proton resonance of G12, which is located at the terminal 
loop, was the next mostly affected resonance (Figure 3.7, black dotted frame) followed by the imino 
proton resonances of G16 and G18. Changes at the G12 site suggests that the  
-GAAA- tetraloop region was affected upon platination. Moreover, G16, which in the previous case 
remained almost unchanged, showed a significant decrease in intensity (Table 3.2).  
Table 3.2: The percentage of the intensity decrease of the imino proton resonances at the end of the time evolution 
NMR experiment for the platination reaction of D1-27GAAA with 5 eq of oxaliPt.
Figure 3.7: Time evolution 1H-NMR experiment for the platination of D1-27GAAA with oxaliPt (left). Right Top: 
Secondary structure of D1-27GAAA, Right Bottom: Plot of the percentage of the intensity of the imino proton 
resonances over time. (5 eq of oxaliPt, 0.1 mM RNA, 25 °C, 120 mM KCl, pH 6, 600 MHz) 
Resonance Intensity decrease (%) 
G2 61.1 
G8 56 
U25 60.4 
G12 47.8 
G16 39.5 
G18 31 
U10 34.3 
U24 11.6 
106 
 
The replacement of the very stable -UUCG- tetraloop for a less stable one (-GAAA-)9 resulted in changes at the 
tetraloop region (G12) and in the neighbouring guanine (G16) suggesting that this area became more susceptible 
to platination. In addition to the high degree of compaction, resulting in great stability, the absence of platination 
at G15-G16 observed in the presence of the -UUCG- tetraloop may be due to the relative orientation of the two 
guanines (Figure 3.8). From the comparison of the NMR solution structures of the two tetraloops, as shown in 
Figure 3.8, it can be seen that in the case of the-UUCG- tetraloop the N7 atoms of G15 and G16 (which represent 
possible platination sites) are pointing at different directions making difficult the formation of intrastrand 
crosslink while in the-GAAA- loop the N7 of the G12 is more exposed. 
In conclusion, the replacement of the -UUCG- tetraloop for the -GAAA- one resulted in similar 
behaviour concerning the changes of the imino proton resonances of the first part of the RNA construct, 
but upon tetraloop replacement, the -GAAA- region was more affected upon platination.  
 
Figure 3.8: NMR solution structures of the -UUCG- tetraloop6 (left) and -GAAA- tetraloop11 (right). The N7 
atoms are indicated with a black arrow. The pictures were prepared with Maestro Schrödinger Version 10.5.014 
using PDB file 2LUO for the -GAAA- tetraloop. 
 
3.3.3 Influence of the internal loop on platination (D1-27 vs RNA 26)  
All time evolution experiments commented until now showed that the imino proton resonances of G2, 
G8 and U25 were always the ones mostly affected. G2 represents a feasible platination site because of 
several reasons. First, it is located at the 5ʹ-end which is a flexible region12; second, the presence of the 
adjacent G1 offers the possibility to form intrastrand platinum cross-link; finally, due to the presence 
of the triphosphate group, the interaction could be favoured by electrostatic attraction. Contrarily, G8 
is located very close to the internal loop and formation of bidentate species would require the formation 
of interstrand cross linked adducts. A possible scenario for the significant changes observed at this site 
could be that platination at the first part of D1-27 causes distortions which, due to the presence of the 
internal loop, could influence the base-pairing at the G8 site. In order to investigate whether the presence 
of the loop plays a role in the observed behaviour, another RNA construct was used which is the 
analogue of the D1-27 without an internal loop (RNA 26) (Figure 3.9, right panel, top).  
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The time evolution NMR experiments on RNA 26 were performed using the same experimental 
conditions used for D1-27. The assignment of the imino proton resonances was performed by 
comparison of the imino proton resonances of D1-27, and confirmed by [1H,1H]-NOESY experiments 
run at 4 °C and 10 °C. After 22 h of interaction most of the imino proton resonances were affected and 
several new peaks appeared. The behaviour observed here refers to the whole platination mixture, and 
the assignment of new peaks would require an isolated homogeneously platinated sample. Isolation of 
a homogeneously platinated sample was not possible in the case of RNA 26 because the platinated RNA 
sample was migrating together with the unreacted RNA (Chapter 2, Paragraph 2.6, Figure 2.29). 
Moreover, after in vitro transcription of this construct, it seemed that a heterogeneous sample was 
obtained which consisted of a mixture of the full length RNA 26 together with a shorter RNA species, 
missing the first nucleotide. The heterogeneity of the starting RNA did not allow any further study of 
this RNA, and only the changes of the G8 imino proton resonance in the 1H-NMR time evolution 
experiments will be commented. Interestingly, despite the several changes observed, the imino proton 
resonance of G8 remained unaffected compared to the rest (Figure 3.9, blue dotted frame).This 
resonance in the case of D1-27 showed similar behaviour to G2 resonance, which could possibly be the 
platination site (Figure 3.3). In the absence of the internal loop this behaviour was not observed. In 
Figure 3.9 (right panel, bottom), it is clearly illustrated the different behaviour of the imino proton 
resonance of G8 in the presence (D1-27) and in the absence (RNA 26) of the internal loop. A possible 
explanation for this could be the following. Internal loops are common RNA structural motifs, which 
consist of unpaired nucleotides on both strands and which are more destabilized compared to normal 
Watson-Crick base paired double helical structures. Also, it is known that when platination takes place 
local distortion is observed which can affect 4-5 nucleobases away13. Combining these two information, 
it could be very probable that the changes observed at the G8 site are due to the presence of the internal 
loop, which allows the local structural changes induced from platination at, e.g., G2 to influence the 
base-pairing at the G8 site. The fact that the imino proton resonance of G8 remains unaffected during 
platination of RNA 26 supports this scenario.  
Summing up, the data commented above suggest platination at G2 in the case of D1-27 and suggest that 
the changes of the imino proton resonance of G8 may be the effect of structural rearrangement rather 
than the result of direct platination. The characterization of the isolated platinated D1-27 further 
confirms these findings (Chapter 4). The same experiment was performed using 5ʹ-end 
dephosphorylated RNA 26 (deph-RNA 26) and the results obtained for the behaviour of G8 imino 
proton resonance were identical (Appendix 2, Figure A 2.1). 
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Figure 3.9: Time evolution NMR experiment for the platination of RNA 26 with oxaliPt (left). Right Top: 
Secondary structure of RNA 26, Right Bottom: Plot of the intensity of the imino proton resonances over time for 
the comparison of the G8 behaviour in D1-27 and RNA 26. (5 eq of oxaliPt, 0.1 mM RNA, 25 °C, 120 mM KCl, 
pH 6, 600 MHz) 
3.3.4 The role of the 5ʹ-triphosphate group on platination 
In order to perform platination reactions starting from a homogeneous starting material, deph-RNA was 
used instead of triph-RNA (Chapter 2, Paragraph 2.9). The platination reactions of deph-D1-27 with 
oxaliPt were performed using the experimental conditions previously optimized using  
triph-D1-27. Interestingly, instead of the appearance of only one new slower migrating band (upper), 
as it was observed from the platination of triph-D1-27, another new faster migrating band appeared 
(Chapter 2, Paragraph 2.9, Figure 2.44). To get a first insight into this different behaviour time evolution 
NMR experiments were performed. The 1H-NMR spectra of the two RNA constructs (with and without 
phosphate group) are very similar (Figure 3.10). The only difference observed is that the imino proton 
resonance of G1 is shifted upfield upon dephosphorylation, which could be related to the absence of the 
triphosphate group.  
Figure 3.10: 1H-NMR spectra, (imino 
proton and aromatic region), 
including labelling of the imino proton 
resonances, of triph-D1-27 (black 
line) and deph-D1-27 (red line). The 
spectra were recorded at 25 °C, in the 
presence of 120 mM KClO4, pH 6, 
600 MHz.  
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The time evolution NMR experiment was performed under the same experimental conditions as 
mentioned above. From the stack plot and the plot of the intensity decrease of the imino proton 
resonances over time for all the nucleobases (Figure 3.11, Table 3.3) it is again evident that G2, G8 
(green and red frame) and U25 are the ones which are mostly affected by platination. Indeed, the 
intensity of their imino proton resonances is reduced by almost 50 %, while less affected, but in a similar 
manner, are the imino proton resonances of G15, G16 and G18. 
Table 3.3: The percentage of the intensity decrease of the imino proton resonances at the end of the time evolution 
NMR experiment for the platination reaction of deph-D1-27 with 5 eq of oxaliPt.  
 
Figure 3.11: Time evolution NMR experiment for the platination of deph-D1-27 with oxaliPt (left). Right Top: 
Secondary structure of D1-27, Right Bottom: Plot of the percentage of the intensity of the imino proton resonances 
over time. (5 eq of oxaliPt, 0.1 mM RNA, 25 °C, 120 mM KCl, pH 6, 600 MHz) 
  
Resonance Intensity decrease (%) 
G2 49.5 
G8 49.1 
U25 45.8 
G15 15.1 
G18 13.1 
G16 11.9 
U10/U24 40.3 
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To understand the different behaviour observed in the gels performed using deph-RNA, the intensity 
decrease found during its time evolution NMR experiment was compared with the corresponding values 
obtained from the platination reaction using triph-D1-27 (Table 3.4). The imino proton resonances of 
G2, G8 and U25 are in both cases the most affected but for deph-D1-27 their intensities are decreased 
to a smaller extend. A possible explanation for this could be that upon removal of the negatively charged 
triphosphate group from the 5ʹ-end, a possible interaction at the G2 site could still took place but not as 
fast as before thus reducing the intensity decrease of the corresponding imino proton signals. U25 that 
is close-by and G8 which probably is not directly platinated as discussed in the previous paragraph were 
also analogously affected. Upon RNA dephosphorylation the G15 imino proton resonance seems to be 
a bit more affected (Table 3.4) without though its intensity decrease being very important suggesting 
that the region of the -UUCG- terminal loop is not significantly influenced from platination, in line with 
previous observations.  
Table 3.4: Comparison of the percentage of the intensity decrease of the imino proton resonances at the end of 
the time evolution NMR experiment for the platination reaction of triph-D1-27 and deph-D1-27 with 5 eq of 
oxaliPt. 
 
In conclusion, the platination of deph-D1-27 with oxaliPt resulted in significant changes at the same 
nucleobases as when triph-D1-27 was used (G2, G8 and U25) while the resonances at the terminal loop 
remained almost unaffected. The differences of the intensity decrease observed may be connected with 
the removal of the negatively charged triphosphate from the 5ʹ-end which resulted in still preferable 
interaction at the 5ʹ-end region (probably at G2) but not with the same specificity as before. The reduced 
specificity at the first part of the RNA could probably lead to the formation of other less preferable 
species which are the ones forming the new faster migrating gel band appeared upon platination of 
deph-D1-27. 
Resonance 
Intensity decrease (%) 
triph-D1-27 
Intensity decrease (%) 
deph-D1-27 
G2 58.8 49.5 
G8 54.6 49.1 
U25 59.9 45.8 
G15 10.3 15.1 
G18 21.3 13.1 
G16 19.7 11.9 
U10/U24 41.5 40.3 
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3.4 Conclusions from the investigation of the interaction between 
oxaliplatin and D1-27 
OxaliPt is the platination agent that is chosen for this study and its interaction with D1-27 was screened 
using time evolution NMR experiments. With this approach, we were aiming at finding which could be 
the nucleobases, which were affected upon platination monitoring the changes induced during the 
platination reaction at the imino proton resonances. In addition to that, the influence of various structural 
features on platination as well as the role of the phosphate group at the 5ʹ-end were investigated. In all 
experiments G2, G8 and U25 imino proton resonances were the ones strongly affected. Using an RNA 
without the internal loop (RNA 26), G8 was excluded as directly platinated site and the changes 
observed were attributed to structural rearrangements caused by platination close-by, which due to the 
presence of the loop affected the G8 resonance as well. Uracils do not represent a platination site and 
therefore U25 is not expected to be platinated, suggesting that the G2 site could be the one that is directly 
platinated. Considering that the 1,2-GG are the most commonly found platinated adducts, in our case 
the platination could take place at the G1-G2 site. As mentioned also before, at the temperature that the 
experiments were performed the resonance of G1 is hardly visible (Figure 3.2). To see if there are 
changes at the G1 site upon platination, the imino proton spectra of D1-27 before platinum(II) addition 
and after 22 h of reaction were recorded at 4 °C at which the imino proton resonance of G1 is more 
pronounced (Figure 3.12). Indeed, the imino proton resonance of G1 at the end of the reaction (Figure 
3.12, red line, purple frame) was significantly broadened and reduced in intensity, which could be 
attributed to platination at this site. Factors which could enhance the platination at the G1-G2 site are 
the presence of the triphosphate, which being negatively charged attracts the positively charged 
platinum(II) complex, and the fact that the 5ʹ-end of the construct is flanking12, thus making this area 
more flexible and therefore easier for the platinum(II) complex to bind. 
 
Figure 3.12: Comparison of the imino proton region of 1H-NMR spectra of unreacted D1-27 (black line) and  
D1-27 after 22 h of reaction (red line) at 4 °C. (5 eq of oxaliPt, 0.1 mM RNA, 25 °C, 120 mM KCl, pH 6,  
600 MHz) 
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From the platination of D1-27 it was also found that the area of the -UUCG- terminal loop remained 
mostly unaffected which, as discussed above, could be the result of the stability of this tetraloop and/ 
or could be due to the orientation of the N7 atoms of the possible platination sites (G15, G16) 
(Figure 3.8). Its replacement with another less stable tetraloop (-GAAA-) indeed changed the 
accessibility of the region with both G12 (which is part of the loop) and G16 (which is very close to the 
tetraloop) being more affected than before. In the end the removal of the triphosphate group from the 
5ʹ-end led to similar changes like when triph-RNA was used with the difference that the changes in 
intensity of the imino proton resonances of G2, G8 and U25 was less pronounced. Despite the removal 
of the negatively charged phosphate group platination was again taking place at the 5ʹ-end region but 
with less specificity compared to when it was present.  
From these experiments, we are suggesting that the possible platination site could be G1-G2. However, 
in order to confirm this isolation of the pure monoplatinated sample is necessary considering that the 
picture of the time evolution NMR experiments corresponds to the whole platination reaction mixture. 
The characterization of the platinated RNA species isolated from the upper gel band is described in 
chapter 4.  
 
3.5 Time evolution NMR experiments: Monoaquated cisplatin 
The choice of oxaliPt over monoaquated cisPt (chemical structure on the 
right) as possible platination agent was done based on its more specific 
RNA binding (Chapter 2, Paragraph 2.4.4). This was concluded from the 
appearance of a new band on the gel, which in the case of oxaliPt was well-
defined and compact while for monoaquated cisPt it was more smeary and less compact, suggesting 
formation of various similarly platinated RNA species. Applying the same experimental reaction 
conditions (best conditions for oxaliPt) the gel obtained showed a clear second band for oxaliPt and a 
dispersed smear for the monoaquated cisPt. This is suggesting that under the same conditions the 
monoaquated cisPt was reacting faster and less specific forming various platinated species (Chapter 2, 
Figure 2.27). To further confirm this behaviour, time evolution NMR experiments were performed 
using the experimental conditions found for oxaliPt.  
3.5.1 Time evolution NMR experiments of the platination reaction of D1-27 with monoaquated 
cisPt and comparison with oxaliPt 
The platination reaction of D1-27 with monoaquated cisPt was followed with time evolution NMR 
experiments using the same experimental conditions used for oxaliPt. Under these conditions as it can 
be seen in Figure 3.13, the platination reaction evolved very fast. Already after platinum(II) addition 
(Figure 3.13, red line) most of the imino proton resonances were strongly affected (broader and 
decreased in intensity). After 22 h of reaction G2, G8 and U25 imino proton resonances disappeared 
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while strong decrease in intensity was observed also for the G18 resonance. The intensity of G15 and 
G16 resonances decreased but they were less affected compared to the rest. The least affected area of 
the terminal loop (G15, G16) is a common characteristic between the platination reaction of oxaliPt and 
monoaquated cisPt. However, the reaction of cisPt evolved much faster and less specific as it can be 
seen from the reduced intensity of the majority of the resonances already immediately after addition of 
cisPt (Figure 3.13, red line). Under the same experimental conditions oxaliPt reacts more specifically 
with D1-27, with G2 and G8 resonances (Figure 3.13, green and red dotted frames) being the ones, 
which were mostly affected, as it was shown in paragraph 3.3.1 (Figure 3.3). This behaviour is in 
accordance with the behaviour observed using PAGEs for the comparison of the reactivity of the two 
platinum(II) complexes (Chapter 2, Paragraph 2.5, Figure 2.27). Under these experimental conditions, 
the use of oxaliPt resulted in the formation of two well separated distinct bands while for the 
monoaquated cisPt an extended smeary band was formed. As it was discussed there, the presence of the 
smeary band could be reflecting the formation of various differently platinated RNA species, which 
was now further confirmed from the significant change of almost all imino proton resonances. It is 
worth noting that the platination reaction progressed very fast despite the fact that it was performed in 
the presence of Cl¯, which is known to reduce the platination reaction rate of cisPt14. Consequently, this 
comparison further supports the choice of oxaliPt as a better platination agent for this study. 
 
Figure 3.13: Time evolution NMR experiment for the platination of D1-27 with 5 eq of monoaquated cisPt in  
120 mM KCl (left). Right: Secondary structure of D1-27. The dotted frames correspond to the nucleobases, which 
were mostly affected upon platination with oxaliplatin. (5 eq of monoaquated cisPt, 0.1 mM RNA, 25 °C, 120 mM 
KCl, pH 5.9, 600 MHz)  
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3.6 Platination reactions with kiteplatin (PtCl2 (cis-1,4-DACH)] 
In chapter 2 it was discussed the evaluation of cisPt and oxaliPt as possible 
platination agents towards D1-27 (Paragraphs 2.3 - 2.5). Additionally to these 
two complexes, the interaction of kiteplatin (kitePt) with D1-27 was also 
briefly investigated, even if no optimization of its platination conditions in 
order to get a homogeneously platinated RNA was performed. For our study the complex  
[PtCl2(cis-1,4-DACH)] (kitePt) (chemical structure on the right) was kindly provided by Prof. James 
Hoeschele (University of Michigan Chemistry Department, USA) and Prof. Nicola Margiotta 
(University of Bari, Department of Chemistry, Italy). We aimed at comparing its interaction with D1-
27 with the behaviour of cisPt and oxaliPt. Therefore, before performing time evolution NMR 
experiments, a platination reaction was performed and analyzed via PAGE. KitePt was activated to its 
monoaquated complex (Chapter 5, Paragraph 5.2.4) before usage, and it was reacted with D1-27 using  
 
the experimental conditions used for oxaliPt (5 eq of platinum(II) 
complex, 0.1 mM RNA, 1 day of incubation at 25 °C in the presence of 120 mM KCl). Interestingly, 
under these conditions a slower migrating band (upper) was formed on a denaturing gel similarly, to 
what was found for oxaliPt (Figure 3.14). The platinated RNA isolated from the upper band was 
analysed with MALDI-MS and it was found to consist of a mixture of monoplatinated (m/z = 9080), 
diplatinated (m/z = 9388) and triplatinated RNA (m/z = 9695), with the diplatinated ones being the 
major species. Despite the fact that oxaliPt and kitePt showed similar gel patterns, the products of the 
upper bands were different. Indeed, while the upper band in the case of oxaliplatin contains 
monoplatinated species, which were further characterized (chapter 4), in the case of kitePt contains a 
mixture of species, with the diplatinated ones being the major species. 
  
Figure 3.14: 20 % denaturing PAGE for the platination reaction of 32P-5ʹ-end 
labelled D1-27 with oxaliPt and kitePt using the experimental conditions found for 
oxaliPt. (0.1 mM RNA incubated with 5 eq of oxaliPt at 25 °C for 1 day in  
120 mM KCl solution). The gel was run at 4 °C. For preparation of the platination 
reactions using labelled RNA see Chapter 5, Paragraph 5.10.4. 
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3.7 Time evolution NMR experiments: kiteplatin [PtCl2 (cis-1,4-DACH)] 
A first comparison of kitePt and oxaliPt was performed by using the same experimental platination 
conditions and utilizing PAGE for visualization of the platination adducts (Paragraph 3.6). To get 
further insights into kitePt-RNA adducts and to attempt a comparison with the oxaliPt-RNA ones, time 
evolution NMR experiment was performed (Figure 3.15). The imino proton resonance of G8 was the 
most affected (Figure 3.15, green dotted frame), followed by U25, G2 and G18 resonances, which 
showed similar decrease in intensity (Figure 3.15, red and green dotted frames, Table 3.5). The imino 
proton resonance of G15 and G16 were the least affected suggesting no interaction at the -UUCG- 
tetraloop region similarly, to what was found for oxaliPt. However, it should be noticed that G15 
resonance during kitePt reaction is more affected compared to the corresponding one in oxaliPt reaction 
(Table 3.5). G2 imino proton resonance in the case of oxaliPt is expected to be an actual platinum 
binding site and as such, it is strongly affected upon platination. For kitePt the most affected imino 
proton resonance was G8, while G2 and G18 imino proton resonances showed similar decrease (Table 
3.5). Expecting to have diplatinated RNA as the major species (from MALDI-MS data, Paragraph 3.6) 
we could assume direct platination at both G1-G2 and G8-G18, the latter leading to formation of 
intrastrand adducts. Nevertheless, formation of a mixture of monodentate adducts at different sites could 
not be excluded. However, to further evaluate the possible platinum binding sites characterization of 
the isolated platinated RNA sample is necessary. 
Table 3.5: Comparison of the intensity decrease of the imino proton resonances during the time evolution NMR 
experiments for the platination of D1-27 with kitePt and oxaliPt.  
 
From Table 3.5 it should be also noted that the decrease in intensity of the imino proton resonances in 
the case of kitePt is more equally distributed between the various nucleobases, while for oxaliPt there 
are significant differences for example between G2 and G15. This, together with the presence of 
Resonance 
Intensity decrease (%)  
D1-27 + 5eq kitePt 
Intensity decrease (%) 
D1-27 + 5eq oxaliPt 
G8 42.6 54.6 
U25 37 59.9 
G2 35.1 58.8 
G18 34.5 21.3 
G16 18.8 19.7 
G15 17.3 10.3 
U10/U24 31 41.5 
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diplatinated RNA species as the major species, suggests that the platination pattern between the two 
platinum(II) complexes is different, with kitePt exhibiting reduced specificity.  
 
Figure 3.15: Time evolution NMR experiment for the platination of D1-27 with 5 eq of monoaquated kitePt in the 
presence of 120 mM KCl (left). Right Top: Secondary structure of D1-27, Right Bottom: Plot of the percentage of 
the intensity of the imino proton resonances over time. (5 eq of monoaquated kitePt, 0.1 mM RNA, 25 °C, 120 mM 
KCl, pH 6, 600 MHz)  
 
3.8 Plasmid binding studies for cisplatin, oxaliplatin and kiteplatin 
Gel mobility shift assays and 1H-NMR time evolution experiments show strong differences in the 
behaviour of kiteplatin, oxaliplatin and cisplatin towards our short RNA construct. Driven by these 
findings, we decided to directly compare the behaviour of the three complexes also towards DNA, using 
DNA plasmid binding assays. These studies were part of a STSM project, which took place in the 
laboratory of Prof. Sofi K. C. Elmroth in Lund, Sweden (Appendix 4). Utilizing the ability of the 
platinum(II) anticancer drugs as DNA unwinding agents15 we studied the DNA binding affinity of the 
monoaquated complexes of cisPt, kitePt and [Pt(DACH)Cl2] with the negatively supercoiled pUC18 
plasmid. The [Pt(DACH)Cl2] was used as activated form of oxaliPt16 and its synthesis and complete 
characterization is described in chapter 5 (Paragraphs 5.2.2-5.2.5). Their behaviour was studied in two 
different phosphate buffers namely 200 mM Na2HPO4 / NaH2PO4 (NaPi) and 200 mM K2HPO4 / 
KH2PO4 (KPi) which were simulating the extracellular and intracellular environment. Upon platination, 
supercoiled and relaxed forms can be visualized by agarose gel electrophoresis (Figure 3.16). By 
increasing the amount of platinum(II) complexes bound to DNA the appearance of a slower migrating 
supercoiled plasmid band could be detected. The point at which the supercoiled and relaxed forms 
coincide is called coalescence point (Figure 3.16, white frame). These studies were performed using 
experimental conditions previously reported from the Elmroth’s group17. The ratio of nucleotide 
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concentration (CDNA) and concentration of platinum(II) compounds (CPt) (rf = CPt/CDNA) was varied from 
0 to 0.5. Each platinum(II) complex has its coalescence point at the same rf in NaPi and KPi buffer, 
meaning that they exhibit similar behaviour in both buffers (Figure 3.16). Cisplatin reacted the fastest, 
as expected, having the coalescence point much earlier (Figure 3.16, lane 5) compared to the other two 
complexes (Figure 3.16, lane 8 in both cases). Among the other two, kiteplatin was faster than 
oxaliplatin, considering that the slower migrating supercoiled band appeared earlier (lane 4 over lane 7 
for [Pt(DACH)Cl2]). It is worth noting that here kitePt reacted faster than the dichlorido analogue of 
oxaliPt, even if the oxalate group, whose hydrolysis was probably slowing down the platination reaction 
in the case of the interaction with D1-27, was not present18. Studies on the reaction rates of these three 
platinum(II) complexes with double-stranded DNA led to comparable results to the ones observed here. 
More specifically it was shown that kitePt and [Pt(DACH)Cl2] exhibit similar behaviour while cisplatin 
has higher reactivity. Their lower reactivity compared to cisplatin was suggested to be connected with 
the greater steric effect introduced by their bulky non-leaving groups16. 
 
Figure 3.16: Gel mobility shift assay of platinum(II) complexes with supercoiled and relaxed forms of the pUC18 
plasmid. The rf varied from 0 to 0.5 with 1 = 0, 2 = 0.01, 3 = 0.05, 4 = 0.076, 5 = 0.15, 6 = 0.2,  
7 = 0.0.3, 8 = 0.5. In the white frame are the bands at which the coalescence point is observed. With M is indicated 
the marker lane.  
 
3.9 Summary of the differences between the platination reactions using 
oxaliPt, monoaquated cisPt, and monoaquated kitePt  
3.9.1 Comparison of cisPt vs oxaliPt 
From the data commended above, it was concluded that cisPt was reacting faster compared to oxaliPt 
and in a non-specific manner with D1-27. This was observed from the appearance of a non-well defined 
gel band (Chapter 2, Paragraphs 2.3 - 2.5, Figure 2.27) and from the change of intensity of the majority 
of the imino proton resonances during the time evolution experiments (Chapter 3, Paragraph 3.5). On 
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the contrary, for the platination reaction using oxaliPt, a well-defined new band was formed (Chapter 
2, Figure 2.26) and from the time evolution experiments it was concluded that most probably a possible 
platination site is G1-G2 (Chapter 3, Paragraph 3.4). The origin of this different behaviour is mostly 
connected with their different non-leaving groups (a bulky DACH moiety and an ammine group) which 
due to the different sterical hindrance are affecting the conformation of the formed adducts19. Finally, 
the faster reaction rate observed for cisplatin is the result of faster hydrolysis of its leaving groups 
compared to the oxalate group of oxaliplatin20 (Chapter 2, Paragraphs 2.4 - 2.5).  
3.9.2 Comparison of oxaliPt vs kitePt 
OxaliPt and kitePt have in common a different isomer of the same non-leaving group (1,2-DACH for 
oxaliPt and 1,4-DACH for kitePt) and oxaliPt has an oxalate ligand as leaving group, while kitePt has 
two chlorides. On the denaturing gels under the same experimental conditions, both complexes 
exhibited the same behaviour, meaning that there was formation of a new slower migrating band  
(Figure 3.14). Despite that, the MALDI-MS analysis of the Pt(II)-RNA species from these upper bands 
were different with oxaliPt major species being the monoplatinated RNA, while for kitePt the major 
species was the diplatinated one. Considering the data from the MALDI-MS analysis different 
behaviour was also expected in the time evolution NMR experiments. Indeed, for oxaliPt the mostly 
affected imino proton resonances were the ones corresponding to G2, G8 and U25 while for kitePt they 
were the ones corresponding to G2, G8 and G18. In both cases, no interaction was detected at the 
terminal -UUCG- tetraloop. OxaliPt binds more specifically compared to kitePt and this was observed 
from the general decrease of the majority of the imino proton resonances intensity for kitePt compared 
to oxaliPt (Table 3.5). The reduced specificity observed for kitePt might be connected with the presence 
of the very labile chloride ligands, as leaving groups, which based on studies with cisplatin are 
hydrolyzed faster compared to the oxalate group of oxaliplatin19,20.  
3.9.3 Comparison of cisPt vs kitePt 
CisPt and kitePt have in common that both possess two chloride ligands as leaving groups while the 
first have two ammines as non-leaving groups and the second has a 1,4-DACH ammine-ligand. Under 
the same experimental conditions the two platinum(II) complexes showed that they do not have strong 
preference for a binding site as it was observed for oxaliPt and in both cases most of the imino proton 
resonances were affected upon platination. The important difference between the two was the fact that 
monoaquated cisPt reacted faster compared to monoaquated kitePt. Being both monoaquated and 
therefore being to the same extent ready to react, the difference observed should result from the 
difference in bulkiness of their non-leaving groups similarly to what is known for the differences 
observed between the cisplatin and oxaliplatin DNA adducts19.  
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3.10  Investigation of the role of K(I) and Cl¯ in the platination reactions 
using PAGE analysis and time evolution NMR experiments 
To improve the platination reactions for both cisPt and oxaliPt the choice of the reaction solution was 
important. For cisPt the use of ddH2O instead of KClO4 solution resulted in the formation of a slower 
migrating band while for oxaliPt the use of KCl significantly improved the platination reaction yield 
(Chapter 2, Paragraph 2.4.4). The presence of K(I) could on the one hand stabilize the secondary 
structure of the RNA and on the other hand it could reduce the platination efficiency due to competition 
with the also positively charged platinum(II) for the same binding sites at the RNA (Chapter 4, 
Paragraph 4.4 - 4.5). The presence of Cl¯ has also a double role. It can replace the water molecules of 
the activated cisPt and kitePt reducing the platination reaction speed14, while in the case of oxaliPt it 
boosted the platination efficiency due to degradation of the oxalate ligand and the formation of the 
activated oxaliPt species18,21–24 (Chapter 2, Paragraph 2.4.3). To have an overview of the behaviour of 
all the platinum(II) complexes used until now, based on the use of different reaction solution (ddH2O, 
120 mM KClO4 and 120 mM KCl), platination reactions were performed using the experimental 
conditions found for oxaliPt (5 eq of platinum(II) complex, 0.1 mM RNA, 1 day of incubation at 25 °C) 
and all samples were run in the same denaturing gel (Figure 3.17). Additionally to the three platinum(II) 
complexes discussed until now carboplatin (carboPt)25 was also used for this comparison (Chapter 1, 
Paragraph 1.2.2).  
Using carboPt no formation of a new gel band was observed meaning either that it does not react under 
these experimental conditions or that the platinated-RNA species formed migrate similarly to the 
control. For oxaliPt, it could be nicely observed the difference in the platination yield upon variation of 
the reaction conditions. In the absence of K(I) (only ddH2O) there is a moderate platination yield, which 
was significantly reduced when K(I) was added (120 mM KClO4). This is connected most probably 
with the competition of the two cations for binding to RNA and with the more compact form that the 
RNA adopts in the presence of cations. The yield is again greatly increased when Cl¯ is used, which as 
discussed before can degrade the oxalate group forming the activated complex of oxaliplatin.  
When platination with monoaquated cisPt was performed in ddH2O and in 120 mM KClO4 formation 
of a new slower migrating band and appearance of a smear were observed on the gel in both cases, 
suggesting that the presence or absence of K(I) does not influence the product formation. However, in 
120 mM KCl, in which the reaction was expected to proceed slower, two different new bands appeared; 
a faster migrating one, which was not formed before, and a slower migrating one much closer to the 
unreacted RNA compared to the other two reactions. Interestingly this behaviour suggests formation of 
differently platinated adducts upon addition of Cl¯.  
The platination reaction with kitePt took place very fast in ddH2O with no unreacted RNA being left 
and an extended slowly migrating smeary band being formed. The platination speed was reduced 
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gradually in the presence of K(I) (120 mM KClO4) with the smeary slowly migrating band migrating 
faster than before. In the presence of 120 mM KCl two well-separated and well-defined bands were 
present with the one corresponding to unreacted RNA and the other slower migrating one (upper) to the 
platinated RNA species. Therefore, kitePt exhibits an intermediate behaviour between oxaliPt and cisPt, 
with the presence of K(I) reducing its reaction rate, similarly to what was observed for oxaliPt, and the 
presence of Cl¯ having the same effect as for cisPt. The transition from a smeary band to a well-defined 
one suggests that the reaction was more specific and platinated RNA species with similar gel mobility 
were formed upon reduction of the reaction speed. 
Summing up, all the above observations are in line with what was found from the time evolution NMR 
experiments and the preliminary DNA plasmid binding studies discussed above (Paragraph 3.9). 
Performing a denaturing PAGE useful conclusions could be made about the reactivity of the different 
platinum(II) complexes in various reaction solution conditions together with a quick first comparison 
of their kinetic behaviour.  
 
 
Figure 3.17: 20 % denaturing gel for the evaluation of the platination behaviour of various platinum(II) 
complexes with D1-27 using different reaction solution conditions. Platination conditions: 5 eq of platinum(II) 
complex, 0.1 mM D1-27 and 1 nM 5ˈ-end labelled D1-27, incubation for 1 day at 25 °C. The gel was run at 
4 °C. 
 
3.10.1 Investigation of the role of K(I) and Cl¯ in the platination reactions of monoaquated cisPt 
using time evolution NMR experiments 
Using 5 eq of monoaquated cisPt in 120 mM KCl the platination reaction was very fast with all the 
imino proton resonances being affected, despite the presence of Cl¯ (Paragraph 3.5). In chapter 2 
(Paragraph 2.3) from the investigation of the platination reaction conditions of cisPt it was concluded 
that 1 eq of monoaquated cisPt, 0.1 mM RNA incubated for 2 days at 37 °C in ddH2O results in a slower 
migrating gel band (upper) which contains mostly monoplatinated RNA. The low resolution of this 
upper band (Chapter 2, Figure 2.13) is probably related with the formation of several similarly platinated 
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RNA species indicating the low specificity of cisPt in binding to RNA. From what was described in the 
current chapter following the platination reactions using time evolution NMR experiments is a good 
way to probe the mostly affected nucleobases and to get an indication of the reaction kinetics. Aiming 
at understanding the platination behaviour of cisPt under the best experimental conditions found for it, 
time evolution experiments were then employed. Towards this direction, the reaction was monitored 
for 1 day at 25 °C using 1 eq of monoaquated cisPt, 0.1 mM RNA, in the presence of 120 mM KClO4. 
Having already performed a similar experiment using 5 eq of monoaquated cisPt in 120 mM KCl 
(Paragraph 3.5) and having seen that the reaction was very fast and unspecific, by reducing the 
platinum(II) concentration we were aiming at slowing down the reaction. However, not significant 
by ClO4¯. In line with this, the time evolution experiment showed that the majority of the imino proton 
resonances were again extensively affected immediately after the addition of the platinum(II) complex 
(Figure 3.18, red line). However, comparing it with the reaction performed using 5 eq of platinum(II) 
in the presence of 120 mM of KCl (Paragraph 3.5, Figure 3.13), now the reaction seemed to be slightly 
slower, because even after 20 h of reaction the imino proton resonance of G2 was still visible, while 
when 5 eq were used this resonance disappeared after 10 h.  
 
 
Figure 3.18: Time evolution NMR experiment for the platination of D1-27 with 1 eq of monoaquated cisPt in 120 
mM KClO4 (left). Right: Secondary structure of D1-27. (5 eq of monoaquated cisPt, 0.1 mM RNA, 25 °C, 120 mM 
KClO4, pH 5.9, 600 MHz) 
 
To be even closer to the experimental conditions optimized for cisPt, KClO4 was replaced by ddH2O. 
In the absence of cations the RNA is less compact and for that reason the imino proton resonances of 
the untreated D1-27 were broader and less sharp (Figure 3.19, blue line). Similarly to the previous 
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experiment, the platination reaction proceeded very fast and in a non-specific manner in the absence of 
cations with the majority of the imino proton resonances being affected to the same extent as when 120 
mM KClO4 was used (Figure 3.18). The formation of similar platinum-RNA adducts under these 
conditions was also suggested from the PAGE analysis of these two reactions where similar gel band 
patterns were observed for both (Figure 3.17).  
 
Figure 3.19: Time evolution NMR experiment for the platination of D1-27 with 1 eq of monoaquated cisPt in 
ddH2O. (1 eq of monoaquated of cisPt, 0.1 mM RNA, 25 °C, dH2O, pH 5.9, 600 MHz) 
 
Summing up, the time evolution NMR experiments recorded with monoaquated cisPt showed that 
independently of the presence of Cl¯, the reaction took place much faster compared to oxaliPt 
(Paragraph 3.5). This behaviour did not change significantly when the platinum(II) concentration was 
reduced (1 eq) and Cl¯ was replaced by ClO4¯ or only water. These data are in line with the data 
obtained from the PAGE analysis of the platination reactions. The time evolution NMR experiment 
performed with 1 eq monoaquated cisPt in ddH2O (Figure 3.19) is the one closer to the experimental 
conditions used for cisPt and showed that upon platination various differently platinated RNAs were 
formed. The heterogeneity of the sample was also suggested by denaturing gels, where not well-defined 
gel band appeared (Chapter 2, Paragraph 2.3, Figure 2.13). Interestingly the MALDI-MS analysis of 
the sample isolated from this band showed that it consisted of mostly monoplatinated RNA (Chapter 2, 
Paragraph 2.3, Figure 2.13), which, based on the current data, may be a mixture of RNA species 
monoplatinated at different positions. 
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3.11 Conclusions 
The main part of this chapter was devoted to the time evolution NMR experiments as a quick way to 
follow and evaluate the platination reactions. For the platination of D1-27 with oxaliPt the influence of 
the terminal tetraloop, the presence of the internal loop and the role of the 5ʹ-end phosphate group on 
the platinum(II) binding sites were investigated. From this study, it was concluded that there is not 
interaction at the terminal -UUCG- tetraloop and a very possible target is the G1-G2 site while the 
changes observed at the G8 site could be linked to structural changes induced upon platination at, for 
example, G1-G2, which were affecting G8 because of the presence of the internal loop. To similar 
conclusion led the removal of the triphosphate group (deph-D1-27), with the difference that the reaction 
at the G1-G2 site was not as fast as before. Lastly, the replacement of the -UUCG- tetraloop for the -
GAAA- one made the terminal loop region more prone to platinum binding (Paragraph 3.3.2). This 
approach cannot be used alone for the evaluation of the platination reactions because the imino proton 
resonances are influenced by many different experimental factors and additionally, as shown for 
example for G8, are very sensitive to local structural changes. With oxaliPt being the platination agent 
chosen for this study, further isolation and characterization of its platinated RNA species is following 
in chapter 4. A first evaluation of the different platinum binding preferences and reaction kinetics of 
monoaquated cisPt and monoaquated kitePt compared to oxaliPt was performed with the combination 
of time evolution NMR experiments and PAGE analysis under the same platination reaction conditions. 
Information about the platination reaction rates of all three platinum(II) complexes were also gathered 
from DNA unwinding experiments (Paragraph 3.8). CisPt was found to be the agent, which was binding 
faster and less specific with RNA and oxaliPt was the one with good specificity and good reaction 
kinetics. KitePt exhibited an average behaviour between the other two, because it seemed to be more 
specific than cisPt but less than oxaliPt. Plasmid binding assays confirmed also the above-mentioned 
behaviour. In the end the kinetics and the role of K(I) and Cl¯ in the platination reactions of all three 
platinum(II) complexes was investigated using PAGE analysis. In addition, time evolution NMR 
experiments were employed for the platination reaction of monoaquated cisPt under different K(I) and 
Cl¯ conditions, which supported its high reactivity and reduced specificity which did not allow its 
further characterization.  
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4 Characterization of the isolated oxaliplatin-RNA 
adducts  
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4.1 Aim 
In this chapter it will be described the characterization of the platinated RNA species, using various 
techniques, mainly focusing on Pt-RNA adducts migrating in the upper band, obtained using  
deph-RNA (Pt-deph-RNA adducts). The platinated RNA species of the triph-RNA, which were isolated 
from the upper band, were also characterized and very similar behaviour was observed. Finally, the last 
part of the chapter will be dedicated to the characterization of the Pt(II)-RNA species deriving from the 
faster migrating band, which appears using deph-RNA as starting material.  
 
4.2 Introduction 
Upon platination of D1-27 with oxaliPt using the experimental conditions optimized (Chapter 2, 
Paragraph 2.4.4), the platinated RNA adducts were isolated and purified with denaturing PAGE. A 
slower migrating band was formed upon platination (upper band), which, according to MALDI-MS 
analysis, contained monoplatinated RNA as major product. As discussed before in order to have a 
homogeneous starting RNA sample, D1-27 was dephosphorylated before use (Chapter 2, Paragraph 
2.9). Because of the homogeneity of deph-RNA over triph-RNA (Chapter 2, Paragraph 2.9), the species 
deriving from the upper band obtained in the first case will be mainly described herein. However, upon 
description of the Pt-deph-RNA adducts a comparison with the corresponding species prepared using 
triph-RNA will follow. It should be reminded that in both cases the platinated samples consisted of a 
mixture of monoplatinated (88 %) and diplatinated RNA (12 %) and they were characterized as such. 
Besides the upper band, the gel corresponding to platination of the deph-RNA showed a third, faster 
migrating band, which also contained platinated adducts (Chapter 2, Paragraph 2.9, Figure 2.44). The 
characterization of the Pt-deph-RNA species responsible for this faster migrating band (Figure 2.44, 
lower band) was also performed in order to get insights into the platinum(II) binding sites, and it will 
be discussed separately, at the end of this chapter.  
 
4.3 Characterization methods of platinated RNA 
In chapter 2 it was described the use of denaturing PAGE for the separation of the platinated RNA 
species and the use of MALDI-MS for their identification. Upon isolation, the platinated RNA species 
were characterized using different techniques, as described in the current chapter. Thermal melting 
studies were performed to determine the effect of platination on RNA stability while circular dichroism 
(CD) was employed for the monitoring of conformational changes upon platination. Moreover, 
enzymatic digestion followed by HPLC analysis was used in order to identify the nucleobases, which 
were involved in platination. Towards the same direction, 5ʹ-end and 3ʹ-end radiolabelled RNA samples 
were platinated and the radiolabelled platinated RNAs were enzymatically and chemically digested 
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giving information about the possible platination sites. Finally, from NMR spectroscopy, information 
about the platination sites with atomic resolution were obtained. 
 
4.4 Thermal melting studies 
The nucleic acids, when are present as random coils, have the ability to pair with a complementary 
strand, based on the intrinsic pairing capabilities of the nucleobases, forming a double stranded helical 
structure. The aromatic bases of the nucleic acids have lower absorbance at 260 nm when a duplex is 
formed compared to when they are in a random coil form. This phenomenon is called hypochromicity 
of nucleic acids and on that are based the thermal melting studies. The stability of the duplexes is 
affected by several factors like the type of nucleic acid (DNA or RNA), the length, the base composition, 
the ionic strength and the pH of the solution1. A melting curve is obtained by monitoring the increase 
of UV absorption at 260 nm over increasing temperature. The thermal melting temperature, Tm, of a 
nucleic acid duplex is defined as the point where half of the oligonucleotides are found in the random 
coil conformation2. The melting curve of D1-27 shows two melting temperatures (Tm1 = 52.2 ± 2.1 °C 
and Tm2 = 74.2 ± 3.0 °C, Figure 4.1), suggesting the presence of a complex melting profile, including 
at least two steps.  
 
Figure 4.1: Representative thermal melting curve of deph-D1-27 (left panel) and representation of Tm 
determination by the first derivative method (right panel). 
Although the unfolding of this construct was not studied in detail, a qualitative simplified interpretation 
of the two observed melting temperatures may be attempted. There are two potential scenarios: 1) Tm1 
corresponds to the opening of the first part of the construct and Tm2 to the complete denaturation of the 
RNA (Figure 4.2, panel A), 2) Tm1 corresponds to the opening of the second part of the RNA, without 
the construct being fully denatured, and Tm2 to the complete denaturing of the RNA (Figure 4.2, panel 
B). The first hypothesis is likely to be the most probable one. Indeed, first of all, hairpins are very stable 
constructs3,4. For example, the theoretical Tm of the 14 nucleotide long RNA hairpin corresponding to 
the second part of D1-27 is 85.1 °C (https://eu.idtdna.com/calc/analyzer), this value being well in 
agreement with Tm2 observed for our RNA construct. Second, the first part of the D1-27 construct 
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consists of an internal loop and a G-U wobble, and it is known that these structural elements are less 
stable compared to a duplex construct1,3,4. Finally, the base pairing at the 5ʹ- and 3ʹ-end are known not 
to be stable4; therefore they contribute little to the stabilization of the first part. Consequently, the first 
part of D1-27 is expected to melt first compared to the second part, thus supporting the first model. The 
thermal melting point was determined by the derivative method2, and corresponds to the maximum of 
the first derivative curve (Figure 4.1).  
 
Figure 4.2: Schematic representation of the two hypothesis about the attribution of the two melting 
temperatures3,4.  
 
Thermal melting curves were recorded both for the unreacted and platinated RNA in order to investigate 
the effect of platinum(II) binding on RNA stability. At first, the effect of increasing monovalent salt 
concentration on RNA structure stabilization was evaluated. Thermal melting studies were performed 
with 0 mM, 20 mM, 60 mM and 120 mM KClO4 (Figure 4.3). Only one low melting temperature is 
observed when the melting curve is recorded in the presence of 0 mM KClO4  
(44.7 ± 2.7 °C). The shape of the curve changes already upon addition of 20 mM KClO4, and two higher 
melting temperatures can be identified. By further increasing salt concentration (60 - 120 mM), a slight 
increase of the melting temperatures is observed, suggesting additional RNA stabilization (Table 4.1). 
Melting profiles of unreacted and platinated RNAs were recorded in the presence of 120 mM KClO4. 
This K(I) concentration was also used for the platination reaction and is closer to the physiological 
conditions.  
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Figure 4.3: Thermal melting profiles for D1-27 in the presence of different KClO4 concentrations. They were 
monitored at 260 nm, data collected from 20 °C to 90 °C at a rate of 1 °C / min. CRNA = 1.3 μΜ. 
 
Table 4.1: Melting temperatures of triph-D1-27 at different KClO4 concentrations. These measurements were 
performed in duplicates. The errors are corresponding to standard deviation. 
KClO4 concentration (mM) Tm1 (°C) Tm2 (°C) 
0 44.7 ± 2.7 - 
20 51.7 ± 1.9 67.8 ± 1.3 
60 53.7 ± 1.9 73.8 ± 2.4 
120 53.8 ± 2.1 74.5 ± 1.9 
 
Upon platination of deph-D1-27 only Tm1 was significantly changed towards a lower temperature 
(ΔTm1 = 7.4 ± 3.3) (Table 4.2) while almost no change was observed for Tm2, whose variation was 
within the experimental error (ΔTm2 = 3.6 ± 3.2). Similar behaviour was also observed for the platinated 
species obtained using triph-RNA (Table 4.2). In this latter case the measurements were performed at 
lower pH, which led to lower absolute values for the melting temperatures for both unreacted and 
platinated samples. However, similar destabilization was observed as before, with 8 °C decrease of the 
first melting temperature, while the second melting temperature was almost not affected by platination, 
with its variation being within the experimental error (Table 4.2). Similar behaviour was also reported 
for the platination of other RNAs with platinum(II) complexes5–7 as well as for DNA5,7. Platinum(II) 
induced destabilization may be attributed to local distortion, as observed in the case of DNA, where 
structural data confirm strong distortion of double stranded oligonucleotides at the platination site8–14. 
The here observed destabilization may derive from intrastrand cross-link, as suggested also by the 
presence of a slower migrating band on the platination gels, likely attributed to intrastrand binding 
mode15. Platinum(II) intrastrand binding causes base pairing weakening, possibly leading to an easier 
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denaturation of the construct. In the case of interstrand cross-linked products, a faster migrating band 
would be expected on the gel15 and the melting profile should show increased melting temperature16,17. 
Similar destabilization (ΔTm = 10.7 °C) as the one here found (ΔTm ≈ 8 °C) was observed for a 15nt 
long duplex RNA containing two central consecutive guanines upon platination with oxaliPt. When a 
similar duplex RNA containing GNG was used instead, the ΔTm was significantly increased  
(– 19.4 °C). Similar behaviour was reported also for the corresponding DNA-oxaliPt adducts5.  
Table 4.2: Summary of the melting temperatures for triph- and deph-D1-27 as well as for their platinated adducts. 
The given Tm values are the average of at least five measurements, and are reported together with their standard 
deviation. The errors reported for ΔTms values were estimated using the standard error propagation 
calculations18. 
RNA construct Tm1 (°C) ΔTm1 (°C) Tm2 (°C) ΔTm2 (°C) 
Triph-D1-27_pH 6.5 53.8 ± 2.1  74.5 ± 1.9  
Triph-D1-27_pH 5 50.5 ± 0.8 
8.1 ± 2.1 
69.9 ± 1.2 
1.6 ± 1.8 
Pt-triph-D1-27_pH 5 42.4 ± 1.9 68.3 ± 1.4 
Deph-D1-27_pH 6.5 52.2 ± 2.1 
7.4 ± 3.3 
74.2 ± 3.0 
3.6 ± 3.2 
Pt-deph-D1-27_pH 6.5 44.8 ± 2.5 77.8 ± 1.0 
 
 
Figure 4.4: Indicative thermal melting profiles 
for unreacted deph-RNA (black line) and 
platinated deph-RNA (red line). They were 
monitored at 260 nm, data collected from  
20 °C to 90 °C at a rate of 1 °C / min. CRNA = 
1.3 μΜ, 120 mM KClO4, pH 6.5. 
 
In addition to the information about the 
stability of the RNA upon platination, 
these thermal melting profiles also give a 
hint about the possible location of the platination site. The only very slightly affected Tm2 indeed 
suggests that the stable hairpin and the terminal loop in the second part of the D1-27 construct are not 
(or only slightly) influenced by platination. The significant change observed only for the first melting 
temperature suggests that the first part of the RNA construct is the one mostly affected from platination, 
and likely contains the platination site.  
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4.5 Circular Dichroism (CD) 
Circular dichroism (CD) is the difference in the absorption of left-handed circularly polarized light and 
right-handed circular polarised light and is observed for chiral molecules. Ellipticity (θ) is the quantity 
used to describe this phenomenon and is measured in degrees (deg)19. In CD spectroscopy the CD of 
molecules is measured over a range of wavelengths and is used to monitor structural changes in proteins 
as well as in nucleic acids19,20. DNA and RNA have specific CD signatures20. A regular  
A-form RNA has a characteristic spectrum showing a large positive ellipticity at 260 nm and a large 
negative one at 210 nm (Figure 4.5). Changes in the band at 260 nm corresponds to hyperchromism of 
nucleobases resulting from the helical stacking, and the band at 210 nm is connected to changes in loop 
structures21–23. Therefore, changes in the shape of the CD spectrum are directly related to 
conformational changes of the RNA.  
The CD spectrum of triph-D1-27 
shows the two typical bands due to A-
form RNA, at 210 nm and  
260 nm. CD spectra were recorded in 
0 mM KClO4 and 120 mM KClO4 in 
order to investigate the effect of K(I) 
on D1-27 structure. It was found that 
already without adding K(I) the 
spectrum of D1-27 had the typical 
shape corresponding to an A-form 
RNA. Upon K(I) addition, the band at 
260 nm and mostly the one at  
210 nm were getting more intense, 
probably due to more properly 
structured RNA formed or higher 
percentage of folded species 
(Appendix 2, Figure A 2.2). Next the 
spectrum of triph-D1-27 was compared to the CD spectrum of a RNA hairpin lacking the internal loop 
(RNA 26) (Chapter 2, Figure 2.28, right), therefore representing a properly A-form RNA (Figure 4.5). 
The slight differences observed between the two spectra can be attributed to the presence of the internal 
loop in D1-27.  
  
Figure 4.5: CD signal of D1-27 and RNA 26 constructs. CRNA = 
1.3 μΜ, in 120 mM KCl, pH 6.5 The raw data obtained were given 
in ellipticity (θ) and were measured in mdeg. To compare the CD 
spectra of different RNAs or of the same RNA under different 
concentrations the ellipticity is converted to molar ellipticity [θ] 
(deg. cm2.dmol-1) (Chapter 5, Paragraph 5.6). 
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CD spectroscopy as method of conformational analysis has been widely employed for the study of metal 
ion-nucleic acids interactions23, RNA-antibiotic interactions21,22 as well as platinum(II) anticancer 
drugs-RNA7 and platinum(II) anticancer drugs-DNA interactions7,24–29. In the current study CD 
spectroscopy has been employed to monitor the conformational changes induced on D1-27 upon 
platination.  
The CD spectra of the platinated RNA with oxaliPt exhibits the features characteristic for an A-form 
RNA, meaning a positive band at 260 nm and a negative one at 210 nm20 showing that platination did 
not influence the overall conformation of the RNA (Figure 4.6). In previous studies it was reported that 
the interaction of monoaquated cisPt with DNA resulted in transformation of B-form DNA to  
Z-form7. In our case, only small changes were observed. Compared to unreacted RNA, the negative 
band at 210 nm was only slightly changed, while for the positive band at 260 nm there was always a 
bathochromic shift (from 260 nm to 266 nm). However, the intensity of the band was not consistent, as 
it was observed to be either increased with respect to the unreacted RNA or remained almost unaffected 
(Figure 4.6, upper and lower panel). Changes of the negative band can be related to changes at the loop 
structures21,22. Here, the change of the negative band was not significant even if, based on the thermal 
melting studies, the first part of the RNA construct, and therefore the internal loop, could be affected 
by platination. More interesting is the red shift of the positive band, which was described also in the 
case of DNA platination with cisPt, and it was related to cis-bidentate platinum fixation25. Finally, the 
behaviour of the intensity of the positive band is not clear. The increase of the intensity suggests local 
changes at the stacking of the duplex, and suggests higher stacking (see D1-27 vs RNA 26 in Figure 
4.5). However, intrastrand cross-linking caused by platination is expected to reduce the stacking, 
resulting in a lower intensity band at 260 nm. Similar behaviour is observed when different spectra are 
recorded at increasing temperature (Figure 4.7). Interestingly, the spectrum of deph-D1-27 at 50 °C, 
which is close to its Tm1, shows a bathochromic shift together with a reduction in the intensity of the 
band at 260 nm, as well as a significant change for the band at 210 nm. Upon further heating both bands 
greatly decreased until spectra corresponding to almost unstructured RNAs were observed. Based on 
these data, the increase in intensity of the band at 260 nm, whenever observed, is difficult to be 
explained, and experimental mishandling and/or artefacts during the measurements could not be 
excluded.  
Summing up, these results suggest an overall retain of the A-form features with the observed changes 
most probably reflecting local disruption of the structure at the platination sites, with only little effects 
on the overall stacking of the entire construct. The red shift of the band at 260 nm, together with the 
previously commented decrease of the first melting temperature, strongly support intrastrand 
platination. 
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Figure 4.6: Comparison of the CD spectra of D1-27 (black) and the platinated D1-27 (red). CRNA and CPt-RNA = 
1.3 μΜ, in 120 mM KClO4, pH 6.5. CD spectra from different platination reactions are represented in which the 
band at 260 nm could be either increased in intensity (upper panel) or remained almost unaffected (lower panel) 
 
 
 Figure 4.7: Changes of the CD spectra of deph-D1-27 with increasing temperature.  
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The results above correspond to the 
platinated species originating from the 
upper band from the platination of 
deph-D1-27. CD spectra were also 
recorded on the corresponding species 
from the platination of triph-RNA.  
First, it was investigated whether the 
presence of the triphosphate group 
could have an influence on the 
conformation of our RNA construct. 
For that reason, the CD spectra of triph- 
and deph-D1-27 were compared. Not 
significant differences were observed 
between the two spectra (Figure 4.8) confirming that the triphosphate group does not play a role on the 
RNA conformation. The same behaviour as for the deph-platinated RNA species was observed for the 
Pt-RNA adducts obtained when triph-RNA was used as starting material, with the difference that a 
clearer decrease in intensity of the band at 260 nm was observed (Appendix 2, Figure A 2.3).  
 
4.6 Enzymatic digestion and HPLC analysis 
To evaluate which nucleobases are affected by platination, D1-27 was digested before and after 
platination with a non specific enzyme (P1 nuclease), dephosphorylated using an alkaline phosphatase 
(TSIAP) and injected into the HPLC machine. The combination of P1 digestion and HPLC is very often 
used for the quantification of DNA30 as well as for its composition analysis31. The P1 nuclease forms 
nucleoside-5ʹ-monophosphates, which upon dephosphorylation with an alkaline phosphatase (TSIAP) 
result in a mixture of nucleosides. The removal of the 5ʹ-phosphate with the alkaline phosphatase leads 
to products which are less polar and have improved separation on a C18 column32. The chromatogram 
obtained from the digestion of D1-27 corresponded to the four different nucleosides. The four peaks of 
the chromatogram were assigned to cytidine (C), uridine (U), guanine (G) and adenine (A) by 
comparing them with the retention time of standard nucleoside solutions.  
4.6.1 Optimization of the digestion and dephosphorylation conditions of D1-27 
The HPLC column used was analytical X-Bridge C18 RP column from Waters and the buffers were: 
buffer A: 40 mM NH4OAc, pH 6.5 and buffer B: methanol. The combination of NH4OAc / methanol is 
extensively used for this kind of studies32,33. First, a HPLC method had to be optimized in order to 
achieve good separation of the four nucleosides. For the method development, mixture of standard 
nucleoside solutions was utilized. A linear gradient of increasing amount of buffer B was used (Chapter 
Figure 4.8: Comparison of the CD spectra of D1-27 (black) and 
deph-D1-27 (blue). CRNA = 1.3 μΜ, in 120 mM KCl, pH 6.5.  
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5, Paragraph 5.5.3, Methods 8 and 9). After having a method, which allows the separation of the four 
nucleosides, the optimal digestion conditions had to be found. The choice of the P1 nuclease was based 
on the fact that it is widely used for digesting DNA, it is very stable and relatively low in cost30,33. For 
the digestion reaction, the amounts of the reactants as well as the incubation times had to be optimized. 
The amount of RNA used was 0.2 nmol and 1 U/μL of P1 nuclease was tested. The mixture was 
incubated at 37 °C for 15 min and afterwards 2 U/μL of alkaline phosphatase (TSIAP) were added. The 
dephosphorylation was performed at 37 °C for 15 min. Afterwards the TSIAP was thermally deactivated 
by heating at 74 °C for 15 min. The mixture was analyzed with HPLC and the chromatogram obtained 
is shown in Figure 4.9 (left panel). In addition to the four main peaks, which were assigned to the four 
nucleosides, several peaks appeared within the first seven minutes (Figure 4.9, left panel, blue frame), 
whose origin had to be investigated. The absence of late-eluting peaks (after 30 min) in the 
chromatogram indicates that the digestion was complete33. This was further confirmed by repeating the 
experiments using longer incubation times (1 h, 2 h, 22 h), which led to similar chromatograms, with 
no extra late-eluting peaks. Therefore, 1 U/μL of P1 nuclease and the incubation for 15 min were 
sufficient. 
 
Figure 4.9: Left panel: HPLC chromatogram of the digested D1-27 using 1 U/μL P1 nuclease (15 min incubation) 
+ 2 U/μL TSIAP (15 min incubation), Right panel: HPLC chromatogram of the digested D1-27 using 1 U/μL P1 
nuclease (15 min incubation) + 2 U/μL TSIAP (30 min incubation). By increasing the dephosphorylation time the 
intensity of the early-eluting peaks decreased suggesting more efficient dephosphorylation. 
 
The early-eluting peaks could not be the result of incomplete digestion due to their very short retention 
time but they could be the result of insufficient dephosphorylation. As mentioned before upon P1 
digestion there is a mixture of nucleotides, which after dephosphorylation are transformed into 
nucleosides. Insufficient dephosphorylation could result in a mixture of nucleotides and nucleosides. 
The nucleotides, due to the presence of a phosphate group should elute faster compared to nucleosides32. 
To confirm this, the RNA was digested and directly injected without dephosphorylation. The 
corresponding chromatogram shows four peaks with the same retention time as the early-eluted ones 
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observed above (Figure 4.9, left panel, blue frame, and Figure 4.10). From the direct injection of AMP 
and GMP, as well as from literature data31,34, the four peaks were assigned to the four nucleotides 
(Figure 4.10). Consequently, in order to decrease the intensity of the early-eluting peaks, the 
dephosphorylation had to be improved. This took place by testing different amounts of TSIAP and 
different incubation times. Higher concentration of TSIAP was tested (4 U/μL instead of  
2 U/μL) which was found to favour the decrease of the intensity of the extra peaks. However, the use 
of higher concentration and therefore higher volume of TSIAP led to increased glycerol amount in the 
reaction solution, making it too viscous, which could cause inhibition of the enzyme diffusion, thus 
reducing its activity1. Therefore, the amount of TSIAP was kept to 2 U/μL and the incubation time was 
varied. Already from increasing the time to 30 min, the extra peaks were significantly decreased (Figure 
4.9, right panel, blue frame). Consequently, the optimal combination of conditions leading to the 
decrease of the early-eluting peaks was 2 U/μL of TSIAP and incubating for 30 min at 37 °C (Figure 
4.9, right panel).  
 
Figure 4.10: HPLC chromatogram of the digested D1-27 using 1 U/μL P1 nuclease (15 min incubation) without 
dephosphorylation. The peak with retention time around 20 min corresponds to guanosine, because, since the 
sample used was the dephosphorylated RNA, not all the 5ʹ-end guanines do contain the phosphate group.  
 
4.6.2 Digestion of the platinated D1-27  
The same digestion conditions used for the unplatinated RNA were also applied to the platinated one. 
Upon digestion of the platinated deph-RNA originating from the upper slower migrating band a new 
peak was observed (Figure 4.11, left panel, blue frame). From the comparison of the relative peak areas 
of the four main peaks before and after platination it was found that the relative peak area of the guanines 
was reduced, and this reduction corresponded to the loss of two guanines. To confirm that the newly 
formed peak contained the Pt-GG fragment, a comparison was performed with the adducts obtained 
                                                     
1 https://ch.promega.com/resources/product-guides-and-selectors/restriction-enzyme resource/applications-and-
reaction-conditions-for-restriction-enzymes/ 
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upon reaction of the GpG dinucleotide with oxaliPt. The GpG dinucleotide was incubated with an 
excess of oxaliPt at 37 °C for 1 day35 and the reaction mixture was analyzed by HPLC. The 
chromatogram of the reaction mixture shows three peaks, two of which were assigned to unreacted 
oxaliPt and GpG dinucleotide upon comparison with the chromatograms of the pure starting materials. 
The third peak has the same retention time as the new peak observed upon digestion of the platinated 
RNA (Figure 4.11, right panel, blue box), suggesting that this peak contains the Pt-GG moiety. This is 
also in accordance with the reduction of the guanosine relative peak area upon platination. Interestingly, 
after 1 day of incubation the dinucleotide was almost fully converted into the platinated adduct.  
 
Figure 4.11: Left panel: HPLC chromatogram of the digestion of the platinated deph-D1-27, which led to the 
appearance of a new peak at 26 min., Right panel: HPLC chromatogram of the reaction of the GpG dinucleotide 
with oxaliPt. After 1 day of interaction, a new peak appeared at 26 min. From the comparison of the two 
chromatograms, the peak at 26 min was assigned to the Pt-GG species. 
 
The Pt(II)-RNA adducts from the upper band using the triph-D1-27 were also digested and injected into 
the HPLC machine. Similarly to what previously commented, an additional peak appeared, and from 
the comparison of the relative peak area before and after platination, loss of two guanines was suggested 
(Figure 4.12, left panel). The difference of this sample was that the retention time of the new main peak 
was 17 min, instead of 26 min, which was observed previously. However, in the present case, a minor 
peak at 26 min was also observed. Interestingly, by increasing the dephosphorylation time from 30 min 
to 1 day the peak at 17 min decreased while the peak at 26 min increased (Figure 4.12, right panel), 
resulting in the same picture obtained for the Pt-deph-RNA species. The extra-peak at 17 min likely 
corresponds to the Pt-GG-triphosphate species, while the peak at 26 min corresponds to its 
dephosphorylated form, whose formation was indeed favoured upon extensive dephosphorylation. The 
fact that the Pt-GG-triphosphate species elute faster from the column is not surprising, since they have 
increased negative charge with respect to their dephosphorylated counterpart. Interestingly, the fact that 
stronger dephosphorylation conditions are needed to obtain the Pt-GG species in this case suggests that 
the presence of platinum(II) partially inhibits the activity of the phosphatase.  
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All the above commented results suggest that the platinated RNA species migrating in the upper band 
on denaturing gels are platinated at a GG site. The thermal melting studies, described above, suggested 
that the first part of D1-27 was mainly affected upon platination. The only platination site that satisfies 
both requirements is G1-G2. This was further supported by the digestion data obtained from platinated 
triph-RNA, which clearly showed that the platination fragment includes the 5ʹ-end phosphate. Summing 
up, all the data collected so far strongly support that G1-G2 is the platination site of the species 
migrating in the upper band on denaturing gels.  
 
 
Figure 4.12: Left panel: HPLC chromatogram of the digestion of platinated triph-D1-27, Right panel: HPLC 
chromatogram of the same reaction with increased dephosphorylation time from 30 min to 1 day.  
 
4.7 32P-3ʹ-end and 32P-5ʹ-end radiolabelling of RNA 
The use of 32P-3ʹ-and 32P-5ʹ-end radiolabelled RNAs in RNA platination studies is extensively 
exploited7,15,36–41. The radioactive labelling allows high-resolution detection of the cleavage pattern of 
RNA or platinated RNA samples. 32P-end labelling can be performed either at 3ʹ- or at 5ʹ-end42. Both 
techniques were employed for this study. Independently of the labelling method used, the labelled RNA 
was purified by denaturing PAGE and was detected on a phosphorimager. To identify the possible 
platination sites, the untreated and platinated RNA samples were subjected to alkaline hydrolysis and 
enzymatic digestions, analyzed by denaturing PAGE and their cleavage patterns were compared 
(Chapter 5, Paragraph 5.10). This strategy is used very often to identify platination sites in RNA and 
DNA15,37–41. Upon RNA alkaline hydrolysis, single 2ʹ- and 3ʹ-monophosphate nucleotides are formed 
and the number of bands appearing on the PAGE corresponds to the number of nucleotides. The 
ribonuclease T1 (RNase T1) is used to map the solvent accessible guanine residues of the RNA43. This 
nuclease cleaves between the 3′-phosphate group of a guanidine ribonucleotide and 5′-hydroxyl of the 
adjacent nucleotide43. The initial product is a 2′,3′-cyclic phosphate nucleoside that is hydrolysed to the 
corresponding 3′-nucleoside phosphate. Additionally to RNase T1, S1 nuclease was used to map 
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mismatches and loops. This nuclease cleaves at mismatches and loops of double stranded nucleic acids 
releasing 5'-phosphoryl monoligonucleotides or oligonucleotides.  
4.7.1 32P-5ʹ-end radiolabelling of RNA 
In the 5ʹ-end labelling method the 5ʹ-terminal phosphate group is removed and a 32P-labelled 
monophosphate nucleotide is transferred to the 5ʹ-end by an enzyme40,42. In the first step, the RNA is 
dephosphorylated using an alkaline phosphatase. This step is not required for the 3ʹ-end labelling while 
is mandatory for the 5ʹ-end one. Upon dephosphorylation, the T4 polynucleotide kinase is used to 
transfer the γ-phosphate group from the γ-32P-ATP to the 5ʹ-end of the RNA (Figure 4.13, left panel). 
 
Figure 4.13: Left panel: Schematic representation of the steps leading to 5'-end labelling42. Right panel: 
Denaturing PAGE of 5ʹ-end labelled D1-27. The main band corresponds to the full-length construct. The gel was 
run at room temperature using 15 % denaturing PAGE. 
 
The 5ʹ-end labelling of D1-27 was improved upon optimization of the dephosphorylation and labelling 
reactions. It was crucial to have efficient dephosphorylation in order to have enough molecules to be 
labelled. Increasing the amount of alkaline phosphatase (from 2 U/μL to 4 U/μL) the labelling efficiency 
was increased from 0.01 % to 3 %. Additionally, using 6 U/μL instead of 4 U/μL of the PKN kinase the 
labelling was improved with labelling efficiency reaching the 25 %. The labelled D1-27 was purified 
by denaturing PAGE (Figure 4.13, right panel) and isolated with the crush and soak method (Chapter 
5, Paragraph 5.10.2). The concentration of the labelled RNA was measured by scintillation counting 
and it was compared to the total RNA concentration measured by UV. The dephosphorylation and 
labelling procedures are described in detail in chapter 5 (Paragraph 5.10).  
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4.7.2 Optimization of partial alkaline hydrolysis and enzymatic digestion of 32P-5ʹ-end labelled 
D1-27 
The isolated 32P-5ʹ-end labelled RNA was subjected to partial alkaline hydrolysis and enzymatic 
digestions (Chapter 5, Paragraph 5.10.5). The parameters to be optimized were the concentration of the 
reactants as well as the incubation time and the temperature. The RNA concentration used in all 
experiments was 0.1 nM. For the alkaline hydrolysis a stock of 0.5 M of sodium carbonate (Na2CO3) 
was used and the reaction temperature was kept at 90 °C. The concentration of Na2CO3 was varied from 
0.2 M to 0.4 M and the incubation time tried first was 10 min. In the presence of 0.4 M Na2CO3 twenty-
four bands were visible on the gel (Figure 4.14, left panel). The bands corresponding to the first 
nucleotides were not visible because small fragments (1-5nt) migrate too fast on the gel15,44. Despite 
that, in order to ensure the maximum efficiency of alkaline hydrolysis, the incubation time was 
increased from 10 min to 15 min. However, no extra bands appeared on the gel (Figure 4.14, right 
panel). Moreover, aiming at increasing the resolution of the gel picture, which could eventually result 
in better defined bands leading to easier attribution, the gel solution used was increased from 15 % to 
25 % (Figure 4.14, right panel). However, very similar picture was obtained in the two cases. 
 
 
  
Figure 4.14: Left panel: Partial alkaline hydrolysis ladder for 
 32P-5ʹ-end labelled D1-27. The reaction took place in 0.4 M 
Na2CO3, for 10 min at 90 °C. 15 % denaturing PAGE. Right panel: 
Partial alkaline hydrolysis ladder for 32P-5ʹ-end labelled D1-27. 
The reaction took place in 0.4 M Na2CO3, for 10 min and 15 min at 
90 °C. 25 % denaturing PAGE. C indicates the control lane in the 
two cases. 
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To confirm the numbering of the partial alkaline hydrolysis ladder and to assign the guanines of the 
RNA construct the RNase T1 was used. Concentration and incubation time were optimized, whilst the 
temperature was kept at 55 °C45, which is the recommended working temperature for this enzyme. The 
reaction was performed under native conditions. The RNase T1 concentration used varied from 
0.1 U/μL to 10 U/μL and the incubation times were 20 (1), 30 (2) and 40 (3) min (Figure 4.15). Under 
these conditions only two bands were visible, corresponding to G23 (Figure 4.15, blue frame) and U5 
(Figure 4.15, green frame). This suggests that G23 was the only guanine accessible to RNase T1 for 
digestion. The cleavage at the U5 site was not expected, but cleavage of uridines from RNase T1 is 
often reported in the literature7,38. Higher concentration of RNase T1 as well as higher incubation times 
were screened in order to test the possibility of cleavage at the other guanine residues. The RNase T1 
concentration varied from 10 U/μL to 100 U/μL. In the case of 10 U/μL and 20 U/μL,  
20 min (1), 40 min (2) and 60 min (3) digestion time was used, while for the 50 U/μL and 100 U/μL the 
reaction was run for 10 min (1), 20 min (2), 30 min (3) and 40 min (4) (Figure 4.16). Despite the 
increased enzyme concentration and incubation time, the same two bands were visible. The new band 
appearing in the lower part of the gel does not correspond to any guanine (Figure 4.16, purple frame). 
The conditions for the RNaseT1 digestion chosen were then: 20 U/μL of RNase T1 and incubation for 
20 min at 55 °C. The RNase T1 is known to specifically cleave guanines in single stranded DNA/RNA, 
and it is used to map solvent accessible guanines43. Our results suggest that under the used experimental 
conditions only G23 in the G-U wobble is accessible to cleavage. G15, even if located within a tetraloop, 
was not cleaved probably due to the compact structure that the -UUCG- tetraloop adopts. This 
characteristic of the -UUCG- tetraloop makes it also an unfavourable metal ion binding site46. 
Digestions with RNase T1 were performed also under denaturing conditions without though leading to 
the appearance of more bands, suggesting that the RNA was not properly denatured under the 
experimental conditions used. Due to flanking 5'-end, G1 and G2 may be cleaved by T1 RNase, but the 
absence on the gel of fragments shorter than 5 nucleotides prevented their evaluation. Next, the use of 
the S1 nuclease (S1) was aiming at mapping the looped and bulged regions. Time and concentration 
dependent experiments were performed in order to find the best reaction conditions. For this purpose 
0.5 U/μL to 1 U/μL of S1 were used and the incubation time was varied from 10 min to 40 min at  
25 °C (Figure 4.17). Long incubation times (30 - 40 min) seemed to have negative effect on the activity 
of the enzyme with the observed bands becoming more faint upon longer incubation (Figure 4.17). With 
S1 nuclease it was possible to map the internal loop (U5 - U7 and U20 - A22, Figure 4.17, light blue 
and blue frames) and a part close to the terminal loop (G15 - A17, Figure 4.17, brown frame). The 
experimental conditions chosen were 0.8 U/ μL of S1 and 10 min of incubation at 25 °C.  
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Figure 4.15: Autoradiogram illustrating partial alkaline hydrolysis and RNase T1 cleavage pattern obtained for 
32P-5ʹ-end labelled D1-27. The C stands for the control RNA, OH¯ for the partial alkaline hydrolysis lane. OH¯ 
lane: 1 corresponds to 10 min and 2 to 15 min of digestion at 90 °C with 0.4 M Na2CO3. T1 RNase lanes: 
concentration and time dependent experiments were performed in the presence of citrate buffer under denaturing 
conditions at 55 °C. The concentrations used are reported directly above the gel image, while 1, 2, and 3 
correspond to 20 min, 30 min and 40 min of digestion. 25 % denaturing PAGE. 
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Figure 4.16: Autoradiogram illustrating partial alkaline hydrolysis and RNase T1 cleavage pattern obtained for 
32P-5ʹ-end labelled D1-27. The C stands for the control RNA, OH¯ for the partial alkaline hydrolysis. The OH¯ 
lane corresponds to 15 min of digestion at 90 °C with 0.4 M Na2CO3. T1 RNase lanes: concentration and time 
dependent experiments were performed in the presence of citrate buffer under denaturing conditions at 55 °C. 
The concentrations used are reported directly above the gel image. In the case of 10 U/ μL and 20 U/ μL, 1, 2, 
and 3 correspond to 20 min, 40 min and 60 min of digestion, whereas in the case of 50 U/ μL and 100 U/ μL, 1, 
2, 3 and 4 correspond to 10 min, 20 min, 30 min and 40 min of digestion respectively. 25 % denaturing PAGE. 
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Figure 4.17: Autoradiogram illustrating partial alkaline hydrolysis and nuclease S1 cleavage pattern obtained 
for 32P-5ʹ-end labelled D1-27. The C stands for the control RNA, OH¯ for the alkaline hydrolysis lane. Both OH¯ 
lanes correspond to 15 min digestion at 90 °C with 0.4 M Na2CO3. S1 lanes: concentration and time dependent 
experiments for the S1 were performed in the presence of zinc sulphate under denaturing conditions at 25 °C. The 
concentrations used are reported directly above the gel image, while 1, 2, 3 and 4 correspond to 10 min, 20 min, 
30 min and 40 min of incubation respectively. 25 % denaturing PAGE. 
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4.7.3 Partial alkaline hydrolysis and enzymatic digestions of 32P-5ʹ-end labelled platinated  
D1-27 
Once the reaction conditions for the partial alkaline hydrolysis and enzymatic digestion of D1-27 were 
optimized, they were also applied to labelled platinated RNA samples. At first, platinated samples were 
prepared using the same experimental conditions as for the not radiolabelled RNA (5 eq of oxaliPt, 
0.25 mM RNA, 1 day of incubation, 25 °C, in 120 mM KCl (Chapter 2, Paragraph 2.4.4 and Chapter 5, 
Paragraph 5.10.2). The gel obtained from the platination reaction with 32P-5ʹ-end radiolabelled RNA is 
shown in Figure 4.18. Despite the fact that deph-RNA was used, always only two bands were observed 
on the gel upon platination, contrarily to what was observed for the platination of unlabelled  
deph-D1-27 (Chapter 2, Paragraph 2.9. Figure 2.44). A possible explanation for this behaviour is the 
shorter running time used for the analysis of the labelled samples. Indeed, in the latter case the gel was 
running for only 15 h, while for the unlabelled samples the running times varied between one to two 
days.  
Figure 4.18: 25 % denaturing gel for the platination reaction of 32P-5ʹ-end 
labelled D1-27 with oxaliplatin. A: Control, B: lower band, C: upper band. 
The gel was run at 4 °C. 
 
 
After platination the reaction mixture was purified via denaturing PAGE, and isolated with crush and 
soak (Chapter 5, Paragraph 5.4). The platinated samples from both upper and lower bands were 
subjected to partial alkaline hydrolysis and enzymatic digestions (Figure 4.19). RNase T1 and S1 
nuclease enzymatic cleavage as well as partial alkaline hydrolysis of unplatinated RNA were also 
performed and the corresponding samples were loaded on the gel for comparison. The OH¯ lane of the 
lower band shows an overall cleavage pattern very similar to that obtained for the control sample. 
Similar behaviour was observed also for the RNase T1 ladder and S1 nuclease lane (Figure 4.19, dark 
blue, brown and light blue frames). This behaviour was expected considering that the lower band 
contains mostly unreacted RNA. The little differences observed may be due to the presence of small 
amounts of platinated RNA, expected to be present in the lower band based on MS experiments 
performed on unlabelled samples (Chapter 2, Figure 2.26). The upper band contains only platinated 
adducts and therefore the OH¯ cleavage pattern was expected to be different compared to the control. 
Indeed, the bands corresponding to shorter fragments were very faint (U5-G8, green frame in Figure 
4.19) and cleavage products with slower mobility were observed, probably due to platinum(II) presence. 
This different cleavage pattern suggests conformational changes likely caused by platination. In the 
RNase T1 lane, the band corresponding to G23 shows higher intensity with respect to the control lane, 
suggesting increased accessibility of this nucleotide upon platination. This may indicate platination 
close-by, and excludes direct platination because less efficient cleavage is expected upon direct 
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platination44. Moreover, new bands appeared in the RNase T1 lane, indicating that this part became 
accessible for cleavage upon platinum(II) binding (Figure 4.19, black dotted frame). The S1 nuclease 
lane showed increased intensity bands in the area corresponding to G16-A17 (Figure 4.19, brown frame) 
suggesting higher accessibility of this area upon platination. Moreover, also in this case, novel cleavage 
sites were detected (Figure 4.19, red dotted line). The appearance of new cleavage sites both in the 
RNase T1 as well as in the nuclease S1 lanes is often reported in the literature and justified as areas 
which became more accessible for digestion upon platination due to different conformation of the 
platinated RNA species compared to the unplatinated ones7,37,38,44. 
In conclusion, the digestions performed on the 32P-5ʹ-end labelled platinated RNA samples originating 
from the upper band suggest that G23 is not a direct platination site and that the conformational changes 
caused by platination affect the solvent accessibility of the loops. Platination at G1, G2 could not be 
investigated, since short fragments could not be detected with this labelling approach. For that reason, 
32P-3ʹ-end labelling technique was used.  
 
 
 
  
Figure 4.19: Autoradiogram illustrating partial 
alkaline hydrolysis and RNase T1 and S1 cleavage 
pattern obtained for the following 32P-5ʹ-end labelled 
samples: unreacted D1-27, platinated samples isolated 
from the upper band (upper) and from the lower band 
(lower). The C stands for the control, OH¯ for partial 
alkaline hydrolysis lane, T1 for the partial RNase T1 
digestion and S1 for the partial RNase S1 digestion 
lane. The two lanes for the T1 correspond to the 
repetition of the same reaction. The coloured frames on 
the gel and on the secondary structure of D1-27 
indicate which areas are affected. 25 % denaturing 
PAGE. 
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4.7.4 32P-3ʹ-end radiolabelling of D1-27 
The "splint-method" was used for the 32P-3ʹ-end labelling of D1-2742,47. In this method a short DNA 
template, which is complementary to the 3ʹ-end of the RNA to be labelled and contains three nucleotide 
overhang (5ʹ-CCG-3ʹ), is hybridized to the RNA. Afterwards, by using the Klenow fragment of DNA 
polymerase I the 3ʹ-end of the RNA is extended with a single α-32P-labelled dCTP nucleotide (Figure 
4.20, left panel). 
 
 
 
Figure 4.20: Left panel: Schematic representation of the steps leading to RNA 3ʹ-end labelling47. Right panel: 
Denaturing PAGE of 32P-3ʹ-end labelled D1-27. All three bands correspond to the same reaction. The gel was 
run at room temperature. 15 % denaturing PAGE.  
 
This labelling reaction, contrarily to the 32P-5ʹ-end labelling, is template dependent. To obtain a single 
labelled product it was necessary to find the correct length of the DNA splint as well as the correct 
number of the overhang nucleotides. For that purpose a 20nt long DNA template with one (5ʹ-G-3ʹ) and 
three (5ʹ-CCG-3ʹ) nucleotide overhang as well as a 13nt long DNA with three nucleotide overhang  
(5ʹ-CCG-3ʹ) were tested (Chapter 5, Paragraph 5.10.3). The DNA template that allowed to obtain a 
single labelled species was the 13nt long DNA with three nucleotide overhang (5ʹ-CCG-3ʹ). Using that 
DNA template, time dependent and DNA template dependent experiments were performed. From these 
experiments, the optimal incubation time was found to be 1 h, and the best DNA template concentration 
was found to be 10 μM. All the labelling reactions were performed at 37 °C. These experimental 
conditions were used for large scale labelling, in order to get enough material for RNA platination. Even 
if the labelling efficiency of the 3ʹ-end labelling was lower compared to the 5ʹ-end one, the recovered 
amount was enough for the platination reactions (Figure 4.20, right panel). The isolation of the 3ʹ-end 
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labelled RNA from the gel as well as the platination reactions and the isolation of the platinated samples 
were performed as described above for the 5ʹ-end labelled samples. 
4.7.5 Partial alkaline hydrolysis and enzymatic digestions of unreacted and platinated  
32P-3ʹ-end labelled D1-27 
Partial alkaline hydrolysis and enzymatic digestions were performed for both untreated and platinated 
RNA (upper and lower band) using the reaction conditions commented above (Paragraph 4.7.2). 
Twenty-three bands (G1-G23) could be counted on the control lane (D1-27) corresponding to partial 
alkaline hydrolysis. The most intense bands of the RNase T1 ladder lane corresponded to G1-G2 (Figure 
4.21, green frame) and G23 (Figure 4.21, dark blue frame) indicating that these guanines are the most 
accessible ones. A band corresponding to G23 was observed also during the cleavage studies performed 
on 32P-5ʹ-end labelled platinated RNA samples. Other faint bands were also observed but did not all 
correspond to guanines (G15, A17, A22)15,38,44. The S1 nuclease lane shows cleavage at the terminal 
loop (Figure 4.21, brown frame). As in the previous case, the cleavage pattern observed in the case of 
partial alkaline hydrolysis and of RNase T1 digestion of the species isolated from the lower band was 
very similar to the control due to the presence of mostly unreacted RNA. However, the internal loop 
seems to be more accessible to cleavage, as new bands appear in the A4-A6 region (Figure 4.21, light 
blue frame, S1 lane). This part of the construct is cleaved also in the case of the platinated species of 
the upper band, suggesting that the lower band contains traces of platinated RNA in addition to the 
unreacted species, which was in line with the results from the MALDI-MS measurements (Chapter 2, 
Figure 2.26). The OH¯ lane of the species isolated from the upper band shows reduced cleavage 
intensity at G1-G2 (Figure 4.21, compare red frames) and all the bands were overall less intense 
compared to the control. The RNase T1 lane suggests that G23 remains the most accessible guanine but 
reduced cleavage intensity was observed for G1-G2 (Figure 4.21, compare green frames), which was 
very pronounced for the control. The inhibition of the cleavage at G1-G2 as well as the increased 
accessibility of A4-A6 upon platination could indicate platination at G1-G2 which made the 
neighbouring nucleobases (A4 - A6) more accessible. These data are in agreement with the results 
obtained from the thermal melting studies and enzymatic digestions followed by HPLC analysis, which 
also suggested G1-G2 as possible platination site.  
In conclusion, the experiments performed on both 5ʹ-end and 3ʹ-end labelled samples exclude G23 as 
possible platination site, since its accessibility remains either similar (in the case of 3ʹ-end labelled 
samples) or is even increased (in the case of 5ʹ-end labelled samples) upon platination. Moreover, in 
both cases, different loop accessibility was found upon platination but no consistent behaviour was 
observed for 5ʹ-end and 3ʹ-end labelled samples, thus preventing detailed comments. Finally, the 
experiments carried on using 3ʹ-end labelled samples allowed to identify G1-G2 as possible platination 
site, as previously suggested by other techniques (Paragraphs 4.4 - 4.6). 
151 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Autoradiogram illustrating partial alkaline hydrolysis and RNase T1 and S1 cleavage pattern 
obtained for the following 32P-3ʹ-end labelled samples: unreacted D1-27, platinated samples isolated from the 
upper band (upper) and from the lower band (lower). The C stands for the control, OH¯ for partial alkaline 
hydrolysis, T1 for the partial RNase T1 digestion and S1 for the partial RNase S1 digestion. The coloured frames 
on the gel and on the secondary structure of D1-27 indicate which areas are affected. 25 % denaturing PAGE. 
The drawback of the use of 32P-3ʹ-end labelled RNA was the reduced stability of the labelled products, which led 
to multiple bands at the control lanes that does not allow us to have a better gel picture. 
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4.8 NMR characterization of the platinated RNA species isolated from the 
upper band 
1D 1H-NMR experiments were first used to characterize the platinated RNA samples. Large-scale 
platination reactions were performed in order to obtain the large amounts of platinated RNA samples 
needed for NMR analysis. An easy and quick way to detect possible platinum(II)-RNA interactions was 
by comparing the changes of the imino proton resonances of uracil NH3 and guanine NH1 in the 
unreacted and platinated RNA samples. The changes of the imino proton resonances during the 
platination reaction were also utilized for the time evolution NMR experiments, which were described 
in the previous chapter (Chapter 3). Imino protons can exchange rapidly with water, making their signals 
hardly visible in the spectra. However, when they are involved in stable base-pairing, the exchange is 
slowed down and the imino proton resonances become sharper and well observable48. All the 
experiments that will be described below were performed in 90 % H2O:10 % D2O in the presence of 
120 mM KClO4, pH 6.5 at 25 °C (Chapter 5, Paragraph 5.9.2). Spectra were also recorded at lower 
temperature (4 °C) at which, due to slower molecular tumbling, sharper signal were observed (Chapter 
3, Figure 3.2). Imino proton resonances were previously assigned by combining  
[1H,1H]-NOESY experiments on exchangeable and non-exchangeable protons at different 
temperatures49.  
1H-NMR spectra of dephosphorylated and 5'-triphosphate D1-27 were first compared. As shown in the 
previous chapter (Chapter 3, Paragraph 3.3.4, Figure 3.10) the imino proton resonances of the two 
species were very similar, with the difference that the G1NH1 resonance was slightly upfield shifted 
upon dephosphorylation. This upfield shift can be related to the absence of the triphosphate. In the same 
manner, the imino proton resonances of the platinated RNA species isolated from the upper band show 
very similar behaviour, using either deph-D1-27 or triph-D1-27 as starting material (Appendix 2, Figure 
A 2.4). For this reason, the NMR characterization which follows refers mainly to platinated triph-RNA 
adducts, which showed the best spectrum resolution. 
In Figure 4.22, are compared the 1H-NMR spectra (imino proton and aromatic region) for 1) non-
platinated triph-D1-27 (black line), 2) platinated triph-RNA sample from the upper band (red line) and 
3) the corresponding sample from the lower band (magenta line). The imino proton resonances profile 
of the upper band is different compared to the one of the unreacted RNA. More specifically, the imino 
proton peaks corresponding to G2 and U25 disappeared, while G8NH1 resonance was reduced in 
intensity and slightly shifted. The intensity of G23NH1 resonance was also slightly reduced, whereas 
the imino proton resonances of G15, G16 and G18 remained mostly unaffected. Since U10NH3 and 
U24NH3 resonances overlap, no safe conclusion on their behaviour can be drawn at this point. Upon 
platinum(II) binding to RNA the base-pairing at the binding site, as well as the overall RNA structure, 
could be affected10 with these changes to be reflected on the changes of the imino proton resonances.  
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Figure 4.22: 1H-NMR spectra (aromatic and imino proton regions), including imino proton assignment of the 
untreated D1-27 (black line), Pt-RNA sample isolated from the upper band (red line) and Pt-RNA sample isolated 
from the lower band (magenta line). The spectra were recorded at 25 °C, in 120 mM KClO4, pH 6,  
600 MHz.  
 
The results commented in the previous paragraphs (Paragraphs 4.4 - 4.7) suggest platination at 
G1-G2. From the 1H-NMR spectrum of the upper band the disappearance of G2NH1 supports direct 
platination at this site. In order to get information for the behaviour of the imino proton resonance of 
G1 (this imino proton resonance is rather low at 25 °C due the dangling bases at the 5ʹ-end50) the  
1H-NMR spectrum of the isolated Pt-triph-D1-27 sample as well as the unreacted triph-D1-27 were 
recorded at 4 °C (Appendix 2, Figure A 2.5). At this temperature, the resonance of G1NH1 is sharper 
and better visible in the unreacted RNA. The absence of G1 and G2 imino proton resonances in the 
1H-NMR spectrum of the isolated upper band at this temperature further supports direct platination at 
this site. As discussed above platination results in hydrogen bond breakage, followed by disappearance 
of their imino proton resonances. The absence of the U25 imino proton resonance is likely due to 
structural changes induced locally upon G1-G2 platination, which eventually lead to base-pairing 
disruption and therefore disappearance of U25NH3 resonance. The shift and intensity decrease of the 
imino proton peak of G8NH1 may be due to local conformational change of the internal loop, following 
G1-G2 platination as was also suggested from the time evolution NMR experiments (Chapter 3, 
Paragraph 3.3.3). The imino proton resonances of the nucleotides located in the second part of the 
construct (U10-G18) remain mostly unaffected, suggesting little destabilization upon platination, being 
in line with the thermal melting studies. As far as the aromatic region of the spectra is concerned, the 
most significant change is the appearance of one (or two) new strongly down-field shifted peak(s) at 
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around 8.5 - 9 ppm, which may confidently be attributed to H8 of the platinated guanosines51. 
Interestingly, the shift is stronger in the samples prepared using triph-D1-27 as starting material 
(Appendix 2, Figure A 2.4, black dotted frame). A [1H,13C]-HSQC experiment performed on an isolated 
platinated sample (Appendix 2, Figure Α 2,6, lower panel) confirmed the findings so far commented. 
As far as guanines are concerned, strong down-field shifts are observed only for C8 resonances of G1 
and G2, suggesting direct metal binding to the neighbouring N7 atoms (Appendix 2, Table A 2.1, red 
boxes in Figure A 2.6, lower panel)52. The C8 resonance of G8 does not significantly shift, further 
suggesting absence of direct platination at this site, while the resonance of G23, barely visible already 
for the unreacted RNA, is no longer visible in the spectrum of the platinated sample, suggesting 
dynamics at this site (Appendix 2, Table A 2.1). Similarly, a [1H,1H]-NOESY spectrum recorded on the 
same sample shows changes in the first part of the construct, and generally sharp peaks are visible in 
the sequential walk region. Interestingly, a cross peak between A6H2 and A21H2 is present, suggesting 
that platination does not completely break adenine stacking in the internal loop (Appendix 2, Figure A 
2.7). 
From the MALDI-MS, it was known that the lower band consists mostly of unreacted RNA, but there 
was also a small amount of platinated species. As such, the imino proton resonances in the 1H-NMR 
spectra of the samples isolated from the lower band are very similar to the ones of unreacted D1-27, 
with a few peaks with reduced intensity and / or shifted (G2, G8 and U25), likely due to the presence 
of little amount of platinated RNA species (Figure 4.22, magenta line). 
The above commented data further support G1-G2 as the preferential platinum(II) binding site of the 
species which migrates in the upper band, no matters the presence of the triphosphate at the 5ʹ-end. It 
should be considered though that the appearance of the new faster migrating band observed upon 
platination of the deph-RNA could be related to the absence of the triphosphate group. Indeed, although 
G1-G2 remains the preferential binding site, the decreased negative charge at the 5ʹ-end could lead to 
the formation of other differently platinated RNA species, responsible for the newly observed faster 
migrating band. The results obtained from all the above mentioned techniques suggest that platinum(II) 
strongly prefers G1-G2 as binding site. In general, metal ions are crucial for RNA structure and activity 
and several studies, mostly utilizing NMR spectroscopy, were focused on the elucidation of RNA metal 
ion binding sites46,52–55. The RNA used for this study (D1-27) derives from D1κζ, a three way junction 
RNA representing the catalytic core of the group II intron ribozyme Sc.ai5γ from baker`s yeast (Chapter 
1, Paragraph 1.1.4). NMR solution structure and metal ion binding properties of D1κζ were recently 
reported52,54. D1-27 comprises a well-known internal loop, which acts as GAAA tetraloop receptor, and 
contains three stacked adenines and a U-U mismatch56,57. A recent study reported on binding preferences 
of Mg(II), Cd(II) and Co(III)hexammine towards D1-27. The latest two were used as mimics of inner-
sphere and outer-sphere Mg(II) binding respectively. All three metal ions were reported to bind to the 
5ʹ-end, favoured by the presence of the negatively charged triphosphate group, while no interactions 
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was detected in the -UUCG- tetraloop. Generalized electrostatic interaction was observed at the internal 
loop, with slightly different behaviour between the divalent and trivalent species46. Similar behaviour 
was observed also in our study: platinum(II) binds mainly at the 5ʹ-end, with G1-G2 being the 
preferential binding site, whereas no interaction was observed at the -UUCG- tetraloop, with the imino 
proton resonance of G15 remaining almost unaffected upon platination (Figure 4.22). Direct interaction 
at the internal loop cannot be investigated by looking at the imino proton resonances. However, the 
results from the different analytic techniques commented so far seem to exclude direct platination at 
uracil or adenines in the internal loop. 
As it was already mentioned in chapter 3, concerning the time evolution NMR experiments, observing 
the changes of the imino proton resonances is a quick way to determine whether the platinum(II) has 
an influence on the RNA structure58 but it also has drawbacks. First, the imino proton resonances are 
strongly sensitive to different pH and temperature, therefore small changes of the experimental 
conditions could cause peak shift and broadening. For this reason, special care should be taken, that all 
the NMR spectra are recorded at the same temperature and pH, in order to be able to attribute the 
observed differences only to platinum(II) binding. Second, and most important point, changes in the 
imino proton resonances only give indirect information on platination sites. Indeed, being indicators of 
base-pairing and therefore used for monitoring the existence or not of a secondary structure, the imino 
proton resonances could shift or disappear not necessarily due to direct metal-RNA interaction, but due 
to general structural changes induced by platination close-by. For example, in the case of G8 and U25, 
their imino proton resonances shifted and disappeared, respectively, without those nucleotides being 
directly platinated. Direct platination can be identified using different NMR techniques, or other 
analytical methods. In our case, enzymatic digestion (Paragraph 4.6) excluded platination at adenines, 
which are known to be possible platination sites for oxaliplatin, and confirmed GG platination.  
Summing up, even if the changes in imino proton resonances do not allow to distinguish between direct 
platination and platination close-by, they give fast qualitative information on the binding site, which 
can be confirmed by combining data from other analytic techniques. 
 
4.9 Sequence- and structure specificity of oxaliplatin with RNA 
Guanine and adenine bases represent the main target for platinum(II) complexes both for DNA59 and 
RNA6. In the case of cisPt, the most frequently observed platinated adducts with DNA are the  
1,2-d(GG) (65 %) and the 1,2-d(AG) (25 %) intrastrand cross-links. However, recent studies on  
oxaliPt-RNA interactions have revealed that it tends to form both intrastrand adducts but also adducts 
involving only adenines have been indentified6,60. Our study showed that the main platinated adduct 
obtained by reacting D1-27 with oxaliplatin contains a 1,2-(GG) intrastrand crosslink at the 5'-end, 
involving G1 and G2. G1-G2 binding was preferred over G15-G16, located at the terminal loop. The 
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absence of platination in this latter case is likely due to the arrangement of the two guanosines, which 
point their N7 opposite from each other, thus not offering the ideal geometry for GG intrastrand 
platination (Chapter 3, Figure 3.8). Our results suggest that the presence or absence of the triphosphate 
group did not play a role in the G1-G2 binding of oxaliPt, given that similar platination behaviour was 
observed in both cases. Indeed, the main platinated RNA species formed are platinated at G1-G2, and 
migrate in the upper band, by using both triph-RNA and deph-RNA (Chapter 2, Figure 2.26 and 2.45) 
as starting material. Structure specificity of platinum(II) binding has been reported61. For example, 
Elmroth and co-workers suggested the G-U wobble base pair as binding site for cisPt37,44. DeRose and 
co-workers reported the cross-linking by cisPt of two guanines located at opposite site of an internal 
loop15. A very recent 2.6 Å-resolution crystal structure of a cisplatin-modified 70S ribosome provided 
us with new insights into platinum(II)-RNA interactions62 (Chapter 1, Paragraph 1.3.5). Nine 
platinum(II) modifications were found in the whole ribosome, despite the presence of two thousand two 
hundred N7-atoms with similar solvent accessibility as the nine platinated sites. This finding suggests 
that RNA platination is not only defined by spatial accessibility. Additionally, it was suggested that 
specific structural motifs may represent preferential platination sites, and differences in adenine vs 
guanine binding were described.  
The RNA used in the current study contains several common RNA structural features like G-U wobble 
base pair, internal and terminal loop as well as various guanines and adenines which could act as 
platinum(II) binding sites. Despite its complicated profile and the many platination sites available, a 
strong preference for the 5ʹ-end G1-G2 site was observed for oxaliplatin. This high selectivity of oxaliPt 
for GG sites is in line with similar results reported recently from cisplatin interaction of bacterial 
ribosomal RNA hairpins38. 
 
4.10 RNA UU 
To study the effect of platination at the G1-G2 site a new RNA 
construct, which is an analogue of D1-27, was used, in which the 
first two G-C base-pairs were replaced by U-A base-pairs 
(RNAUU) (Figure 4.23, bottom). 1H-NMR spectra, thermal 
melting studies and CD measurements were recorded on this new 
construct. The data obtained were compared with the 
corresponding data from non-platinated and platinated D1-27. 
The 1H-NMR spectrum of RNAUU showed less imino proton 
resonances than expected (Figure 4.24, red line). Their 
assignment was based on comparison with the imino proton 
resonances of D1-27, and confirmed by a [1H,1H-NOESY] 
Figure 4.23: Secondary structures 
of D1-27 (top) and RNAUU (bottom). 
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spectrum recorded at 4 °C. Interestingly, no clear imino proton resonances for U1, U2, U24 and U25 
could be identified, suggesting that the first part of the construct is very unstable. This is likely due to 
the presence of consecutive U-A base-pairs at the 5'-end, which resulted in destabilizing the first part 
of the construct and led to the disappearance of the imino proton peaks of the first nucleotides. 
Interestingly, the pattern of the 1H-NMR spectrum of the RNAUU construct was almost identical to the 
one of the platinated RNA species isolated from the upper band, suggesting that the presence of 
platinum(II) at the G1-G2 site has similar effect on the stability of the RNA construct like the 
replacement of a stable G-U for an U-A base-pair (Figure 4.24, blue and red lines). 
 
 
 
 
 
 
 
 
 
 
Next, the thermal melting profile of RNAUU was recorded. Similarly to D1-27, also for this construct 
two melting temperatures could be identified (Appendix 2, Figure A 2.8). Interestingly, Tm1 of RNAUU 
was much lower than the one of D1-27 (ΔTm = 20.4 ± 3.1 °C) while Tm2 was very similar (Table 4.3). 
This suggests that the first part of the construct is highly destabilized, which also justifies the absence 
of the imino proton resonances corresponding to this part of the construct (Figure 4.24, red line). 
Changes of Tm1 and almost unaffected Tm2 were also reported for our isolated platinated RNA species 
(Paragraph 4.4), even if ΔTm1 was not as pronounced as it was found for RNAUU (Table 4.2).  
  
Figure 4.24: 1H-NMR spectra (aromatic and imino proton regions), including imino proton assignment,  
of RNAUU (red line), Pt-triph-D1-27 (blue line) and non-platinated triph-D1-27(black line). The spectra  
were recorded at 25 °C, in 120 mM KClO4, pH 6, 600 MHz.  
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Table 4.3: Summary of the melting temperatures for the deph-D1-27, Pt-deph- D1-27 and RNAUU constructs. 
The given Tm values are the average of at least five measurements. The errors of the melting temperatures 
correspond to standard deviation. The errors of the ΔTm were estimated using the standard error propagation 
calculations18. 
RNA construct Tm1 (°C) ΔTm1 (°C) Tm2 (°C) ΔTm2 (°C) 
Deph-D1-27_pH 6.5 52.2 ± 2.1 - 74.2 ± 3.0 - 
Pt-deph-D1-27_pH 6.5 44.8 ± 2.5 7.4 ± 3.3a 77.8 ± 1.0 3.6 ± 3.2a 
Pt-triph-D1-27_pH 5 31.8 ± 2.3 20.4 ± 3.1b 76.4 ± 1.0 2.2 ± 3.2b 
a The values refer to the difference between melting temperatures of D1-27 and platinated D1-27. b The values 
refer to the difference between melting temperatures of deph-D1-27 and RNAUU. 
 
Lastly, the CD spectrum of RNAUU shows the characteristic pattern for an A-form RNA, but compared 
to the corresponding spectrum of deph-D1-27 few differences were found (Figure 4.25, black and blue 
line). Bathochromic shift of the band at 260 nm and reduced intensity of the band at 210 nm were 
observed. The changes at 260 nm can be attributed to changes of the helical parts of the RNA, while 
the changes of the 210 nm band may be connected with changes at the loop regions23–25. The 
destabilization of the first part of RNAUU due to replacement of the G-C with U-A base-pairs may be 
responsible for the bathochromic shift of the band at 260 nm , while the changes at 210 nm may reflect 
changes of the internal loop (the terminal loop is expected not to be affected based on the value of Tm2 
(Table 4.3). The bathochromic shift of the band at 260 nm was a characteristic observed in all  
Pt(II)-RNA adducts studied here showing that platinum(II) binding affects the base-pairing while only 
slight changes were observed for the band at 210 nm (Figure 4.25, red line) suggesting that the internal 
loop is not significantly affected upon platination. 
Figure 4.25: Comparison of the CD spectra of 
deph-D1-27 (black), RNAUU (blue line) and  
Pt-deph-D1-27 (red line). CRNA /CPt-RNA = 
1.3 μΜ, in 120 mM KClO4, pH 6.5. 
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Summing up, the RNAUU construct was used as a model RNA in order to investigate the effect of 
platination at the G1-G2 site. The two U-A base-pairs that were used instead of the more stable G-C 
ones could mimic the modification induced upon platination considering that the platinum(II) binding 
to nucleobases induces RNA destabilization. The characterization of RNAUU showed that the latter 
has a very similar behaviour as the Pt(II)-RNA adducts. The imino proton resonance profile of both 
species was almost identical suggesting the presence of similar structural modifications (Figure 4.24, 
red and blue line). Additionally, in both cases the first melting temperature was mostly affected, even 
if in the case of RNAUU a much larger ΔΤm1 was found (Table 4.3), suggesting stronger destabilization 
in this case. From the comparison of the CD spectra, a bathochromic shift of the band at 260 nm was 
seen for both the species, while only RNAUU showed significant change of the intensity of the band at 
210 nm, indicating that the internal loop was probably affected. This is in line with the large ΔTm1 
found for RNAUU and suggests that in the case of the platinated RNA species the destabilization 
induced upon platination was not as pronounced as for the RNAUU species to influence the internal 
loop structure. Therefore, this comparison further supports the platination at the G1-G2 site and 
additionally suggests that the degree of changes upon platination is similar to some extent to the one 
induced by substituting the first two G-C base pairs with less stable U-A base-pairs.  
 
4.11 Conclusions 
The characterization of the Pt-RNA adducts migrating in the upper band was performed using various 
methods. Platinated adducts obtained using homogeneous Pt-deph-RNA as starting material were 
mainly characterized. However, very similar behaviour was observed for the Pt-triph-RNA adducts, 
thus suggesting the same platination pattern for the upper band species in the two cases. Each technique 
used provided us with an information about the binding of oxaliPt to the RNA. The thermal melting 
studies showed that the platination affects significantly only the first part the RNA construct, because 
only Tm1 changed upon platination. Therefore, platination in this area was suggested. The observed 
reduction of Tm1 compared to the unreacted RNA indicates destabilization of the RNA construct upon 
platinum(II) binding, thus suggesting intrastrand cross-link. Information about the binding sites could 
not be provided from this method. The CD spectra of the unreacted and platinated RNA showed that 
the platination did not change the overall RNA conformation, and the little changes observed are likely 
due to local perturbations caused by the presence of the platinum(II) moiety. More specifically the 
bathochromic shift of the band at 260 nm can be connected to intrastrand platinum(II) binding to RNA. 
The first indication about a possible platination site came from the enzymatic digestion / HPLC 
treatment of the non-platinated and platinated RNA species. The platinated RNA species have an extra 
peak in the HPLC chromatogram and from the comparison of the relative peak areas a loss of two 
guanines was postulated. The new peak has the same retention time as the Pt-GG species, which was 
formed upon platination of the GpG dinucleotide, thus suggesting platination at a GG site. Combining 
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the information collected so far, it seemed that two adjacent guanines were platinated, which should be 
located in the first part of the construct. The only two guanines fulfilling these criteria are G1 and G2. 
Further characterization, like 32P-5ʹ- and 32P-3ʹ-end radiolabelling techniques were employed in order 
to get information about the platination site. The 32P-5ʹ-end labelling approach showed that G23, which 
is located in the first part of the construct, is not directly platinated. However, no information on the 
first two nucleotides could be obtained with this technique. Therefore, we moved to 32P-3ʹ-end labelling, 
which showed changes of the intensity of the gel bands corresponding to G1 and G2 upon platination. 
This suggests platination at G1-G2, in agreement with the previous findings. At the end, 1H-NMR 
spectra were recorded on isolated samples, and comparison of the imino proton resonances before and 
after platination was performed. The guanine imino proton resonances mostly affected by platination 
correspond to G1 and G2. Interestingly, the imino proton resonances of the sample isolated from the 
upper band are very similar to the ones of the RNAUU construct, confirming destabilization at the  
5'-end in the presence of platinum(II), thus further supporting G1-G2 platination. Further confirmation 
that platination occurs at G1-G2 site came from the [1H,13C]-HSQC experiment performed on an 
isolated platinated sample, which suggests direct platination at these two guanines.  
Summing up, upon interaction of oxaliPt with D1-27 under the experimental conditions used for this 
study, despite the presence of many possible platinum(II) binding sites, strong preference for platination 
at G1-G2 was observed, leading to monoplatinated RNA species with decreased gel mobility. The GG 
site of DNA is the most common platinum(II) binding site for platinum(II) anticancer complexes59 and 
strong preference for this motif has been reported also for RNA platination with cisplatin38. Our data 
revealed that oxaliplatin also showed a strong preference for the most accessible GG site (G1-G2) which 
is in line with the currently reported finding on RNA platination. 
 
4.12 Analysis and characterization of the platinated RNA species isolated 
from the lower band 
As described in chapter 2, dephosphorylated RNA was used in order to have a homogeneous starting 
material (Paragraph 2.9). Interestingly, the number of bands on the gel increased from two to three when 
deph-RNA was used. More specifically a new faster migrating band appeared, which, from the 
MALDI-MS analysis, was found to contain a mixture of monoplatinated and diplatinated RNA, like the 
upper band, with the difference that the relative intensity of the diplatinated RNA species was higher 
(Chapter 2, Paragraph 2.9, Figure 2.45). Faster migrating bands upon platination of RNA were reported 
to contain cross-linked platinated RNA species15. Additionally, in our case, platination at different sites 
than G1-G2 (which was found for the species migrating in the upper band) could lead to more compact 
RNA conformation, resulting in the faster migrating band. To investigate the nature of the platinated 
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species responsible for this band, their characterization with CD, thermal melting studies and enzymatic 
digestion/ HPLC was performed. The analysis were carried out by using several different samples. 
The thermal melting studies performed revealed that both melting temperatures were very similar to the 
untreated RNA (Table 4.4) while for the sample from the upper band the Tm1 was significantly reduced. 
Similar melting temperatures to untreated RNA suggest that the changes induced upon platination did 
not affect RNA stability. This fact excludes the presence of platinum(II) cross-linked species, which 
would have stabilized the RNA construct resulting in increased melting temperatures. 
 
Table 4.4: Summary of the melting temperatures for deph- D1-27 as well as for its platinated adducts isolated 
from the upper and lower band. The given Tm values are the average of at least five measurements and are 
reported together with their standard deviation. 
RNA construct Tm1 (°C) Tm2 (°C) 
Deph-D1-27_pH 6.5 52.2 ± 2.1 74.2 ± 3.0 
Pt-deph RNA lower band_pH 6.5 52 ± 2.4 77.5 ± 1.6 
Pt-deph RNA upper band_pH 6.5 44.8 ± 2.5 77.8 ± 1.0 
 
The investigation of the nucleobases affected by platination using enzymatic digestion/HPLC was then 
performed. In the case of the platinated species isolated from the upper band, the analysis showed that 
the guanine content was reduced by two, and that a new peak appeared in the chromatogram, which had 
the same retention time as the independently prepared Pt-GpG species (Figure 4.11). In the case of the 
species isolated from the lower band, a new broader peak at the same retention time as before (26 min) 
appeared (Figure 4.26, right, lower panel) but the nucleobases affected differed from sample to sample. 
In some cases there was reduction by one G and one A, and in other cases there was reduction by one 
G and one U. That could indicate the formation of either GpA/ApG-Pt and GpU/UpG-Pt species or 
could correspond to a mixture of Pt-G / Pt-A and Pt-G / Pt-U monodentate platinum(II) species. 
Monodentate platination mode do not affect significantly the structure of the RNA (or DNA) and as 
such no significant changes of the melting temperature of the Pt(II)-RNA species are expected as well 
as no significant changes of their gel band mobility on a gel. Formation of these species could be in 
agreement with the results from the thermal melting study where Tm similar  to the unreacted RNA 
were observed but is in contrary with the way that the band was migrating on the gel (faster migrating 
band). Given that the digestion studies indicated different nucleobases being affected compared to the 
upper band species, the fact that the peak corresponding to the platinum(II) containing moiety has the 
same retention time (26 min) in the two cases (upper and lower band) was somehow surprising. 
However, from a closer look of the new peak in the case of the lower band products (Figure 4.26, right, 
lower panel), it can be seen that the peak is broader than the one observed in the case of the upper band 
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products (Figure 4.26, right upper panel). This finding suggests that it consists of more than one species, 
whose nature is difficult to assess.  
 
Figure 4.26: Upper panel, left: HPLC chromatogram of the platinated RNA species isolated from the upper band, 
right: Zoom of the newly appeared peak at 26 min. Lower panel, left: HPLC chromatogram of the platinated RNA 
species isolated from the lower band, right: Zoom of the newly appeared peak at 26 min.  
 
With guanines and adenines being the most probable binding sites for oxaliPt6, platination reactions of 
the dinucleotides GpG, GpA and ApG were performed35 to investigate the nature of the composite peak 
observed in the case of the lower band species. Additional reactions were performed with 1:1:1 ratio of 
oxaliplatin and either AMP, GMP or a mixture of the two35 (Appendix 2, Figure A 2.9). The platination 
of the dinucleotides led to the formation of platinated species, which eluted earlier compared to the peak 
at 26 min, excluding the possibility of having the formation of Pt-ApG and/ or Pt-GpA species 
(Appendix 2, Figure A 2.9). The reactions of oxaliPt with 2 eq of GMP and 1:1 GMP and AMP did not 
result in peaks which could have helped with the interpretation of the new peak from the lower band (at 
26 min) with the peaks appearing having different retention time than 26 min (Appendix 2, Figure A 
2.10). However, the reactions of oxaliPt with 2 eq of AMP was more informative. The main peak 
appeared in this latter case had retention time of 26.5 min, that is very similar to the new peak observed 
for the species isolated from the lower band. The presence of a mixture of Pt-GpG and A-Pt-A species 
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could be then responsible for the broad band observed (Figure 4.27). However, if only G and A were 
affected, we should have observed a loss of two guanosines and two adenosines, which was not the 
case. Therefore, with the current data, we can only conclude that the lower band contains multiple 
species platinated at different sites, which are not as homogeneous as the species isolated from the upper 
band.  
 
 
 
 
 
 
 
 
 
Figure 4.27: HPLC chromatogram zoomed on the newly appeared peaks corresponding to Pt-GG moiety (blue 
line), to A-Pt-A moiety (red line) and to platinated RNA sample isolated from the lower gel band (black line). The 
mixture of Pt-GG and A-Pt-A moieties could be responsible for the tailing of the black line. 
 
The CD measurements of the platinated species isolated from the lower band revealed that, similarly to 
the species isolated from the upper band, the overall A-form conformation of the RNA was retained. 
Additionally, the bathochromic shift of the positive band at 260 nm was also observed, without though 
any change of the intensity. The only difference detected was the more pronounced reduction of 
intensity of the negative band at 210 nm suggesting further destabilization of the loops upon 
platination21,22 in this case (Figure 4.28).  
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Figure 4.28: Comparison of the CD spectra of deph-D1-27 (black) and the platinated deph-D1-27 isolated from 
the upper (red) and from the lower band (blue). CRNA /CPt-RNA = 1.3 μΜ, in 120 mM KClO4, pH 6.5. 
 
Summing up, the data collected on the platinated RNA species migrating in the lower band showed that 
their stability is similar to that of the untreated RNA, since similar thermal melting temperatures were 
observed (Table 4.4). This excluded the presence of platinum(II) cross-linked species, which was 
hypothesized due to the appearance of the faster migrating gel band. Indeed, if cross-linked species 
were present, stabilization of the construct was to be expected. Considering that the appearance of the 
faster migrating band was very reproducible, a possible scenario for the unexpected melting temperature 
observed was the transformation of the platinated RNA species upon isolation from the gel. The cross-
linked RNA, which was initially formed, could be upon isolation transformed in a form which does not 
alter significantly the stability of the RNA63. Then, the CD signal of the platinated species isolated from 
the lower band suggested an overall similar conformation as the species isolated from the upper band, 
even if the negative band at 210 nm was more affected than before (Figure 4.28). Changes at the band 
at 210 nm is connected with changes at the loop regions, which could potentially explain the different 
mobility on the gel. The enzymatic digestion/ HPLC characterization clearly showed that different 
nucleobases were affected upon platination compared to the species isolated from the upper band. 
However, no precise information on the nature of the affected nucleotides were collected. The platinated 
RNAs migrating in the lower band represent secondary species considering that the main ones are 
platinated at the G1-G2 site. As such, they could be strongly influenced by slight changes of the 
experimental conditions. Additionally, the MALDI-MS spectra of the isolated species showed that they 
contained increased amount of diplatinated RNA compared to the species from the upper band making 
the interpretation of the results more difficult. Therefore, no clear conclusion could be drawn about the 
way that platinum(II) was bound to D1-27 in the case of the species isolated from the lower band.  
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In conclusion, even if different platinated species seem to be present in the lower migrating band as 
well as in the band containing unreacted RNA, they were not characterized because, in the first case 
they seem to be non-homogeneous, whereas in the second case it was not possible to separate them 
from unreacted RNA in our experimental conditions. For this reason, only the main homogeneous 
platinated species responsible for the slower migrating band was fully characterized, as extensively 
commented in this chapter. 
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5.1 Preparation of RNA sample 
5.1.1 General Procedure 
5.1.1.1  Chemicals / Instrumentation 
The DNA templates were obtained from Microsynth (Balgach, Switzerland) HPLC-purified. The 
nucleoside 5'-triphosphates (GTP, CTP, UTP) were purchased from Carl Roth GmbH (Karlsruhe, 
Germany) except for ATP, which was from GE Healthcare (Glattbrugg, Switzerland). Homemade  
T7 RNA polymerase was used for in-vitro RNA transcription1. All chemicals for the preparation of the 
RNA were at least puriss p.a. grade (or molecular biology grade) and obtained from Sigma-Aldrich 
(Buchs, Switzerland) or Merck (Zug, Switzerland). Denaturing polyacrylamide gels were prepared 
using AccuGel (40 % (w/v), 29:1 and 19:1 Acrylamide-Bisacrylamide) which was obtained from 
National Diagnostics (Hessle, UK). Ammonium persulfate (APS) was purchased from Carl Roth GmbH 
and Co (Karlsruhe, Germany). N,N,N,N tetramethylendiamine (TEMED), tris(hydroxymethyl)-
aminomethane (TRIS), 4-(2-hydroxyethyl)piperazine-1-ethansulfonic acid (HEPES), 
ethylenediaminetetraacetic acid (EDTA), sodium chloride, potassium chloride, dithiothreitol (DTT), 
TritonTM X-100 were bought from Sigma-Aldrich (Buchs, Switzerland). 10x TBE buffer (0.89 M Tris 
Borate pH 8.3, 0.2 M Na2EDTA) from National Diagnostics (Atlanta, USA) was used for the 
preparation of 1x TBE running buffer for electrophoresis. Homemade vertical gel electrophoresis 
apparatuses were used, equipped with power supplies from Thermo Fisher Scientific (Reinach, 
Switzerland) (EC 600 - 90; 4'000 V, 300 W, 300 mA maximum). Gels were visualized with a Bio-
Vision system from Vilber (Eberhardzell, Germany). RNA was isolated via electroelution using the 
Elutrap System with BT1 and BT2 membranes (Whatman) and for RNA desalting and concentration 
ultrafiltration devices Vivaspin 2-mL with 3 kDa molecular weight cut off were purchased from 
Sartorius Stedim biotech (Aubagne, France). The Centrifuges Sorvall RC 6 Plus from Thermo Fischer 
Scientific (Reinach, Switzerland) with rotors SA-600, SH-3000 and SLA-3000, and Eppendorf 5804R 
with rotor A-4-44 were used. RNA samples were vacuum dried with a Concentrator 5301 from 
Eppendorf or a freeze dryer Alpha 2-4 LDplus from Christ (Osterode am Harz, Germany). The pH 
values of the RNA samples were determined using a Metrohm 605 pH-meter and a Minitrode glass 
electrode from Hamilton. UV/Vis measurements for RNA concentration were recorded on  
Cary 100 Bio and Cary 500 scan instruments from Varian, on a Lambda 25 UV spectrophotometer from 
PerkinElmer using a quartz cuvette of 10 mm path length, and on a Nanodrop 2000 from Thermo 
Scientific. In order to avoid RNA degradation and possible contamination of our samples all buffers, 
salt solutions and platination reactions were prepared in deionized RNAse-free water obtained from a 
TKA GenPure water purification system from TKA Wasseraufbereitungssysteme (Niederelbert, 
Germany). Deionized water was further purified by Millipore-filtration and autoclaved before use. All 
the solutions were filtered prior usage with 0.2 μm Filtropur syringe filters from Sarstedt AG 
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(Nümbrecht, Germany) or 0.22 μm Steritop bottle top filter units from Merck Millipore (Billerica, MA, 
USA). 
5.1.1.2 Solutions / Buffers 
15% denaturing gel solution (29:1) (7 M Urea, 1x TBE, 275 mL Acryl-Bisacryl): 420 g Urea,  
100 mL 10x TBE, 375 mL Acryl-Bisacryl 29:1, filled up with water until 1 L and filtrate with 
0.22 μm SteritopTM bottle top filter. 
15% denaturing gel solution (19:1) (7M Urea, 1x TBE, 275 mL Acryl-Bisacryl): 420 g Urea,  
100 mL 10x TBE, 375 mL Acryl-Bisacryl 19:1, filled up with water until 1 L and filtrate with  
0.22 μm SteritopTM bottle top filter. 
20% denaturing gel solution (29:1) (7 M Urea, 1x TBE, 250 mL Acryl-Bisacryl): 420 g Urea,  
100 mL 10x TBE, 500 mL Acryl-Bisacryl 29:1, filled up with water until 1 L and filtrate with  
0.22 μm SteritopTM bottle top filter. 
20% denaturing gel solution (19:1) (7 M Urea, 1x TBE, 250 mL Acryl-Bisacryl): 420 g Urea,  
100 mL 10x TBE, 500 mL Acryl-Bisacryl 19:1, filled up with water until 1 L and filtrate with  
0.22 μm SteritopTM bottle top filter. 
Transcription Buffer: 40 mM Tris-HCl (pH 7.5), 40 mM DTT, 2 mM spermidine, 0.01 %  
Triton X-100. 
Denaturing Loading Buffer: 11.7 M urea, 40 mM Tris-HCl (pH 7.5), 0.1 % xylene cyanol (XC),  
0.1 % bromphenol blue (BB), 230 mM sucrose, 0.8 mM EDTA pH 8.0. 
 
Urea loading buffer for PAGE: 11.8 M Urea, 8.3 % sucrose, 42 mM Tris-HCl (pH 7.5), 0.8 mM 
EDTA (pH 8.0), 0.08 % (w/v) dye xylene cyanol (XC) and bromophenol blue (BB). Store at 4 °C. 
 
TBE buffer for electrophoresis and electroelution (diluted to 1x from the 10x): 0.89 M Tris-HCl (pH 
8.3), 0.89 M boric acid, 0.002 M EDTA. 
 
5.1.1.3 DNA Templates 
The DNA templates used to transcribe the RNA samples (see below) contained 2'-methoxy groups on 
the two 5'-terminal guanosines, to avoid 3'-end inhomogeneity2. The 55 in the OT template sequences 
in the table below represents the modification inserted (e.g. a methoxy group).  
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RNA   DNA templates 
D1-27 
OT(met) 5ʹ-55AACTTAGCTCCGAAGAGCATATTCCTATAGTGAGTCGTATTAATTTC-3ʹ  
TS 5ʹ-GAAATTAATACGACTCACTATAGGAATATGCTCTTCGGAGCTAAGTTCC-3ʹ  
D1-
27GAAA 
OT(met) 5ʹ-55AACTTAGCTCTTTCGAGCATATTCCTATAGTGAGTCGTATTAATTTC-3ʹ  
TS 5ʹ-GAAATTAATACGACTCACTATAGGAATATGCTCGAAAGAGCTAAGTTCC-3ʹ  
RNA 26 
OT(met) 5ʹ-55AACATGCTCCGAAGAGCATATTCCTATAGTGAGTCGTATTAATTTC-3ʹ  
TS 5ʹ-GAAATTAATACGACTCACTATAGGAATATGCTCTTCGGAGCATGTTCC-3ʹ  
5.1.1.4 RNA constructs 
The following RNA constructs were transcribed: 
1. D1-27:  5ʹ-GGAAUAUGCUCUUCGGAGCUAAGUUCC-3ʹ 
2. D1-27GAAA : 5ʹ-GGAAUAUGCUCGAAAGAGCUAAGUUCC-3ʹ 
3. RNA 26:  5ʹ-GGAAUAUGCUCUUCGGAGCAUGUUCC-3ʹ 
One more RNA construct was used for our study, which was bought form IBA (Goettingen, Germany), 
HPLC purified and was used without further purification. 
4. RNAUU: 5ʹ- UUAAUAUGCUCUUCGGAGCUAAGUUAA-3ʹ 
 
5.1.1.5 Experimental procedure 
In the following, a general procedure for RNA preparation, isolation and purification is described. 
All the RNA samples were synthesized by in vitro transcription with T7 polymerase from  
double-stranded DNA1,3. In order to achieve higher transcription yield, the concentration of DNA 
templates, MgCl2, NTPs and T7 polymerase had to be optimized. For the 27nt-long RNA constructs 
(D1-27 and D1-27GAAA) the following transcription conditions were used: 0.5 μM DNA template,  
30 mM MgCl2, 5 mM of each NTP (ATP, CTP, GTP, and UTP), and 1x T7 polymerase (from 20x) and 
for the 26 nt-long construct (RNA 26) were: 1 μM DNA template, 10 mM MgCl2, 5 mM of each NTP 
(ATP, CTP, GTP, and UTP), and 1x T7 polymerase (from 20x). It should be noted that the amount of 
T7 polymerase used depended on polymerase activity, and had to be optimized for each polymerase 
batch. It usually varied between 20 and 50 μL per 1 mL transcription solution. All the above mentioned 
were mixed in 1x transcription buffer and the reaction was proceeding for 4 h at 37 °C while shaking at 
300 rpm. After transcription, the RNA samples were purified by PAGE (15%) and extracted from the 
gel by electroelution. This was followed by ethanol precipitation, performed by adding 3x sample 
volume of ice-cold ethanol and 1/20 parts sample volume of 5 M NaCl. Upon centrifugation (30 min at 
9500 rpm and 4 °C) the isolated precipitated RNA pellet was dried in a Concentrator 5301 from 
Eppendorf, re-dissolved in water, and desalted by ultrafiltration in Vivaspin devices. The final 
concentration was determined by UV absorption at 260 nm (D1-27: ε260 nm = 266.4 mM ̶ 1 cm ̶ 1,  
RNA 26: ε260 nm = 254 mM ̶ 1 cm ̶ 1, D1-27GAAA: ε260 nm = 277.6 mM ̶ 1 cm ̶ 1). All the RNA samples were 
lyophilized and kept at   ̶  20 °C. 
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5.1.2 Preparation of D1-27 and D1-27 GAAA 
Further details on preparations of the two constructs are described below. 
5.1.2.1 Transcription 
All the reagents were mixed and aliquoted in a volume of 1 mL in Eppendorf tubes. Last was added the 
T7 polymerase and the transcription was carried out in a thermomixer at 37 °C, 300 rpm for 4 h. After 
an hour, precipitation of magnesium pyrophosphate was visible. When the transcription was finished 
the Eppendorf tubes were centrifuged (10 min, 10000 rpm, 25 °C) and the supernatant was collected in 
Falcon tubes. Next step is the ethanol precipitation. 5 M sodium chloride (NaCl), 1/20 parts of the total 
volume, and 3x of the total volume 100 % ethanol (EtOH) were added to the solution. The samples 
were stored either for 1 h at  ̶  80 °C or overnight at  ̶  20 °C. Afterwards the Falcon tubes were 
centrifuged (30 min, 9500 rpm, 4 °C). The supernatant was collected and the RNA pellet was vacuum 
dried for 15 min at 30 °C in an Eppendorf concentrator. The dried RNA pellets were dissolved in ddH2O 
in order to be further purified by polyacrylamide gel electrophoresis (PAGE). 
5.1.2.2 RNA purification by 15% denaturing PAGE 
The denaturing polyacrylamide gel solutions were prepared in advance, stored at 4 °C and protected 
against the light with aluminium foil. While being covered with aluminium foil, the beaker was 
transferred to a heating plate where was stirring for 1 h at 50 °C. Once the solution was clear, it was 
filtered through a membrane filter (Stericup, 0.22 μm) and stored at 4 °C. 
For 5 mL transcription of D1-27, two gel plates were used. The glass plates (45 x 30 cm with 1.5 mm 
spacers) were assembled first and then the solution was prepared. For each gel 200 mL of gel solution 
were needed. This volume was transferred in a beaker and TEMED (100 μL) and APS (10 %, 1000 μL) 
were added and mixed. The gel solution was transferred with a 50 mL syringe into the assembled glass 
plates and the combs to create the pockets for sample loading were added at the end. The gel solution 
was allowed to polymerize for half an hour. Once it was ready, the combs for the pockets were removed 
and the gel plates were positioned to the vertical electrophoresis apparatus and pre-ran for 30 min at 20 
W per plate. 500 μL of urea loading buffer were added to the RNA samples in water (usually 1 mL total 
volume). The loading buffer contains dyes (bromophenol blue and xylene cyanol) that serve as markers. 
This solution was loaded into the gel pockets and the gel was run for either 5 - 6 h at 25 - 40 W per 
plate, or overnight at 4 W per plate, with 1x TBE as running buffer. Images of the gels were recorded 
with BioVision 3026, under UV light. The RNA bands were excised from the gel, covered with cling 
film and stored at  ̶  20 °C until electroelution. 
5.1.2.3 RNA collection with electroelution 
Electroelution was performed in order to collect the RNA from the gel. The gel pieces were transferred 
to the electroelution chambers, which were positioned into the electroelution apparatus. The whole 
apparatus was filled with 1x TBE and electric current was applied (200 V). Every hour  
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1 mL of solution was removed from the chambers and put into a Falcon tube, on ice. The procedure 
was repeated for 4-5 times. The gel pieces were checked with UV-shadowing to confirm that all RNA 
was extracted from the gel. Electroelution was followed by ethanol precipitation. In the Falcon tubes 
containing the RNA sample 3x sample volume of ice-cold ethanol and 1/20 sample volume of 5 M 
NaCl were added (final volume 10 - 12 mL). The falcons were kept for 1 h at   ̶ 80 °C and centrifuged 
for 30 min (9500 rpm, 4 °C). The supernatant was collected and the RNA pellet was vacuum dried. The 
concentration before desalting was determined by UV absorption at 260 nm (D1-27: ε260 nm = 
266.4 mM ̶ 1 cm ̶ 1 , D1-27GAAA: ε260 nm = 277.6 mM ̶ 1 cm ̶ 1). 
5.1.2.4 RNA desalting and concentration  
Once the sample was isolated, desalting by ultrafiltration in Vivaspin devices took place both to desalt 
and concentrate it. The Vivaspin devices were first activated by washing twice with 70% EtOH and 
autoclaved ddH2O. Afterwards the RNA sample was loaded and it was washed twice with 1 M NaClO4 
and ten times with autoclaved ddH2O. The centrifugation was performed at 20 °C, 5000 rpm, long 
enough for the volume to be reduced from 2 mL to 200 μL. Each cycle lasted 15 - 30 min according to 
how concentrated the sample was. After collection of the sample the final concentration was determined 
by UV absorption at 260 nm (D1-27: ε260 nm = 266.4 mM ̶ 1 cm ̶ 1, D1-27GAAA: ε260 nm =  
277.6 mM ̶ 1 cm ̶ 1). All the RNA samples were lyophilized and kept at  ̶  20 °C.  
The yield for these two constructs was 150 - 300 nmol per 5 mL transcription. 
5.1.3 Preparation of RNA 26 
5.1.3.1 Transcription 
The conditions mentioned above for the transcription of the 27nt-long constructs had to be modified for 
the 26nt-long one (RNA 26) in order to increase the yield. A colleague PhD student, Elena Alberti, 
performed the optimization. The following conditions were found to be the best: 1 μM DNA template, 
10 mM MgCl2, 5 mM of each NTP (ATP, CTP, GTP, and UTP), and 1x T7 polymerase (from 20x). 
After transcription, the RNA was purified by 15% PAGE, isolated by electroelution, desalted and 
concentrated by vivaspin, following the same procedures as mentioned above. The yield was  
50 - 70 nmol per 5 mL transcription. 
5.1.4 Large scale RNA dephosphorylation 
Dephosphorylated RNA was used in order to have a homogeneous starting material for platination 
reactions (Chapter 2 Paragraph 2.9). In order to have enough material to work with, large scale 
dephosphorylation was performed. The dephosphorylation could take place either on a purified RNA 
sample or immediately after RNA transcription. In the second case, the RNA pellet was dissolved in 
ddH2O and desalted with a NAP-10 column. Skipping this step led to reduced dephosphorylation 
efficiency. Because of reduced yield following the second way, the majority of the RNA samples were 
dephosphorylated upon purification.  
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The RNA samples were dephosphorylated with CIAP (Alkaline Phosphatase, Calf Intestinal), using the 
following procedure. In five 12 mL Falcons tubes 10x CIAP buffer, 10 mM Tris-HCl pH 8, RNA 
samples and CIAP were added. Each Falcon tube contained 100 μL RNA sample (100 - 400 nmol),  
1 mL 10x CIAP buffer, 200 μL from 1 U/μL CIAP and was filled with ddH2O until 10 mL. The five 
tubes were incubated at 37 °C for 15 min and then at 56 °C for other 15 min. Further 150 μL from  
1 U/μL CIAP was added in each Falcon tube and the same incubation as mentioned before was repeated. 
1 M EDTA (10 μL) was added to each tube in order to stop the reaction. The content from all the Falcon 
tubes was combined and transferred to two 50 mL Falcon tubes, and lyophilized overnight. Purification 
(15 % denaturing gel), isolation (electroelution) and desalting (Vivaspin) of the dephosphorylated RNA 
samples took place following the same procedures described above. To check the efficiency of the 
dephosphorylation, the RNA samples were analyzed with MALDI-MS and 31P-NMR experiments were 
also recorded (Chapter 2, Paragraph 2.9, Figure 2.43). 
 
5.2 Platination agents 
This study was mostly dedicated to cisplatin and oxaliplatin as platination agents (Chapter 2 and 4). 
However, the behaviour of carboplatin, kiteplatin and [Pt(DACH)Cl2] in comparison with the previous 
two was also briefly investigated (Chapter 3).  
5.2.1 Chemicals / Instrumentation 
All chemicals were bought at the highest purity grades (puriss p.a. or molecular biology grade), and 
synthesis were carried out with standard glassware. The Microbalance XS3DU was from Mettler Toledo 
(Greifensee, Switzerland). IR spectra were recorder with a FTIR Spectrometer (Perkin–Elmer, 
Switzerland) equipped with a Specac Golden GateTM ATR (attenuated total reflection) accessory. For 
the Flame Atomic Absorption Spectrometry a Varian AA240FS (Agilent Technologies, USA), using 
an UltraAA platinum lamp was used. The software was the SpectrAA. 1H-NMR spectra were recorded 
on a Bruker DRX 500 MHz spectrometer using a cryo BBO probe using 3-(trimethylsilyl)-1-
propanesulfonic acid sodium salt (TSP, δ = 0.0 ppm) as reference and on a Bruker AV-400 (400 MHz) 
(Bruker Biospin AG, Fällanden, Switzerland) at the NMR facility of the University of Zurich. K2[PtCl4], 
cis-diamminedichloridoplatinum(II) (cisplatin), [(1R,2R)-cyclohexane-1,2-diamine](ethanedioato-
O,O')platinum(II) (oxaliplatin) and cis-diammine(cyclobutane-1,1-dicarboxylate-O,O')platinum(II) 
(carboplatin) were bought from Sigma Aldrich (Buchs, Switzerland) and used as received or activated 
before usage (see below). The complex [PtCl2(cis-1,4-DACH)] (kiteplatin) was kindly provided by 
Prof. James Hoeschele (University of Michigan, Chemistry Department, USA) and Prof. Nicola 
Margiotta (University of Bari, Department of Chemistry, Italy). The complexes dichloro(1R,2R-
diaminocyclohexane)platinum(II) [Pt(DACH)Cl2] was synthesized based on literature procedures4. 
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According to the needs, the complexes cisplatin, kiteplatin and [Pt(DACH)Cl2] were activated 
following standard procedures (Paragraph 5.2.4).  
5.2.2 Synthesis of (1R,2R)-diaminocyclohexane dichloroplatinum(II) [Pt(DACH)Cl2] 
Equimolar amounts of K2[PtCl4] (189.2 mg, 0.455 mmol) and C6H10(NH2)2 (52 mg, 0.455 mmol) were 
dissolved in 1 mL and 400 μL of ddH2O, respectively (Figure 5.1). The colourless C6H10(NH2)2 solution 
was added dropwise to the red K2[PtCl4] solution under stirring, at room temperature, forming yellow 
precipitation. The reaction mixture was kept in the fridge for 1 h to complete the precipitation. The solid 
was separated from the supernatant, suspended in cold-water and transferred to a glass tube. The 
suspension was centrifuged, and the supernatant separated from the solid. The solid was further washed 
three times with cold water. The yellow precipitate was left in the glass tube overnight under the hood 
to air dry. Alternatively, the sample was transferred into an Eppendorf tube and lyophilized for a few 
hours. Yield: 52 mg, 30.8 %. 
 
Figure 5.1: Reaction scheme for the synthesis of [Pt(DACH)Cl2] 
 
5.2.3 Characterization of [Pt(DACH)Cl2] 
Elemental analysis 
Expected: C: 18.96 %, N: 7.37 %, H: 3.71 % 
Measured: C: 18.79 %, N: 7.31 %, H: 3.72 % 
IR (solid) [cm-1]: 3274m, 3184m, 3102w, 2933w, 2920s, 2866m, 1566m, 754m. The IR spectrum is 
shown in Appendix 3. (Figure A 3.1, lower panel) 
1H-NMR (in DMSO, 500 MHz): 5.55 (m, NH2); 5.05 (m, NH2); 3.38 (H2O); 2.65 (DMSO); 2.05  
(s, C6H10); 1.95 (m, C6H10); 1.45 (m, C6H10); 1.20 (m, C6H10); 1.00 (m, C6H10). The NMR spectrum is 
shown in Appendix 3. (Figure A 3.3) 
1H-NMR (in 90% H2O: 10% D2O, 500 MHz): 1.1 (m, 2H); 1.3 (m, 2H); 1.5 (m, 2H); 2 (m, 2H); 2.3 
(m, 2H); 4.7 (H2O); 5.7 (s, NH2). The NMR spectrum is shown in Appendix 3. (Figure A 3.4, blue line) 
ESI-MS: m/z expected: 380; m/z measured: 386.1 [Pt(DACH)Cl2].  
IR and 1D-1H-NMR spectra of the starting material 1,2-diaminocyclohexan (DACH) were also 
collected:  
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IR (liquid) [cm-1]: 3360 w, 3279 w, 3177 w, 2920 s, 2853 m, 1595 m, 766 m. The IR spectrum is shown 
in Appendix 3. (Figure A 3.1, upper panel) 
1H-NMR (in DMSO, 500MHz): 0.95-1.09 (m, 2H); 1.12-1.24 (m, 2H); 1.57-1.67 (m, 2H); 1.70-1.80 
(m, 2H); 2.06-2.16 (m, 2H); 2.56 (DMSO), 3.6 (H2O). The NMR spectrum is shown in Appendix 3. 
(Figure A 3.2) 
5.2.4 Activation of the platinum(II) compounds 
Activation of the platinum(II) complexes is the hydrolysis of the Pt-Cl bonds to form Pt-water bonds. 
The activation can lead to either mono- or diaquo derivatives (Figure 5.2). These aqua derivatives are 
formed also in the cellular environment and this step is considered crucial for the further interactions of 
platinum(II) complexes with their cellular targets5. Cisplatin, [Pt(DACH)Cl2] and kitePt were activated 
following the same procedure. 0.9 or 1.9 eq of 0.1 M AgNO3 were added to the solution containing the 
platinum(II) complexes in order to form the mono- or diaquo platinum(II) complexes (Figure 5.2). The 
reaction mixture was incubated for 3.5 h at 37 °C in the dark. In the meanwhile, white precipitation of 
AgCl was formed. The reaction mixture was centrifuged (10 min, 9000 rpm, 25 °C) and the supernatant 
was collected. The platinum content of each sample was measured by F-AAS. The concentration of the 
platinum(II) complexes solutions varied between 0.6 and 1 mM. The [Pt(DACH)Cl2] complex was 
activated in two different ways. In the first procedure, AgNO3 was added to a clear solution of the 
complex. Complete dissolution of the complex in water was achieved by heating the solution at 37 °C 
for one hour, before addition of AgNO3. In the second procedure, AgNO3 was added to a suspension of 
the complex. Addition of AgNO3 facilitates complete dissolution of [Pt(DACH)Cl2]. Data from AAS 
confirm that both the procedures lead to the same results. However, 1H-NMR spectra recorded on the 
samples prepared using the first procedures show extra peaks, probably due to degradation of the 
platinum(II) complex taking place during the heating step (Appendix 3, Figure A 3.5). For this reason, 
the second procedure was followed. The platinum(II) complex solutions were stored at  ̶  20 °C.  
 
Figure 5.2: Activation reactions for the formation of the monoaquated and diaquated [Pt(DACH)Cl2] complexes. 
Activation of cisPt and kitePt took place under the same experimental conditions. 
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5.2.5 NMR characterization of the [Pt(DACH)Cl(H2O)]+ complex  
1D-1H-NMR (in 90% H2O:10%D2O): 1.1 (m, 2H); 1.3 (m, 2H); 1.5(m, 2H); 2 (m, 2H); 2.3 (m, 2H); 
4.7 (H2O); 5.7 (s, NH2). The NMR spectrum is shown in Appendix 3. (Figure A 3.4 red line) 
 
5.3 Flame Atomic Absorption Spectrometry (F-AAS) 
This technique was used to determine the concentration of the platinum(II) complexes. Standard 
solutions were prepared for 2 ppm (50 L), 5 ppm (125 L), 10 ppm (250 L), 15 ppm (375 L) and 
20 ppm (500 L) from 1000 ppm Pt stock solution, with final volume 25 mL, in order to build the 
calibration curve. 0.5 M LaCl3 was prepared by dissolving 3.73 g of LaCl3 in water. 3.6 mL (1 %) of 
0.5 M LaCl3 solution was added to all the samples and the standard solutions, which were then diluted 
with ddH2O to 25 mL. All solutions were filtered before use. As baseline water solution with 1 %  
0.5 M LaCl3 was used. The LaCl3 is used in F-AAS measurements in order to reduce the chemical 
interferences which could result in incomplete atomization of the sample. For the sample preparation a 
specific amount of the platinum(II) complex (0.4 - 0.6 mg) was weighted and dissolved in water. A 1% 
LaCl3 solution was added to this sample, which was then filled with water until 5 mL in a volumetric 
flask. In the case of the activated platinum(II) complexes their solution was diluted with ddH2O in a  
5 mL volumetric flask with their final concentration to vary between 0.1 - 0.2 mM. The measurements 
were performed on a Varian AA240FS, using an UltraAA platinum lamp. The software used was the 
SpectrAA.  
 
5.4 Platination reactions  
5.4.1  Chemicals / Instrumentation 
RNA samples for platination were prepared and purified as described above. Platinated samples were 
isolated using gels and electroelution in a similar way. They were desalted either by Vivaspin (see 
above) or by using NAP-10 columns (GE Healthcare, UK) depending on their amount.  
5.4.2 Solutions / Buffers 
60 mM KClO4 - 10 μM EDTA: 40 μL from 150 mM KClO4 and 100 μL of 10 mM EDTA were mixed 
and dissolved in water, in a final volume of 100 mL, and filtered with 0.22 μm filter. 
1 M KCl: 7.4 g KCl was dissolved in water to a final volume of 100 mL; the resulting solution was 
then filtered with 0.22 μm filter. 
150 mM KClO4: 207.7 mg KClO4 were dissolved in water to a final volume of 10 mL; the resulting 
solution was then filtered with 0.22 μm filter. 
Na(I) MOPS: 1 mM MOPS + 5 M NaOH until pH 7.40. Final sodium(I) concentration is 1 mM. 
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5.4.3  Experimental procedure 
For all the platination reactions, the following procedure was followed. The RNA sample was dissolved 
in ddH2O and its concentration was determined via UV/Vis spectroscopy. The platinum agents were 
dissolved in water also, and their concentration was determined via F-AAS. The appropriate volumes 
of RNA and platinum agent were transferred into an Eppendorf tube. The reaction solutions and 
additional water were added, and the reaction mixture was placed in a thermomixer at 25 ° - 50° C (see 
below) for 15 h to 5 days. The RNA platination conditions differ for different platination agents, and 
had to be optimized. This was done for oxaliplatin and cisplatin (Chapter 2, Paragraph 2.3 - 2.5). 
Optimization of reaction buffer, time, temperature, salt concentration, RNA and platinum concentration 
took place. Different reaction solutions were used, namely MOPS buffer, plain water, and solutions 
containing different concentration of KClO4 or KCl. The tested temperature were 25 °C, 37 °C and 50 
°C and the reaction time varied from 15 h to 5 days. The RNA concentration tested was 0.1 - 0.5 mM 
and 1 - 10 eq of platinum(II) complexes were added. The final reaction volume was usually between 10 
μL and 20 μL. The platinated samples were analysed by PAGE in denaturing conditions, and the 
reaction conditions were optimized until clear separation between the band corresponding to platinated 
and unreacted RNA was achieved on the gels. Gel percentage, temperature and running time were also 
subjected to optimization. Pictures of the gels were taken using UV shadowing. The gel bands were 
excised from the gel and recovered either with crush and soak or with electroelution. The samples were 
desalted with NAP-10 columns or with Vivaspin.  
Detailed description of the optimization of the platination conditions for cisplatin and oxaliplatin 
reacting with D1-27 is provided in Chapter 2. 
5.4.4 Separation / purification of the platinated RNA with PAGE 
Separation between platinated and unreacted RNA samples was achieved by using denaturing PAGE. 
The platinated species due to higher molecular weight and different overall charge migrate slower on 
the gel compared to pure RNA. In order to increase the separation of the bands, gel percentage of the, 
temperature and running time were modified. The higher gel percentage the more intact the gel net 
becomes and therefore the better the separation is. The gel percentage used were 15 %, 18 % and  
20 %. Additionally, to further improve the gel resolution 19:1 acrylamide - bis acrylamide gel solution 
was used instead of 29:1 (Chapter 2, Figure 2.44). The temperatures tested were room temperature and 
4 °C (fridge). By running the gel in the fridge, the speed was lower and the separation was better. Lastly, 
by increasing the time that a gel run, the separation could be improved. For that reason, the running 
time was increased from 6 h to overnight and finally to 2 days. Another way to increase the running 
time was to use longer gel plates. Finally, the best conditions which allowed the maximum separation 
of the platinated from the unreacted RNA were: 20 % denaturing gel solution (19:1), using 45 cm long 
gel plates, running in the fridge for 2 days. 
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Both analytical and preparative gels were used. In the analytical gels small amounts of sample  
(0.5 -1 nmol) were loaded and the gels were used mostly for the optimization of the platination 
conditions. On the contrary, the preparative gels were used in order to isolate enough sample for the 
characterization (20 - 100 nmols). For the analytical gels 3 mm spacers were used and for the preparative 
gels the 1.5 mm ones. Gel preparation, sample loading and running and RNA isolation, purification and 
recovery were performed as described above (Paragraph 5.1.2.2). 
5.4.5 Collection of the RNA samples with electroelution or crush and soak 
The RNA samples were collected from the gel pieces by either electroelution or crush and soak 
technique. The first was the method of choice for samples isolated from preparative gels, while gel 
pieces isolated from analytical gels were processed with crush and soak. Electroelution and crush and 
soak were performed as described in paragraphs 5.1.2.3 and 5.10.2.  
5.4.6 Desalting and concentration of the RNA samples (Vivaspin, NAP-10 columns) 
The samples were desalted via Vivaspin or NAP-10 columns according to their amount. Consequently, 
all samples used for NMR studies (20 - 30 nmols) were desalted with Vivaspin. On the contrary, samples 
used for all the other studies were often desalted using NAP-10 columns  
(0.5 - 10 nmols). An advantage of using the Visaspin is that the Tris, coming from the previous used 
buffers, could be effectively removed. A disadvantage of the Vivaspin was that the recovery of the 
sample was maximum 60 - 70 % while with NAP-10 columns could be up to 85 - 95 %. Vivaspin 
desalting was performed as described above (Paragraph 5.1.2.4)  
 
5.5 High performance liquid chromatography (HPLC) 
5.5.1 Chemicals / Instrumentation 
All chemicals were bought in the highest commercial grades and used without further purification. 
HPLC solvents (methanol, acetonitrile, triethylamine) were obtained in HPLC grade from Sigma 
Aldrich (Buchs, Switzerland). Deionised water was purified by Millipore-filtration and was always 
autoclaved before use. All buffers were filtered through 0.2 μm filters from Sarstedt AG (Nümbrecht, 
Germany). The P1 nuclease, ammonium acetate, sodium acetate and zinc chloride were purchased from 
Sigma Aldrich (Buchs, Switzerland) and the Thermosensitive Alkaline Phosphatase (TSAP) from 
Promega (Dübendorf, Switzerland). The Microbalance XS3DU was from Mettler Toledo and was used 
for the preparation of the standard nucleoside solutions (Greifensee, Switzerland). The analytical HPLC 
analyses were performed on a Dionex Ultimate 3000 HPLC system equipped with a Diode Array 
Detector (DAD) using the software Chromeleon 7.1. An analytical X-Bridge C18 RP column (3.5μm, 
4.6 x 150 mm) from Waters (Baden-Dättwil, Switzerland) was used for the isolation, purification and 
quantification of the platinated RNA samples as well as for the enzymatic digestion of the unreacted 
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and platinated RNA samples. In addition to the chosen column, the performances of the following 
columns were investigated in order to find the appropriate stationary phase: Reverse Phase C18 
Ultraphere(R) (5 μm, 80Å, 4.6 x 250 mm) from Beckman & Coulter (Fullerton, USA), reverse phase 
cross-linked poly(styrene-co-divinylbenzene) polymer PRP(R)-h1 (5 μm, 100 Å, 4.6 x 250 mm) from 
Hamilton (Bonaduz AG, Switzerland) and reverse phase Nucleodur C18 Gravity column (5 μM, 4 x 
250 mm) from Macherey-Nagel (Switzerland). 
5.5.2 Buffers  
Standard nucleoside solutions: Guanosine (ε253nm = 13700 M ̶ 1cm ̶ 1), 0.7 mg in 1 mL; Adenosine 
(ε260nm = 15400 M ̶ 1 cm ̶ 1), 1 mg in 1 mL; Uridine (ε260nm = 10000 M ̶ 1 cm ̶ 1), 1.3 mg in 1 mL; Cytidine: 
(ε270nm = 9000 M ̶ 1 cm ̶ 1), 1.19 mg in 1 mL. 
P1 nuclease buffer: 30 mM NaOAc pH 5.2 and 250 μM ZnCl2. 
TEAA buffer for HPLC analysis: 0.1 M TEA, pH = 7.0 adjusted with acetic acid, 0.5 % Acetonitrile.  
Ammonium acetate buffer for HPLC analysis: 0.04 M NH4OAc, pH = 6.5 adjusted with acetic acid. 
Ammonium acetate buffer for HPLC analysis: 0.02 M NH4OAc, pH = 6.0 adjusted with acetic acid. 
5.5.3 HPLC methods 
Different methods were tested to find the best separation conditions. The methods 6 and 7 were chosen 
for the evaluation of the RNA samples as well as for the purification and quantification of the Pt(II)-
RNA adducts (see Chapter 2, Paragraph 2.8.1). In the following, details of all the methods investigated 
are listed.  
Method 1: Column: RP cross-linked poly(styrene-co-divinylbenzene) polymer PRP®–h1 column  
(5 μm, 4.6 x 250 mm) from Hamilton; Wavelength: 260 nm; Flow rate: 1 mL / min; Buffer A: 23 mM 
TEAA, pH = 6.9; Buffer B: Acetonitrile; Gradient: 2 min equilibration 0 % B, 0 - 8 min 0 % B, 
8 - 22 min 0 - 18.5 % B, 22 - 23 min 18.5 - 100 % B, 23 - 24 min 100 - 100 % B, 24 - 24.5 min  
100 - 0 % B, 24.5 - 27.0 min 0 % B. 
Method 2: Column: Waters X-Bridge C18 (3.5 μm, 4.6 x 150 mm); Wavelength: 260 nm; Flow rate:  
1 mL / min; Buffer A: 23 mM TEAA, pH = 6.9; Buffer B: Acetonitrile; Gradient: 2 min equilibration 
0% B, 0 - 4 min 2 -2 % B, 4 - 18 min 2 - 35 % B, 18 - 25 min 35 - 50 % B, 25 - 28 min 50 % B, 
28 - 35min 50 - 90 % B, 35 - 40 min 90 % B, 40 - 42 min 90 - 2 % B, 42 - 45 min 2 % B. 
Method 3: Column: Waters X-Bridge C18 (3.5 μm, 4.6 x 150 mm); Wavelength: 260 nm; Flow rate:  
1 mL / min; Buffer A: 100 mM TEAA, pH = 6.9; Buffer B: Acetonitrile; Gradient: 2 min equilibration 
2% B, 0 - 4 min 2 -2 % B, 4 - 9 min 2 - 35 % B, 9 - 12 min 35 - 25 % B, 12 - 15 min 
25- 35 % B, 15- 17 min 35 - 2 % B, 17 - 19 min 2- 0 % B.  
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Method 4: Column: Waters X-Bridge C18 (3.5 μm, 4.6 x 150 mm); Wavelength: 260 nm; Flow rate:  
1 mL / min; Buffer A: 100 mM TEAA, pH = 6.9; Buffer B: Acetonitrile; Gradient: 2 min equilibration 
2% B, 0 - 4 min 2 % B, 4 - 40 min 2 - 35 % B, 40 - 43 min 35 % B, 43 - 45 min 35- 2 % B, 45- 50 min 
2% B.   
Method 5: Column: Waters X-Bridge C18 (3.5 μm, 4.6 x 150 mm); Wavelength: 260 nm; Flow rate: 
1 mL / min; Buffer A: 100 mM TEAA, pH = 6.9; Buffer B: Acetonitrile; Gradient: 5 min equilibration 
2% B, 0 - 4 min 2 -2 % B, 4 - 60 min 2 - 30 % B, 60 min 30 - 30 % B, 60 - 68 min  
30- 2 % B, 68- 70 min 2% B.  
Method 6: Column: Waters X-Bridge C18 (3.5 μm, 4.6 x 150 mm); Wavelength: 260 nm; Flow rate:  
1 mL / min; Buffer A: 100 mM TEAA and 0.5 % acetonitrile, pH = 6.9; Buffer B: Acetonitrile; Gradient: 
5 min equilibration 2% B, 0 - 10 min 2 -10 % B, 10 - 10.5 min 10 - 40 % B, 10.5 - 17 min 40 % B, 17 
- 19 min 40- 2 % B, 19- 20 min 2% B.  
Method 7: Column: Waters X-Bridge C18 (3.5 μm, 4.6 x 150 mm); Wavelength: 260 nm; Flow rate:  
1 mL / min; Buffer A: 100 mM TEAA and 0.5 % acetonitrile, pH = 7.0; Buffer B: Acetonitrile; Gradient: 
5 min equilibration 2 % B, 0 - 10 min 2 - 8 % B, 10 - 15 min 8 - 9.2 % B, 15 - 18 min 
9.2 - 9.2 % B, 18 - 25 min 9.2 - 9.4 % B, 25 min 9.4 - 30 % B, 25 - 27 min 30 % B, 27 - 30 min 
30 - 2% B 
Method 8: Column: Waters X-Bridge C18 (3.5 μm, 4.6 x 150 mm); Wavelength: 260 nm; Flow rate: 
0.5 mL / min; Buffer A: 40 mM NH4CH3CO2, pH = 6.5; Buffer B: Methanol; Gradient: 15 min 
equilibration 100 - 0 % B, 0 - 5 min 0 % B, 5 - 33 min 0 - 16.8 % B, 33 - 35 min 16.8 - 100 % B, 
35 - 38 min 100 % B. 
Method 9: Column: Waters X-Bridge C18 (3.5 μm, 4.6 x 150 mm); Wavelength: 260 nm; Flow rate: 
0.5 mL / min; Buffer A: 40 mM NH4CH3CO2, pH = 6.5; Buffer B: Methanol; Gradient: 15 min 
equilibration 100 - 0 % B, 0 - 5 min 0 % B, 5 - 55 min 0 - 30 % B, 55 - 65 min 30 - 100 % B, 
65 - 68 min 100 % B. 
5.5.4 Experimental procedure 
5.5.4.1 Preparation of RNA and platinated RNA samples for HPLC analysis 
0.2 - 0.4 nmol of RNA and platinated RNA samples were diluted in water to final volume of 20 μL. 
15 μL were injected in the HPLC machine, corresponding to 0.15 - 0.3 nmol of sample. The RNA 
samples were separated on a X-Bridge C18 RP column (3.5 μm, 4.6 x 150 mm). The mobile phase 
components were A: 100 mM TEAA and 0.5 % acetonitrile, pH 7.0; B: Acetonitrile. Methods 2, 6 and 
7 were used for analysis and purification of the RNA and Pt(II)-RNA samples as well as to directly 
follow platination reactions (Chapter 2, Paragraph 2.8). All the chromatograms were recorded at 25° C.  
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5.5.4.2 Enzymatic digestion and analysis of unreacted and platinated RNA samples with HPLC 
Nuclease P1 is a zinc-dependent endonuclease that cleaves single stranded DNA and RNA to yield 
nucleoside 5′-phosphates and 5′-phosphooligonucleotides6. Samples containing 0.2 nmol of unreacted 
and platinated RNA were digested with 2.3 μL (1 U/μL) P1 nuclease and buffer containing 30 mM 
NaOAc pH 5.2 and 250 μM ZnCl2, in a final volume of 20 μL for 15 min at 37 °C. The digested 
nucleotides were dephosphorylated with 4 μL (4 U/μL) of thermosensitive alkaline phosphatase (TSAP) 
for 30 min at 37 °C. The TSAP was irreversibly inactivated by heating at 74 °C for 15 min. The solution 
was then ready for immediate analysis by HPLC. The injection volume was 15 μL. The nucleosides 
were separated on a X-Bridge C18 RP column (3.5 μm, 4.6 x 150 mm). All the chromatograms were 
recorded at 25 °C. Methods 8 and 9 were used for the separation (mobile phase components: A: 40 mM 
NH4OAc, pH 6.5 and B: Methanol). Nucleoside standards were used to determine the retention time of 
the four nucleosides. The standards were prepared by dissolving the pure nucleosides in water and 
calculating their concentration via UV/Vis. The chromatograms of the digested platinated RNAs were 
evaluated based on the differences of the relative peak area with respect to unreacted RNA samples. 
Appearance of new peaks was also observed (Chapter 4, Paragraph 4.6). Relative peak areas were 
measured directly using the software of the HPLC machine (Chromeleon 7.1). All the HPLC 
chromatogram pictures were prepared with OriginPro 9.1G. 
5.6 Circular dicroism (CD) measurements 
5.6.1  Chemicals / Instrumentation 
KClO4 was bought from Merck (Zug, Switzerland). CD measurements were carried out on a Jasco  
J-810 spectropolarimeter from Jasco (Easton, MD, USA) equipped with a peltier thermostat, with 
continuous flow of N2 with a rate of 5 L / min at room temperature. Data evaluation was done using the 
supplied software, Spectra Manager and Spectra Analysis. All the CD spectra pictures were prepared 
with OriginPro 9.1G. 
5.6.2  Experimental procedure 
CD Spectra were recorded at 25 °C on a Jasco J-810 spectrometer using a 1 cm path length quartz 
cuvette with volume capacity of 1 mL (Hellma Analytics, Germany). The RNA concentration was in 
the range 1.1 - 1.5 μM and the pH was 5 - 6.5. The final salt concentration in the samples was 120 mM 
KClO4, obtained using a 400 mM KClO4 starting solution. Continuous scans were performed between 
200 and 350 nm with scanning speed of 50 nm / min, data pitch of 1 nm, response of 0.5 s, and band 
width of 1 nm. Ten scans were averaged, the blank was subtracted from each spectrum, and data were 
zero-corrected at 350 nm. Each measurement was repeated twice. In the graphs, circular dichroism is 
represented as molar ellipticity [θ] using the following equation:  
[θ] (deg.cm2.dmol ̶ 1) = θ (mdeg) / (10 x c x l) 
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where: [θ] is Molar ellipticity, θ is Ellipticity, c is the Molar concentration of the sample in mole / L 
and l is the cuvette pathlength in cm. Using molar ellipticity the plotted data are concentration 
independent7. 
 
5.7  UV thermal melting experiments 
5.7.1  Chemicals / Instrumentation 
UV-thermal melting measurements were performed on Cary 100 UV/Vis, Lambda 25 and 850 UV/Vis 
(PerkinElmer, Schwerzenbach, Switzerland) spectrophotometers. The cuvettes used for these 
measurements were 1 cm path-length quartz cuvettes with total volume capacity of 1 mL and were 
purchased from Hellma (Müllheim, Germany) or Starna (Hainault, UK). 
5.7.2  Experimental procedure 
Thermal melting studies were conducted for the unreacted and platinated RNA samples using a 
concentration of 1.1 - 1.5 µM at pH 5.0 and pH 6.5 in water with 120 mM KClO4 on Lambda 25 and 
850 UV/Vis spectrophotometers (PerkinElmer) equipped with a temperature control unit. The 
experiments were performed recording the absorption at 260 nm during heating and cooling of the 
sample. All the samples were covered with paraffin oil to avoid sample evaporation and furthermore 
the cuvettes were closed with their caps. The heating and cooling cycles were performed at a rate of  
1 °C / min for a temperature range of 25 °C to 90 °C with starting and returning temperature of 25 °C. 
The heating and cooling cycles were repeated three to four times and the melting temperatures were 
obtained by calculating the first derivative of each melting curve8. The values of each Tm was averaged 
and the errors correspond to standard deviation. All the pictures for the thermal melting studies were 
prepared with OriginPro 9.1G. 
 
5.8  MALDI-MS measurements 
Matrix-assisted laser desorption ionization mass spectrometry (MALDI-MS) spectra were recorded at 
the Functional Genomics Center Zurich (FGCZ) by Dr. Serge Chaesnov. More details on mass 
measurements are provided and discussed in Chapter 2, Paragraph 2.7. Selected mass spectra are given 
in the Appendix 1. All the mass spectrum pictures were prepared with OriginPro 9.1G. 
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5.9 NMR experiments  
5.9.1  Chemicals / Instrumentation 
RNA samples for NMR studies were prepared by transcription using natural abundance nucleotides. 
The Pt(II)-RNA samples were purified by denaturing gels, isolated with electroelution and desalted via 
Vivaspin as described above. 1H-NMR spectra were recorded on deph- and triph-D1-27, and their 
corresponding platinated species. 31P-NMR spectra were recorded to confirm successful 
dephosphorylation (Chapter 2, Paragraph 2.9). The samples were dissolved either in D2O (Armar 
Chemicals, Switzerland) or in H2O / D2O (90:10) using deionized, millipore-filtered water, in the 
presence of 120 mM KCl or KClO4, based on the requirements of each experiment. The time evolution 
NMR experiments were performed in the presences of 120 mM KCl, while all the other experiments in 
120 mM KClO4. The RNA concentration was checked via UV/Vis and varied from 0.1 to 0.4 mM while 
the platinum(II) concentration was usually 5x the RNA concentration in the time evolution experiments. 
The pH was between 6.5 and 7.0 and it was adjusted with addition of KOH, KOD, HCl or DCl, 
according to the needs. For all NMR measurements, 5 mm Shigemi® tubes were used. 4,4-dimethyl-4-
silapentane-1-sulfonic acid (DSS) (Bruker Biospin AG, Fällanden, Switzerland) was used as an external 
direct reference for 1H resonances and indirect reference for 13C resonances9. 31P spectra were 
referenced to external 85% H3PO4. NMR spectra were recorded on a Bruker Avance 700 MHz 
spectrometer with a 5 mm CRYO TXI inverse triple-resonance probe-head with z-gradient coil, on a 
Bruker Avance 600 MHz spectrometer with a 5 mm CRYO TCI inverse triple-resonance probe head 
with z-gradient coil, and on a Bruker DRX 500 MHz spectrometer using a cryo BBO probe at the NMR 
facility of the University of Zurich. The software used for processing the data and preparing the 1D 
NMR pictures was TopSpin 3.0 or TopSpin 3.2. (Bruker Biospin AG, Switzerland) and all assignments 
were made in Sparky (http://www.cgl.uscf.edu/home/sparky/). The 2D NMR pictures were prepared 
using CorelDraw X3 and MestReNova version 10.0 (Mestrelab Research S.L.) 
 
5.9.2  Experimental procedure 
Time evolution NMR experiments were used to study RNA platination by following the changes 
induced by the platinum binding in the imino proton region. Imino proton resonances are visible when 
there are stable hydrogen bonds between the bases10. Therefore, changes affecting the imino resonances, 
like chemical shift and / or intensity, are indicative of structural modifications. The platination reactions 
were performed using 0.1 mM RNA, 5 eq of platination agent, 120 mM KCl, and were allowed to 
proceed for 1 day at 25 °C in the NMR tube. These are the conditions that were found to favour a clear 
separated upper band on the gel, containing the platinated species, in the case of oxaliplatin (Chapter 2, 
Paragraph 2.4.4). First, 1H-NMR spectra were recorded before the addition of the platination agent. 
After addition, 1H-NMR spectra were recorded every 1 h for 24 h. Time evolution NMR experiments 
were recorded for D1-27, deph-D1-27, D1-27GAAA and RNA 26 using oxaliplatin as platination agents. 
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In the case of D1-27, different amounts (1-20 equiv) as well as different kind of platination agents 
(monoaquated cisPt and monoaquated kitePt) were also used (Chapter 3, Paragraphs 3.5 - 3.7). To 
evaluate the changes, the percentage of the intensity of the imino proton resonances was plotted over 
time.  
1H-NMR spectra in the range 4 - 25 °C were also recorded on platinated samples isolated from the 
various bands on the gel (Chapter 4, Paragraph 4.8). Moreover, a [1H,13C]-HSQC spectrum on the 
aromatic region (C8 and C2 of purines, C6 of pyrimidines) and a [1H,1H]-NOESY spectrum were 
recorded on a natural abundance platinated sample isolated from the upper band of a gel corresponding 
to a platination reaction performed on triph-D1-27 (Chapter 4, Paragraph 4.8, Appendix 2, Figures 
A 2.6 - A 2.7).  
 
5.10  32P 5ʹ- and 3ʹ-end labelling of RNA 
5.10.1 Chemicals / Instrumentation - Solutions / Buffers 
5.10.1.1  Chemicals / Instrumentation 
The general procedures to prepare, isolate and purify RNA samples and to prepare and run gels are the 
same as commented above. For radioactive labelling [γ-32P]-ATP (150 mCi / mL, 6000 Ci / mmol) and 
[-32P]-dCTP (6000 Ci / mmol, 20 mCi / mL) from PerkinElmer were used. For measuring the 
concentration of the labelled RNA, scintillation counts were performed on a scintillation counter 
22000CA Liquid Scintillation Analyzer from Canberra Packard. RNase T1 1000 U/μL and Nuclease 
S1 100 U/μL were obtained from Termo Scientific (Reinach, Switzerland). T4 polynucleotide kinase 
10 U/μL, thermosensitive alkaline phosphatase (TSAP) 1 U/μL and alkaline phosphatase calf intestinal 
(CIAP) 1 U/μL were bought from Promega (Dübendorf, Switzerland). The concentration of the labelled 
RNA was measured by scintillation counting. The overall RNA concentration was determined 
spectroscopically using a Picodrop CUBE (Labgene, Switzerland) from the absorbance at 260 nm in 
order to determine the labelling efficiency The gels were dried on WhatmannTM Chromatography 
paper from GE Healthcare (Little Chalfont, UK) on gel driers from Uniequip (Planegg, Germany) or 
Biometra (Goettingen, Germany). For visualization of the labelled RNA bands screening was performed 
using Storage Phosphor Screens from GE Healthcare. Phosphoimaging was performed with a Typhoon 
scanner FLA 9000 from GE Healthcare.  
5.10.1.2  Solutions / Buffers 
15% denaturing gel solution (29:1) (7 M Urea, 1x TBE, 375 mL Acryl-Bisacryl): 420 g Urea, 
 100 mL 10 x TBE, 375 mL Acryl-Bisacryl 29:1, filled up with water until 1 L and filtrate with  
0.22 μm SteritopTM bottle top filter. 
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15% denaturing gel solution (19:1) (7 M Urea, 1x TBE, 375 mL Acryl-Bisacryl): 420 g Urea,  
100 mL 10x TBE, 375 mL Acryl-Bisacryl 19:1, filled up with water until 1 L and filtrate with  
0.22 μm SteritopTM bottle top filter. 
20% denaturing gel solution (29:1) (7 M Urea, 1x TBE, 250 mL Acryl-Bisacryl): 420 g Urea,  
100 mL 10x TBE, 500 mL Acryl-Bisacryl 29:1, filled up with water until 1 L and filtrate with  
0.22 μm SteritopTM bottle top filter. 
20% denaturing gel solution (19:1) (7 M Urea, 1x TBE, 250 mL Acryl-Bisacryl): 420 g Urea, 
 100 mL 10 x TBE, 500 mL Acryl-Bisacryl 19:1, filled up with water until 1 L and filtrate with 
0.22 μm SteritopTM bottle top filter. 
Formamide loading buffer: 82 % (v/v) formamide, 0.16 % (w / v) xylene cynol (XC), 0.16 % (w/v) 
bromophenol blue (BB), 10 mM EDTA (pH 8.0 at 20 °C).  
 
Urea loading buffer for PAGE: 11.8 M Urea, 8.3 % sucrose, 42 mM Tris-HCl (pH 7.5), 0.8 mM 
EDTA (pH 8.0), 0.08 % (w/v) dye xylene cyanol (XC) and bromophenol blue (BB). 
  
TBE buffer for electrophoresis and electroelution (diluted to 1x from the 10x): 0.89 M Tris-HCl 
(pH 8.3), 0.89 M boric acid, 0.002 M EDTA. 
 
10x Sodium carbonate (Na2CO3) solution: 0.5 M Na2CO3 (pH 9.0 at 23 °C), 10 mM EDTA (pH 8.0 
at 20 °C).  
10x Sodium citrate buffer: 0.25 M trisodium citrate (pH 5.0 at 23 °C). Adjust the pH by addition of 
concentrated HCl.  
5x Reaction buffer (S1): 200 mM sodium acetate (pH 4.5), 1.5 M NaCl, 10 mM ZnSO4. 
2x Quenching solution (colourless gel loading solution): 82 % (v/v) Formamide and 10 mM EDTA 
(pH 8.0).  
ME Buffer: 10 mM MOPS (pH 6.0), 1 μM EDTA. 
5.10.2 5'-end radiolabelling of D1-27 
D1-27 was transcribed from double stranded DNAs and carried a 5'-triphosphate. This needs to be 
removed before 5'-end labelling. Dephosphorylation of 120 pmol RNA in a final volume of 50 μL took 
place with Thermosensitive Shrimp Alkaline Phosphatase (TSAP). 4 μL of the TSAP (1 U/μL) were 
added to the RNA sample, followed by incubation at 37 °C for 30 min with 300 rpm shaking. The RNA 
was subsequently purified by phenol-chloroform extraction and dissolved in 16 μL of ME buffer. 
Dephosphorylated RNA (240 pmol) was dissolved in 28 μL of ME buffer and mixed with 3 μL of  
32P-γ-ATP (3000 Ci / mmol), 4 μL of T4 polynucleotide kinase (PNK, 10 U/μL) and 4 μL of PNK buffer 
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(10x). The reaction mixture was incubated at 37 °C for 30 min without mixing. Afterwards an equal 
amount of formamide loading buffer was added to the mixture. The 5ʹ-labelled RNA was purified by 
denaturing PAGE (15% w/v). The RNA in the gel was visualised by phosphoimaging and the RNA 
bands were excised from the gel. The RNA gel band was placed into a small Eppendorf tube with a 
hole, which was placed in a bigger Eppendorf tube, in order to be crushed into smaller pieces by 
centrifugation at 9500 rpm at room temperature for 2 min. 500 μL of crush and soak buffer were added 
to each Eppendorf tube. The samples were soaked in the buffer at 4 °C for 5 - 8 hours vortexing every 
30 min, or overnight, with comparable recovery efficiency. Afterwards the samples 
werecentrifugedat9500 rpm and at 4° C for 3 min and the supernatant was collected. The RNA in the 
supernatant was precipitated adding 3 volumes of ice cold absolute ethanol and keeping the sample at 
‒ 20 °C overnight or at ‒ 80 °C for 1 hour. After ethanol precipitation the samples were centrifuged at 
9500 rpm and at 4 °C for 40 min and the pellets were dried in a Speed Vac evaporator and dissolved in 
20 -80 μL of water. The concentration of the labelled RNA was measured by scintillation counting. The 
overall RNA concentration was determined spectroscopically from the absorbance at 260 nm in order 
to determine the labelling efficiency. Upon optimization of the labelling reaction conditions 
(concentration of the reactants and incubation time) the labelling efficiency increased from 0.01 to 
10 %. The radiolabelled RNA samples were stored at  ̶  20 °C. 
5.10.3 3ʹ-end radiolabelling of D1-27 
In this case, D1-27 was 3ʹ-end labelled with -32P-dCTP using the Szostak (splint) method11. The length 
of the DNA oligo splint (DNA 16, 21, 23), its concentration (1 μM - 50 μM) as well as the reaction time 
(5 min - 2 h) were optimized (Chapter 4, Paragraph 4.7.4). The optimal procedure was the following: 
Five samples of 25 pmols with final volume of 5 μL each were mixed with 0.5 μL 10x annealing buffer, 
2 μL DNA 16 (3ʹ-CCTCGATTCAAGGGCC-5ʹ) oligo splint (10 μM) and 2.5 μL water. The samples 
were heated to 95 °C for 30 sec and then cooled down to 59 °C with 0.3 °C / min. Afterwards they were 
kept in ice for 15 min. The five samples were combined and to the annealing mixture 5 μL Klenow 
buffer (1x), 10 μL α-32P-dCTP (20 μCi / μL), 3.3 μL Klenow enzyme (10 U/μL) and water to final 
volume of 50 μL were added. The reaction mixture was incubated at 37 °C for 1 h. Afterwards an equal 
amount of formamide loading buffer was added to the mixture. The 3ʹ-labelled RNA was purified and 
isolated using the same procedure as described above for the 5ʹ-end labelled RNA.  
Oligo DNA splints used for 3ʹend labelling 
During the optimization of the labelling procedure three DNA constructs were tested but the best 
labelling efficiency was achieved using the DNA 16.  
DNA 23: 5ʹ-CCGGGAACTTACGTCCGAAGAGC-3ʹ 
DNA 21: 5ʹ-CCGAACTTAGCTCCGAAGAGC-3ʹ 
DNA 16: 5ʹ-GCGGGAACTTAGCTCC-3ʹ 
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5.10.4 Preparation of radiolabelled platinated D1-27 
For the preparation of labelled platinated RNA the experimental procedure followed is exactly the same 
as when unlabelled platinated RNA is prepared. The only difference is that both labelled and unlabelled 
RNA are used. More specifically the platination reactions of D1-27 with oxaliplatin were performed 
using the optimal conditions found for oxaliplatin (0.1 mM un labelled RNA, 5 eq of oxaliplatin, 
incubation for 1 day at 25 °C in 120 mM KCl) but also 1 - 2 nM of end radiolabelled  
D1-27 was added in the platination reaction mixture.  
5.10.5 Alkaline hydrolysis and enzymatic digestions of the radiolabelled RNA samples 
Both unreacted and platinated 32P-end labelled RNAs were subjected to alkaline hydrolysis and 
enzymatic digestions. For all samples four lanes were loaded: control, partial hydrolysis ladder lane 
(OH–), RNase T1 lane (T1) and S1 nuclease lane (S1). Equal amount of 32P-end labelled RNA and final 
volume of 10 μL were used in all cases. The final concentration of the labelled RNA was  
0.1 nM. 25 % denaturing gels were used and they were run at room temperature for 4 - 6 h. 
Control lane: The control is crucial in order to check the extent of degradation of the RNA sample. 
Ideally this lane should contain only one band corresponding to the full-length RNA. In this case, all 
cleavage products seen in the other lanes are real and can be considered for further evaluation. For the 
preparation, 32P-end labelled RNA is diluted in water and equal volume of formamide buffer is added. 
The sample is stored in liquid nitrogen until loaded on the gel. 
Partial alkaline hydrolysis ladder lane: 32P-end labelled RNA in water was mixed with 8 μL of 
0.5 M Na2CO3 and 8 μL of ddH2O. The mixture was gently mixed by pipetting and incubated for  
10 min at 90 °C. Equal volume of formamide buffer was added. The sample was stored in liquid nitrogen 
until loaded on the gel. 
RNase T1 ladder lane: RNase T1 was used to digest the 32P-end labelled RNAs. RNase T1 cleaves 
single-stranded RNA after guanosine residues on their 3'-end and therefore digestion of 3' or  
5' labelled RNA with this enzyme leads to a ladder of G residues. 32P-end labelled RNA in water was 
mixed with 6 μL colourless gel loading buffer, 1 μL citrate buffer and 2 μL T1 (20 U/μl). The mixture 
was gently mixed by pipetting and incubated for 20 min at 55 °C. Equal volume of formamide buffer 
was added. The sample was stored in liquid nitrogen until loaded on the gel. 
S1 nuclease ladder lane: The S1 nuclease is known to cleave single-stranded region caused by, e.g., 
mismatches or loops. This enzyme was used to identify loop regions and/or structural changes induced 
by platination on the labelled samples. 32P-end labelled RNA in water was mixed with 2 μL reaction 
buffer (5x), 4.1 μL ZnSO4, 0.8 μL S1 (0.8 U/μL) and 2.1 μL water. The mixture was gently mixed by 
pipetting and incubated for 20 min at 25 °C. Equal volume of formamide buffer was added. The sample 
was stored in liquid nitrogen until loaded into the gel. 
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5.11 Plasmid binding studies 
The plasmid binding studies were performed during a short-term scientific mission (STSM) funded by 
the COST Action CM1105 which was performed in the laboratory of Prof. Sofi K. C. Elmroth in Lund, 
Sweden. For this study the pUC19 plasmid (2686 bp) (pUC18 plasmid, purified by use of a midi-prep 
kit from Sigma– Aldrich) was used and the platination agents investigated were the monoaquated 
complexes of cisPt, kitePt, and [Pt(DACH)Cl2]. 
5.11.1 Buffers 
200 mM Na2HPO4 / NaH2PO4 (NaPi) buffer pH 5.8: Mixing 23 mL of 200 mM NaH2PO4 solution with 
2 mL of 200 mM Na2HPO4 solution. 
200 mM K2HPO4 / KH2PO4 (KPi) buffer pH 5.8: Mixing 23 mL of 200 mM KH2PO4 solution with 
2 mL of 200 mM K2HPO4 solution. 
Loading dye with NaCl: 1.1 M urea, TBE, 33 % (v/v) formamide, 0.025 % (w/v) bromophenol blue, 
0.025 % (w/v) xylene cyanol, 500 mM NaCl. 
5.11.2 Experimental procedure 
The ratio between DNA plasmid concentration (CDNA) and the concentration of the platinum(II) 
complexes (CPt) (rf = CPt/CDNA) used for the binding study varied between 0 and 0.5. All platination 
reaction experiments were performed in 200 mM Na2HPO4 / NaH2PO4 (NaPi) and K2HPO4 / KH2PO4 
(KPi) buffer pH 5.8, incubating at 37 °C for 1 day. The reactions were quenched by addition of 5 µL 
loading dye with NaCl. The platination reactions were analyzed on 2% agarose-TAE gel containing  
0.6 µg / mL ethidium bromide (EB) using 1x Tris-Acetic acid-EDTA (TAE) as running buffer. The gels 
were run for 1.5 h at 70 V. The gel images were visualized by UV light and a photo was taken using a 
MP-4 Polaroid camera and analyzed by DiMAGE Capture A2. 
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6 Summary 
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The nucleic acids, DNA and RNA, are chemically very similar, but, since DNA is considered the source 
of all the vital information for life, it was the one that was mostly studied as potential drug target. 
However, studies of the past decades revealed new classes of biologically relevant non-coding RNAs, 
which are involved in crucial biological functions, like regulation of transcription and translation, 
control of gene expression and catalysis of protein synthesis. The multiple biologically important roles 
of RNA together with the great variety of new classes of functional non-coding RNAs found, have 
promoted RNA to an important potential drug target. The variety of RNA roles is to a great extent 
connected with its peculiar structure. More specifically RNA molecules can adopt a wide range of 
alternative conformations, which vary from local (e.g. bulged nucleotides) to drastic rearrangements of 
its secondary structure and tertiary folding. Due to the negative charge of its backbone, metal ions are 
crucial for correct RNA folding and are eventually involved in catalysis. Formation of complex three-
dimensional RNA structures create binding pockets, which could be specifically targeted by metal ions. 
Targeting these complex structures with small molecules could interfere with RNA function. 
Considering this, the development of small molecules for RNA targeting has received a lot of attention.  
Cisplatin, oxaliplatin and carboplatin are the three platinum(II) complexes which are used in clinics 
worldwide (Figure 6.1). Despite their success, their severe side effects and tumour resistances are 
limiting their usage. Platinum(II) anticancer drugs in general are thought to exert their anticancer 
activity mainly upon covalent binding to nuclear DNA. However, numerous studies showed that 
cisplatin toxicity could result also from various sources including interactions with proteins, lipids, 
peptides and RNA. For this purpose research has been dedicated on the one hand to the development of 
new platinum(II) complexes which could have better performance, on the other hand to the in-depth 
understanding of their mechanism of action, performing studies on their interaction with biological 
targets other than DNA. Toward this direction, besides platinum(II)-DNA studies, the interaction 
between platinum(II)-protein have also received a lot of attention but much less studied are the 
platinum(II)-RNA interactions. 
 
Figure 6.1: Platinum(II) drugs which are in clinical use worldwide: Left: cisplatin; middle: carboplatin: right: 
oxaliplatin. 
 
Recent reports revealed that platinum accumulated in total 4- to 20-fold more in total cellular RNA than 
in genomic DNA and that important RNA-based activities like transcription, splicing and translation 
are inhibited upon administration of cisplatin. Studies on RNA duplexes, hairpin models as well as more 
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structured RNAs revealed that a common characteristic of all the Pt(II)-RNA adducts is the binding of 
platinum(II) in non-Watson-Crick base paired regions and its high selectivity towards the GG sites 
(Chapter 1). 
In this thesis we mainly investigated the interaction of oxaliplatin (Figure 6.1, right) with a model RNA 
construct (D1-27) (Figure 6.2) and characterized its isolated monoplatinated RNA adducts using various 
biochemical and spectroscopic techniques. D1-27 represents a good RNA model for many reasons: 1) 
it contains biologically relevant RNA structural motifs (internal and terminal loops) and various 
guanines and adenines which represent potential platinum(II) binding sites, allowing to study possible 
sequence and structure preferences of platinum binding, 2) its NMR characterization in solution is 
known making easier the NMR investigation of its platinated adducts and 3) NMR studies on its 
interaction with metal ions have been recently reported, giving us information about the regions which 
are available for metal-ion binding. Additionally to D1-27, few other RNA constructs were employed 
in this study, mostly to evaluate the influence of the various structural elements of D1-27 in its 
interaction with oxaliplatin (Figure 6.2). 
 
Figure 6.2: The secondary structures of all RNAs used in this study. Starting from the main construct D1-27 other 
three D1-27 analogues were used. RNA 26 does not contain the internal loop, D1-27GAAA has a -GAAA- tetraloop 
instead of a -UUCG- and the RNAUU has two U-A base-pairs instead of 2 G-C base-pairs. 
 
In the first part of Chapter 2 are discussed the reasons why this study was conducted using oxaliplatin 
as platination agent. Upon platination a slower migrating band (upper) was formed and, from  
MALDI-MS characterization, it was found that it contained a mixture of monoplatinated and 
diplatinated RNA, with the first being the major species (Figure 6.3, red frame). The lower band (Figure 
6.3, green frame) contained mostly unreacted RNA but also monoplatinated and diplatinated RNA 
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species as its MALDI-MS revealed. However, due to 
its heterogeneity, the sample isolated from the lower 
band was not used for further characterization. 
Considering the sample isolated from the upper 
band, since no separation between the two species 
was achieved using denaturing PAGE, the use of 
HPLC was attempted. Despite the optimization, the 
retention time of the mono- and diplatinated RNA 
were very close, and no successful separation was 
obtained. Next, the use of HPLC for the isolation and 
purification of the platinated RNAs instead of 
dPAGE was attempted, with the platination mixture 
being directly injected in the HPLC machine after 
the end of the reaction. However, no advantage with 
respect to dPAGE separation was obtained, and all 
the samples were then purified and isolated using 
denaturing gels. Unfortunately, isolation of pure 
monoplatinated RNA was not possible, likely 
because of the heterogeneity of the reaction mixture. 
However, HPLC could be used to quantify the 
diplatinated species (12 %). The heterogeneity 
observed could be the result of the use of RNA 
samples with triphosphate and diphosphate groups at 
the 5ʹ-end, which led to the formation of platinated 
RNA species with different number of phosphate 
groups. In order to have a homogeneous starting 
material, D1-27 was dephosphorylated before being 
used for platination.  
The platination of deph-D1-27 resulted in a gel with 
three bands instead of the two always observed 
when triphosphate-D1-27 (triph-D1-27) was used 
(Figure 6.4). In addition to the slower migrating 
band observed also in the previous case (upper), a 
new faster migrating band (lower), which consisted 
of monoplatinated and diplatinated RNA, appeared. By using deph-RNA the chromatogram of the 
platinated RNA species isolated from the upper band was improved and two main peaks were observed 
Figure 6.3: 20 % denaturing PAGE for the platination 
reaction of D1-27 with oxaliPt  
(0.25 mM RNA incubated with 5 eq of oxaliPt at  
25 °C for 1 day in the presence of 120 mM KCl). The 
gel was run at 4 °C. Characteristic mass spectra of the 
samples isolated from the upper and lower band are 
depicted. 
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corresponding to monoplatinated and diplatinated RNA. Now, contrary to what previously observed, 
isolation of a more homogeneous platinated sample seems to be possible, but further optimization is 
required if the method is to be used to obtain large amount of homogeneous sample. However, since 
the monoplatinated species in the sample isolated from the upper band always accounted for around 90 
% of the total sample, we proceeded with further characterization of these isolated platinated RNA 
species (see below).  
 
Figure 6.4: 20 % denaturing PAGE for the platination reaction of triph-D1-27 (left) and deph-D1-27 (right) with 
oxaliPt. In the same colours are indicated the bands that had similar MS spectra. The gel was run at 4 °C. 
 
Chapter 3 is mainly devoted to the time evolution NMR experiments as a quick way to follow and 
evaluate platination reactions. These NMR experiments together with denaturing PAGE, were utilized 
in order to compare the behaviour of different platination agents, namely oxaliplatin, cisplatin and 
kiteplatin, towards D1-27. Information about the platination reaction rates of all three platinum(II) 
complexes were also collected from DNA unwinding experiments. The most important results obtained 
from these experiments are summarized in Table 6.1. For the platination of D1-27 with oxaliPt the 
influence of the terminal tetraloop (D1-27GAAA), the presence of the internal loop (RNA 26) and the role 
of the 5ʹ-end phosphate group (deph-D1-27) on the platinum(II) binding sites were investigated. From 
this study it was concluded that there is no interaction at the terminal -UUCG- tetraloop and a very 
possible target is the G1-G2 site. Contrarily, the variations observed at G8 could be linked to structural 
changes induced upon platination at, for example, G1-G2, which may affect G8 because of the presence 
of the internal loop. The removal of the triphosphate group (deph-D1-27) led to similar conclusions, 
with the difference that the reaction at the G1-G2 site was not as fast as before. Lastly, the replacement 
of the -UUCG- tetraloop for the -GAAA- one made the terminal loop region more prone to platinum 
binding.  
Even if changes in the imino proton resonances allow collecting important information on platination 
reactions, this approach cannot be used alone for the evaluation of direct platinum binding sites, because 
the imino proton resonances are influenced by many different experimental factors and are very 
sensitive to local structural changes (see behaviour of G8). 
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A first evaluation of the different platinum binding preferences and reaction kinetics of monoaquated 
cisPt and monoaquated kitePt [(Pt(cis-1.4DACH)Cl (H2O)]+ compared to oxaliPt was performed with 
the combination of time evolution NMR experiments and PAGE analysis under the same platination 
reaction conditions (Table 6.1). CisPt was found to be the agent, which was binding faster and less 
specific to RNA and oxaliPt was the one with good specificity and good reaction kinetics. KitePt 
exhibited an average behaviour between the other two, because it seemed to be more specific than cisPt 
but less than oxaliPt. Indeed, in addition to G1-G2 platination, another site seems to be platinated, in 
line with the results obtained from the MALDI-MS spectrum of its isolated platinated species, which 
show that the diplatinated species is the major one. However, further experiments are required to 
identify the second platination site. Plasmid binding assays confirmed the above-mentioned behaviour. 
In the end the kinetics and the role of K(I) and Cl¯ in the platination reactions of all three platinum(II) 
complexes was investigated using PAGE analysis. Furthermore, time evolution NMR experiments were 
employed to follow the platination reaction of monoaquated cisPt in the presence and absence of K(I) 
and Cl¯, which further supported its high reactivity and reduced specificity. 
Table 6.1: Summary of the results obtained from the experiments commented in chapter 3. Time evolution  
1H-NMR experiments and denaturing PAGE assays were performed under the same experimental conditions. 
 D1-27 
Method Oxaliplatin Kiteplatin Cisplatin 
Time evolution 
1H-NMR 
experiments 
G1-G2 
G1-G2 & a second 
platination site 
non-specific interaction 
Plasmid 
binding assays 
Coalescent point at 
rf=0.5 
Coalescent point at rf=0.5 
but the smeary band 
appeared earlier than 
oxaliPt = faster than 
oxaliPt 
Coalescent point at rf=0.15 
Faster compared to the 
other two complexes 
PAGE 
Two bands 
Upper: mainly 
monoplatinated 
species 
Two bands 
Upper: mainly 
diplatinated species 
Extended smeary band 
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Chapter 4 is dedicated to the characterization of the 
platinated species, which were isolated from the upper 
band of denaturing gels run on reaction mixtures 
performed with both triph- and deph-D1-27. In all cases, 
the main species contained in the samples is 
monoplatinated RNA (88 %), even if a small percentage 
of diplatinated RNA (12 %) is present. The 
characterization of the Pt-RNA adducts migrating in the 
upper band was performed using various methods. 
Platinated adducts obtained using homogeneous  
Pt-deph-RNA as starting material were mainly 
characterized. However, very similar behaviour was 
observed for the Pt-triph-RNA adducts, thus suggesting 
the same platination pattern for the upper band species 
in the two cases. Each technique used provided us with 
an information about the binding of oxaliPt to the RNA 
construct. The thermal melting studies (Figure 6.5, A) 
showed that the platination affects significantly only the 
first part the RNA construct, because only Tm1 changed 
upon platination. Therefore, platination in this area was 
suggested. The reduction of Tm1 compared to the 
unreacted RNA indicates destabilization of the RNA 
construct upon platinum binding, thus suggesting 
intrastrand cross-link. No information about the binding 
sites could be provided from this method. The CD 
spectra of the unreacted and platinated RNA showed 
that the platination did not change the overall RNA 
conformation, and the little changes observed are likely 
due to local perturbations caused by the presence of the 
Figure 6.5: Summary of the most important methods used for the characterization of the Pt-RNA sample isolated 
from the upper band. A: Indicative thermal melting profiles for deph-D1-27 (black) and Pt-deph-D1-27 (red). B: 
Comparison of the CD spectra of D1-27 (black) and Pt-D1-27 (red). C: HPLC chromatograms of the digestion 
of Pt-deph-D1-27, which led to the appearance of a new peak (black) and of the reaction of the GpG dinucleotide 
with oxaliPt (red). The chromatogram in red is shifted to facilitate comparison. D: 1H-NMR spectra (aromatic 
and imino proton regions) of the D1-27 (black) and Pt- D1-27 sample isolated from the upper band (red line). 
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platinum moiety (Figure 6.5, B). More specifically the bathochromic shift of the band at 260 nm can be 
connected to intrastrand platinum binding to RNA. The enzymatic digestion / HPLC treatment of the 
non-platinated and platinated RNA species gave us the first indication about a possible platination site 
(Figure 6.5, C). The platinated RNA species have an extra peak in the HPLC chromatogram and from 
the comparison of the relative peak areas a loss of two guanines was estimated. The new peak has the 
same retention time as the Pt-GpG species, which was formed upon platination of the GpG dinucleotide, 
thus suggesting platination at a GG site. From the combination of the collected information so far, it 
seemed that two adjacent guanines were platinated, which should be located in the first part of the 
construct. The only two guanines fulfilling these criteria are G1 and G2. Further characterization, like 
32P-5ʹ- and 32P-3ʹ-end radiolabelling techniques were employed in order to get information about the 
platination site. Partial alkaline hydrolysis and enzymatic digestions on platinated 32P-5ʹ-end labelled 
samples showed that G23, which is located in the first part of the construct, is not directly platinated. 
However, no information on the first two nucleotides could be obtained with this technique. Therefore, 
we used 32P-3ʹ-end labelled samples. In this case, we observed changes of the intensity of the gel bands 
corresponding to G1 and G2 upon platination. This suggests platination at G1-G2, in agreement with 
the previous findings. At the end, 1H-NMR spectra were recorded on isolated samples, and comparison 
of the imino proton resonances before and after platination was performed (Figure 6.5, D). The guanine 
imino proton resonances mostly affected by platination correspond to G1 and G2. Interestingly, the 
imino proton resonances of the isolated upper band are very similar to the ones of the RNAUU construct 
(Figure 6.2), confirming destabilization at the 5'-end in the presence of platinum(II), likely due to G1-
G2 platination. Also, a [1H,13C]-HSQC experiment performed on an isolated platinated sample further 
supports direct platination at G1 and G2. Finally, in order to investigate the nature of the species 
responsible for the faster migrating band (lower) observed when dephosphorylated RNA is used as 
starting material in the platination reactions, (Figure 6.4) a preliminary characterization was performed, 
consisting of CD, thermal melting studies and enzymatic digestion/ HPLC. The platinated RNAs 
migrating in the lower band represent secondary species considering that the main ones are platinated 
at the G1-G2 site. MALDI-MS spectra of the sample isolated from this band showed that there is an 
increased amount of diplatinated RNA compared to the species isolated from the upper band. Moreover, 
enzymatic digestion / HPLC analysis were not consistent, since the results vary as different samples 
were used and a mixture of differently platinated species was found to be formed. Due to their 
heterogeneity as well as to the presence of increased amount of diplatinated species, no clear conclusion 
could be drawn about the way that platinum was bound to D1-27 in these minor species.  
Summing up, upon interaction of oxaliplatin with D1-27 under the experimental conditions used for 
this study, despite the presence of many possible platinum(II) binding sites, strong preference for 
platination at G1-G2 was observed, leading to monoplatinated RNA species with decreased gel 
mobility. The GG site of DNA is the most common platinum binding site for platinum(II) anticancer 
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drugs47 and strong preference for this motif has been reported also for RNA platination with cisplatin. 
Our data revealed that oxaliplatin also showed a strong preference for the most accessible GG site (G1-
G2) which is in line with the currently reported finding on RNA platination. 
Despite their widespread use, platinum(II) anticancer drugs have severe side effects as well as some 
tumours display intrinsic or acquired resistance towards them. Moreover, despite their importance, there 
is still lack of comprehensive understanding of their complex biological activity, including how 
intracellular molecules are targeted by them. An approach to eliminate their side effects is trying to 
develop a better understanding of their mechanism of action, which may be achieved by in-depth studies 
on their interaction with biomolecules other than DNA. RNA may represent a good platinum(II) drug 
target, considering its importance and involvement in crucial cellular functions. Along this line, early 
studies revealed that platinum(II) drugs can inhibit important RNA-based activities which are crucial 
for the survival of the cell. Considering this we performed a detailed study on the interaction of 
oxaliplatin with an RNA model (D1-27) from which we aimed at investigating the possible platinum 
binding sites. An accurate knowledge on platinum binding sites in RNA molecules does not only 
provide a way for predicting modification sites in other biologically relevant RNA molecules but also 
helps towards the better understanding of the versatile nature of platinum(II) drugs anticancer activity. 
All these could lead to the design of new less toxic and more effective platinum(II) drugs and/ or to 
novel therapies towards cancer treatment. 
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7 Zusammenfassung 
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Die Nukleinsäuren DNS und RNS sind sich chemisch gesehen sehr ähnlich. Da die DNS der Träger der 
Erbinformation in allen lebenden Organismen ist, wurde jedoch hauptsächlich nur sie als potentielles 
Zielmolekül für Medikamente wahrgenommen und untersucht. In den vergangenen Jahrzehnten haben 
aber zahlreiche Studien gezeigt, dass nichtkodierende RNS in vielen essentiellen biologischen 
Prozessen involviert ist, wie z.B. Kontrolle der Genexpression durch die Regulierung von Transkription 
und Translation oder als Katalysator in der Proteinbiosynthese. Bis heute werden stetig neue Klassen 
nichtkodierender RNS mit neuen Funktionen gefunden, wodurch die RNS als potentielles Ziel für 
Medikamente immer mehr in den Fokus rückt. Dass die RNS so eine grosse Vielfalt von Aufgaben 
übernehmen kann, ist hauptsächlich auf ihre einzigartige Struktur zurückzuführen. Die einzelsträngigen 
RNS Moleküle können sich in verschiedene komplexe Strukturen falten, die neben den typischen 
doppelsträngigen Bereichen, die auch in DNS zu finden sind, viele Alternativkonformationen 
aufweisen. Strukturvariationen in der RNS-Struktur reichen von kleinen lokalen Unterschieden (z.B. 
Wölbung formende Nukleotide) bis hin zu verschiedenen Sekundärstrukturen und tertiären Faltungen. 
Die Metallionen sind für die korrekte Faltung und somit auch für die Funktion von RNS entscheidend. 
Metallionen schirmen zum einen die negativen Ladungen des Phosphatrückgrats voneinander ab, 
können aber auch spezifisch in Strukturmotive der RNS binden und so zum Beispiel eine bestimmte 
Faltung stabilisieren oder auch direkt in der Katalyse von Ribozymen (katalytisch aktive RNS) 
mitwirken. Das zunehmende Interesse gezielt Funktionen von RNS Molekülen zu beeinflussen, hat in 
den letzten Jahren die Entwicklung und Synthese kleiner RNS-bindender Moleküle stark 
vorangetrieben. 
Die drei Platin(II)-Komplexe Cisplatin, Oxaliplatin und Carboplatin werden heutzutage weltweit als 
Krebsmedikamente in Kliniken verwendet (Abbildung 7.1). Trotz ihres Erfolges, ist ihr Einsatz mit 
schwerwiegenden Nebenwirkungen verbunden und durch Tumorresistenzen begrenzt. Es wird 
angenommen, dass ihre Wirkungsweise gegen den Krebs hauptsächlich auf eine kovalente Anbindung 
an die nukleare DNS beruht. Zahlreiche Studien mit Cisplatin haben jedoch ebenfalls gezeigt, dass die 
toxische Wirkung auch andere Gründe haben kann, einschliesslich der Wechselwirkungen mit 
Proteinen, Fettsäuren, Peptiden und RNS.Die Forschung hat sich deshalb einerseits der Entwicklung 
neuer Platin(II)-Komplexe verschrieben, mit dem Ziel die Nebenwirkungen zu begrenzen und das 
Problem der Resistenzen zu lösen. Auf der anderen Seite wird seit Jahren der genaue 
Wirkungsmechanismus nicht nur mit DNS, sondern auch mit anderen Biomolekülen untersucht. In 
diesem Zusammenhang hat vor allem die Interaktion zwischen Platin(II) und Proteinen viel Beachtung 
gefunden, wohingegen die Platin(II)-Interaktion mit RNS viel weniger studiert wurde. 
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Abbildung 7.1: Platin(II)-Medikamente, die weltweit klinisch verwendet werden: Links: Cisplatin; Mitte: 
Carboplatin; Rechts: Oxaliplatin. 
Aktuelle Studien belegen, dass Platin(II)-Komplexe sich 4 bis 20 mal mehr in zellulärer RNS als in 
genomischer DNS ansammeln, und dass wichtige RNS-basierte Prozesse wie Transkription, Spleissen 
und Translation durch die Verabreichung von Cisplatin unterbunden werden. Studien mit RNS-
Doppelhelixen, RNS-Haarnadelstrukturen und anderen RNS-Strukturen zeigen, dass alle Pt(II)-
Komplexe besonders gern an Stellen ohne Watson-Crick-Basenpaarung und an GG-reiche RNS-
Regionen binden. (Chapter 1). 
In dieser Dissertation wurde die 
Wechselwirkung der drei verschiedenen 
Pt(II)-Komplexen Oxaliplatin, Cisplatin und 
Kiteplatin mit einem modellhaften RNS-
Konstrukt (D1-27) (Abbildung 7.2) 
untersucht. Oxaliplatin ist dabei der Fokus 
dieser Arbeit, da nur mit diesem Komplex 
monoplatinierte RNS-Addukte isoliert 
werden konnten, die anschliessend mit Hilfe  
Abbildung 7.2: Die Sekundärstrukturen aller in dieser Studie verwendeten RNS-Konstrukte. Ausgehend vom 
Hauptkonstrukt D1-27 wurden drei weitere D1-27-Analoga verwendet. RNS 26 enthält keine interne Schleife,  
D1-27GAAA hat eine -GAAA- anstelle einer -UUCG- Tetraschleife und das RNAUU hat zwei U-A Basenpaare 
anstelle zweier G-C Basenpaare. 
von diversen biochemischen und spektroskopischen Techniken charakterisiert wurden. Die D1-27 RNA 
ist aus folgenden Gründen ein gut geeignetes RNS-Modell: 1. Es enthält biologisch relevante RNS-
Sekundärstrukturen (interne und terminale Schleifen, sogenannte loops) und mehrere 
aufeinanderfolgende Guanine und Adenine, die potentielle Liganden für die Platin(II)-Bindungen 
darstellen. Dadurch können mögliche Struktur- und Sequenzpräferenzen der Platinierung gut untersucht 
werden. 2. Die NMR-Struktur von RNS D1-27 in Lösung ist bekannt, was die NMR-Charakterisierung 
seiner platinierten Addukte sehr erleichtert. 3. NMR-Studien, die die Wechselwirkung von D1-27 mit 
Metallionen analysiert haben, wurden kürzlich veröffentlicht. Die dort gefundenen und beschriebenen 
Metallionenbindungsstellen sind auch potentielle Bindungsstellen für die Platin(II)-Komplexe. Um den 
Einfluss der einzelnen Strukturelemente in D1-27 auf die Wechselwirkung mit Oxaliplatin zu 
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analysieren, wurden zusätzlich zu D1-27 noch drei weitere RNS-Konstrukte verwendet (Abbildung 
7.2). 
Im ersten Teil des zweiten Kapitels (Chapter 2) werden die 
Resultate gezeigt und erläutert, die erklären warum 
hauptsächlich Oxaliplatin als Platinierungswirkstoff in 
unsere Studie verwendet wurde. Denaturierende 
Polyacrylamid-Gelelektrophorese (dPAGE) nach der 
Platinierungsreaktion von D1-27 RNS mit Oxaliplatin 
ergab zwei Banden, B und C (Abbildung 7.3 oben rechts). 
Mittels MALDI-Massenspektrometrie (MALDI-MS) 
wurde festgestellt, dass die langsamer laufende Bande B 
eine Mischung aus mono- und di-platinierter RNS war, mit 
der monoplatinierte Spezie als Hauptprodukt (roter 
Rahmen, rotes MS Spektrum). Die untere Bande C (grüner 
Rahmen, grünes MS Spektrum) enthielt hauptsächlich 
unreagierte RNS, aber wie das MALDI-MS Spektrum 
zeigt, zu einem kleinen Anteil auch mono- und di-
platinierte RNS. Aufgrund ihrer Heterogenität wurde die 
untere Bande nicht für eine weitere Charakterisierung 
verwendet. Mit Hilfe von Hochleistungsflüssigkeits-
chromatographie (HPLC)  
haben wir versucht die mono- und di-platinierten Spezien 
der Bande B voneinander zu trennen. Trotz Optimierung 
der Trennungsbedingungen waren die Retentionszeiten der 
mono- und di-platinierten RNS zu 
ähnlich, um die beiden Spezien 
erfolgreich separieren zu können. Es 
wurde daher versucht das 
Reaktionsgemisch direkt nach der 
Platinierung mit Hilfe der HPLC aufzutrennen, aber auch das ohne Erfolg. Da gegenüber der dPAGE-
Trennung kein Vorteil erzielt werden konnte, wurden alle RNS-Proben nach erfolgter Platinierung 
weiterhin mit denaturierenden Gelen aufgereinigt und isoliert. Die Isolation einer reinen 
monoplatinierter RNS war leider nicht möglich, wahrscheinlich aufgrund der Heterogenität des 
Reaktionsgemisches. Nichtsdestotrotz konnte mittels HPLC die diplatinierte Spezie quantifiziert 
werden (12 %). Die direkte Verwendung transkribierter RNS könnte der Grund für die beobachtete 
Heterogenität der Proben sein, da diese sowohl Tri-, Di- also auch Monophosphatgruppen am 5ʹ-Ende 
Abbildung 7.3: 20 % denaturierendes PAGE für die Platinierungs-
reaktion von D1-27 mit oxaliPt (0.25 mM RNS inkubiert mit 5 eq 
oxaliPt bei 25 °C für 1 Tag in Gegenwart von 120 mM KCl). Das 
Gel lief bei 4 °C. Die charakteristischen Massenspektren der oberen 
(rot) und der unteren Bande (grün) sind dargestellt. 
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tragen können. Um mit einem homogenen Ausgangsmaterial zu starten, wurde D1-27 vor der 
Platinierung dephosphoryliert. Die Platinierung von deph-D1-27 resultierte in einem Gel mit drei 
Banden anstatt der zwei Banden die für D1-27 beobachtet wurden (Abbildung 7.4). Zusätzlich zu den  
langsamer laufenden Banden B (upper) und C (middle), die auch bei der nicht dephosphorylierten Probe 
beobachtet wurden, erschien noch eine neue, schneller laufende Bande (lower), die mono- und di-
platinierter RNS enthielt. Das Chromatogramm der oberen Bande von deph-D1-27 zeigte nun neu 
Hauptfraktionen, welche der mono- und di-platinierten RNS entsprechen. Im Gegensatz zu den nicht 
dephosphorylierten Proben, scheint nun die Isolation einer homogeneren platinierten Probe möglich. Es 
sind dennoch weitere Optimierungsschritte notwendig, um mit dieser Methode eine grössere Menge an 
homogener platinierter RNA zu isolieren. Da aber  90 % der oberen Bande der monoplatinierten Form 
entsprach, fuhren wir ohne eine weitere Aufreinigung mit der Charakterisierung fort (siehe unten). 
 
 
 
 
 
Abbildung 7.4: 20 % denaturierendes PAGE für die Platinierungsreaktion von D1-27 (links) und deph-D1-27 
(rechts) mit oxaliPt. Die Banden mit ähnlichen MS-Spektra sind mit gleicher Farbe markiert. Das Gel lief bei  
4 °C. 
In Kapitel 3 (Chapter 3) werden hauptsächlich die Ergebnisse der NMR-Zeitentwicklungsexperimente, 
eine Methode mit der die Platinierungsreaktionen schnell und einfach qualitativ verfolgt und 
ausgewertet werden können, beschrieben und diskutiert. Diese Ergebnisse zusammen mit den der 
denaturierenden PAGE Experimente wurden verwendet um das Verhalten der drei verschiedenen 
Platinierungsstoffe, namentlich Oxaliplatin, Cisplatin und Kiteplatin, gegenüber D1-27 zu vergleichen. 
Platinierungsreaktionsraten aller drei Platin(II)-Komplexe wurden zusätzlich aus DNS-
Entwindungsexperimenten abgeschätzt. Die wichtigsten Resultate dieser Experimente sind in Tabelle 
7.1 zusammengefasst. Die Platinierung von D1-27 mit oxaliPt wurde hinsichtlich des Einflusses der 
terminalen Tetraschleife (D1-27GAAA), der Gegenwart einer internen Schleife (RNS 26) und der Rolle 
der Phosphatgruppe am 5ʹ-Ende (deph-D1-27) auf die Platin(II)-Bindungsstellen untersucht. Aus dieser 
Studie wurde geschlossen, dass es mit Oxaliplatin keine Wechselwirkung an der terminalen  
-UUCG- Tetraschleife gibt und dass G1-G2 eine sehr wahrscheinliche Bindungsstelle ist. Im Gegensatz 
dazu wurden die beobachtete Variationen am G8 nicht einer direkten Platinierung sondern einer 
Strukturänderung zugeordnet. Vermutlich wird durch die Platinierung von G1-G2  die Struktur der 
internen Schleife verändert und so auch die Umgebung von G8 beeinflusst. Das Entfernen der 
Triphosphatgruppe (deph-D1-27) liess ähnliche Schlüsse zu, mit dem Unterschied, dass die Reaktion 
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an der G1-G2-Stelle nicht so schnell ablief wie zuvor. Zu guter Letzt machte das Ersetzen der  
-UUCG- durch die -GAAA- Tetraschleife die Region der terminalen Schleife empfänglicher für 
Platinbindungen.Auch wenn die Änderungen der Imino-Protonen-Resonanzen wichtige Rückschlüsse 
auf die Platinierungsreaktionen erlauben, kann dieser Methode nicht eigenständig für die Bestimmung 
der  Platinbindungsstellen verwendet werden, da die Imino-Protonen-Resonanzen sehr stark auch von 
anderen experimentellen Bedingungen abhängig sind (wie z.B. Temperatur, pH, etc.). 
Die Platinbindungspräferenzen und Reaktionskinetiken von monohydratisierten cisPt und monohy-
dratisierten kitePt wurde mit der von oxaliPt, durch Kombination von NMR-Zeitentwicklungs-
experimenten und PAGE-Analyse unter gleichen Platinierungsreaktionsbedingungen, verglichen 
(Tabelle 7.1). CisPt reagierte am schnellsten und am unspezifischsten mit D1-27, während oxaliPt recht 
spezifisch aber viel langsamer an D1-27 bindet. Das Verhalten von KitePt liegt zwischen dem von cisPt 
und oxaliPt, es ist spezifischer als cisPt aber unspezifischer als oxaliPt. Die Reslutate des MALDI-MS-
Spektrum weisen auf eine diplatinierte Spezie als Hauptprodukt hin und lassen so eine zusätzliche 
Platinierungsstelle zu G1-G2 vermuten. Um die zweite Platinierungsstelle genau zu identifizieren sind 
aber noch weitere Experimente nötig. Das generell gefundene Verhalten der Komplexe wurde 
zusätzlich durch Plasmidbindungsuntersuchungen bestätigt. Weiterhin wurde die Kinetik und die Rolle 
von K(I) und Cl¯ in den Platinierungsreaktionen aller drei Platin(II)-Komplexe mit Hilfe der PAGE-
Analyse untersucht und im Fall von monohydratisierten cisPt NMR-Zeitentwicklungsexperimentein 
An- und Abwesenheit von K(I) und Cl¯ durchgeführt, die zusätzlich die schnelle unspezifische 
Reaktion von cisPt bestätigten.  
Tabelle 7.1: Zusammenfassung der Resultate aus Kapitel 3. 1H-NMR-Zeitentwicklungsexperimente und 
denaturierende PAGE-Untersuchungen wurden unter den gleichen Experimentalbedingungen durchgeführt. 
 D1-27 
Methode Oxaliplatin Kiteplatin Cisplatin 
1H-NMR 
Zeitentwicklungs- 
experimente 
Platinierung von  
G1-G2 
Platinierung von  
G1-G2 & eine zweite 
Platinierungsstelle 
Unspezifische 
Wechselwirkung 
Plasmidbindungs- 
untersuchungen 
Koaleszenzpunkt bei 
rf=0.5 
Koaleszenzpunkt bei rf=0.5, 
aber die schmierige Bande 
erschien früher als bei 
oxaliPt  Reaktion ist 
schneller als bei oxaliPt 
Koaleszenzpunkt bei 
rf=0.15 
schnellste Reaktionsrate  
PAGE 
Zwei Banden 
Oberes: hauptsächlich 
monoplatinierte Formen 
Zwei Banden 
Oberes: hauptsächlich 
diplatinierte Formen 
Erweiterte schmierige 
Bande 
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In Kapitel 4 (Chapter 4) werden die platinierten 
Addukte, die aus der oberen Bande der denaturierenden 
Gele von deph- und D1-27 RNS mit oxaliPt extrahiert 
wurden, mit verschiedenen spektroskopischen 
Methoden und Verdauungsexperimenten 
charakterisiert. Sowohl für die deph-D1-27 als auch für 
D1-27 wurde vorwiegend monoplatinierte RNS (88 %) 
mit einem kleinen Anteil diplatinierter RNS (12 %) 
gefunden. Die Pt-RNS-Addukte aus den oberen Banden 
der beiden D1-27 Spezien weisen ein sehr ähnliches 
Verhalten auf, was auf ein identisches 
Platinierungsschema hindeutet. Thermische UV-
Schmelzstudien (Abbildung 7.5, A) zeigten, dass durch 
die Platinierung nur Tm1, der Schmelzpunkt, welcher 
der Helix G1-U5 und G23-C27 zugeschrieben wird, 
signifikant von der Platinierungsreaktion beeinflusst 
wird. Die starke Destabilisierung (ΔTm= 7.4 °C ) lässt 
eine Intrastrang Platinierung in diesem Bereich 
vermuten. Ein Vergleich der CD-Spektren der RNS vor 
und nach der Platinierungsreaktion zeigte, dass die 
Platinierung keinen sichtbaren Einfluss auf die RNS-
Struktur hatte und die kleinen Unterschiede vermutlich 
auf minimalen lokalen Variation beruhen, verursacht 
durch die Anbindung der Platingruppe (Abbildung 7.5, 
B). Genauer gesagt, die bathochrome Verschiebung der 
Bande bei 260 nm kann auf eine Intrastrang-
Platinbindung an RNS zurück geführt werden.  
Abbildung 7.5: Zusammenfassung der wichtigsten genutzten Methoden, um die aus dem oberen Band extrahierte Pt-
RNS-Probe zu charakterisieren. A: Indikative thermische Schmelzprofile des deph-D1-27 (schwarz) und Pt-deph-
D1-27 (rot). B: Vergleich der CD-Spektren von D1-27 (schwarz) und Pt-D1-27 (rot). C: HPLC-Chromatogramme 
der Verdauung von Pt-deph-D1-27 mit Nuclease P1, welche zum Erscheinen eines neuen Signals führte (schwarz), 
und der Reaktion des GpG-Dinukleotids mit oxaliPt (rot). Das rote Chromatogramm wurde verschoben, um ihren 
Vergleich zu erleichtern. D: 1H-NMR-Spektra (aromatische und Imino-Protonen-Regionen), der D1-27 (schwarz) 
und der Pt- D1-27-Probe, die aus dem oberen Band extrahiert wurde (rote Linie). 
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Das HPLC-Chromatogramm nach enzymatischer Verdauung der unreagierten und der platinierten RNS 
ergab das erste Indiz einer möglichen Platinierungsstelle (Abbildung 7.5, C). Die platinierten RNS-
Arten hat zusätzlich zu den vier Signalen der einzelnen Nukleoside noch ein zusätzliches Signal. Der 
Vergleich der relativen Flächen der Signale ergab ein Verlust von zwei Guaninen und das neue Signal 
hat die gleiche Retentionszeit wie ein Pt-GpG, welches bei der Platinierung vom Dinukleotid GpG 
entsteht. Somit weist alles auf die Platinierung zwei benachbarter Guanine im Helixteil G1-U5 und 
G23-C27 von D1-27 hin. Die einzigen zwei Guanine, die diese Kriterien erfüllen, sind G1 und G2. Um 
die Platinierungsstelle weiter zu charakterisieren, wurde D1-27 am 5ʹ- bzw. 3ʹ-Ende mit 32P 
radiomarkiert sowie anschliessend alkalisch und enzymatisch verdaut. Gelauswertungen der  
32P-5ʹ-Ende-markierten und verdauten Proben zeigten, dass G23, welches im ersten Teil des Konstrukts 
vorkommt, nicht direkt platiniert wird. Allerdings konnten mit diesem Verfahren keine Informationen 
über die zwei Nukleotide G1 und G2 erhalten werden. Mit Hilfe der 32P-3ʹ-Ende-markierten Proben 
konnten wir aber zeigen, dass die Intensitäten der Gelbanden von G1 und G2 durch die Platinierung 
stark beeinflusst werden und somit in Übereinstimmung mit den vorherigen Ergebnisse eine 
Platinierung von G1-G2 zeigen. Zusätzlich wurde mittels 1H-NMR-Spektroskopie die Imino-Protonen-
Resonanzen der extrahierten platinierten Probe mit denen der unplatinierten Probe verglichen 
(Abbildung 7.5, D). Die Imino-Protonen-Resonanzen von G1 und G2 sind in der platinierten Probe 
nicht mehr sichtbar. Interessanterweise sieht das Spektrum der extrahierten platinierten Bande dem des 
RNAUU-Konstrukts sehr ähnlich (Abbildung 6.2), was wiederum für eine Destabilisierung am 5ʹ-Ende 
durch Platinierung von G1-G2 spricht. Wie vorher erwähnt, ergab die Platinierungsreaktionen der 
dephosphorylierten RNS nicht nur die Banden B und C sondern zusätzlich auch noch eine schneller 
laufende Bande (Abbildung 7.4, lower). Auch diese Bande wurde aus dem Gel extrahiert und mittels 
CD Spektroskopie, thermische UV-Schmelzstudien und enzymatischer Verdauung / HPLC 
charakterisiert. Die platinierte RNS der unteren Bande enthielt eine zweite Form einer monoplatinierten 
RNA, angesichts dessen, dass die primären an der G1-G2-Stelle platiniert werden. MALDI-MS-
Spektren dieser Bande zeigten, im Vergleich zur langsamer laufenden Bande B, einen grösseren Anteil 
an diplatinierter RNS. Leider waren die enzymatische Verdauung und HPLC-Analyse nicht konsistent. 
Da die Messungen mit verschiedenen Proben durchgeführt wurden, bildeten sich wahrscheinlich ein 
Mix aus unterschiedlich platinierter RNA. Aufgrund dieser Probenheterogenität sowie dem 
Vorkommen einer höheren Menge an diplatinierter RNA, konnten keine Schlussfolgerungen gezogen 
werden, auf welchem Weg Platin noch an D1-27 binden kann. 
Unsere Studie hat gezeigt, dass die Wechselwirkung zwischen Oxaliplatin und D1-27, trotz der 
Gegenwart mehrer möglicher Platinierungsstellen, eine starke Präferenz für die Platinierung von  
G1-G2 zeigt. Die gebildete monoplatinierte RNS-Form konnte im Gel aufgrund ihrer verringerten 
Gelmobilität identifiziert und analysiert werden. In DNS ist das GG-Motiv die häufigste Bindungsstelle 
für Platin(II)-Antikrebsmedikamente und auch bei der RNS-Platinierung mit Cisplatin wurde sie als 
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präferierte Sequenz identifiziert. Unsere Resultate zeigen, dass auch Oxaliplatin eine starke Präferenz 
für GG-Motive (G1-G2) hat, was mit den bekannten Erkenntnissen über RNS-Platinierung 
übereinstimmt. 
Trotz grosser Verbreitung von Platin(II)-Komplexe als Antikrebsmedikamente, ist die Anwendung 
meist mit schweren Nebenwirkungen verbunden und etliche Tumore weisen intrinsische oder 
akquirierte Resistenzen auf. Obwohl diese Medikamente teilweise seit Jahrzehnten im Einsatz sind, ist 
ihre komplexe Wirkungsweise z.B Wechselwirkung mit den verschiedensten intrazellulären 
Molekülen, noch nicht vollständig verstanden. Ein Ansatz zur Eliminierung ihrer Nebenwirkungen ist 
ein besseres Verständnis des Wirkungsmechanismuses durch eingehende Studien, die nicht nur die 
Wechselwirkung mit DNS sondern auch mit anderen Biomolekülen wie Proteine und RNS zum Ziel 
haben. Gerade RNS könnte ein gutes Platin(II)-Zielmolekül darstellen, da es zum einem dem DNS 
Molekül gleicht und zum anderen in vielen wichtigen Zellfunktionen involviert ist. Frühere Studien 
haben bereits gezeigt, dass Platinmedikamente wichtige RNS-basierte Aktivitäten blockieren können, 
die für das Überleben der Zelle ausschlaggebend sind. Basierend auf diesen Kenntnissen, führten wir 
eine detaillierte Studie durch in der die Wechselwirkung zwischen Oxaliplatin und einer Modell-RNS 
(D1-27) im Mittelpunkt stand, um mögliche Platinanbindungsstellen zu lokalisieren. Die Bestimmung 
und genaue Untersuchung von Platinbindungsstellen in RNS-Molekülen eröffnet nicht nur die 
Möglichkeit, Platinierungsstellen in anderen biologisch relevanten RNS-Molekülen vorherzusagen, 
sondern verbessert auch das allgemeine Verständnis des komplexen Antikrebswirkungsmechanismus 
von Platin(II)-Medikamenten. Diese Ergebnisse sind von grosser Bedeutung um neue, weniger giftige 
und effektivere Platin(II)-Medikamente herzustellen und/ oder neuartigen Krebsbehandlungsmethoden 
zu entwickeln.  
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8 Appendices 
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Appendix 1 - Chapter 2 
In appendix 1 the MALDI-MS spectra of untreated and platinated RNA samples as well as a HPLC 
chromatogram are reported. They all refer to experiments described in chapter 2 and are related mostly 
to the optimization of the platination reaction conditions for cisplatin and oxaliplatin. 
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – {HPO3} 8997 8996 
Diplatinated D1-27 – {HPO3} 9226 9226 
Diplatinated D1-27 9306 9303 
Triplatinated D1-27 – {HPO3} 9438 9434 
Tetraplatinated D1-27 – {HPO3} 9650 9660 
Figure A 1.1: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gels 
corresponding to platination performed using 4 eq and 5 eq of monoaquated cisPt.  
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RNA species  Predicted mass (m/z) Experimental mass (m/z) 
D1-27– {HPO3} 8768 8769 
D1-27 8848 8847 
Monoplatinated D1-27 – 2{HPO3} 8917 8917 
Monoplatinated D1-27 – {HPO3} 8997 8996 
Monoplatinated D1-27 9076 9076 
Figure A 1.2: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination performed using 1 eq of monoaquated cisPt at 37 °C.  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
D1-27– {HPO3} 8768 8770 
Monoplatinated D1-27 – 2{HPO3} 8917 8918 
Monoplatinated D1-27 – {HPO3} 8997 8996 
Monoplatinated D1-27 9076 9077 
Diplatinated D1-27 – {HPO3} 9226 9224 
Diplatinated D1-27 9306 9306 
Figure A 1.3: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination performed using 1 eq of monoaquated cisPt at 50 °C.  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
D1-27 – {HPO3} 8768 8769 
D1-27 8848 8849 
Monoplatinated D1-27 – {HPO3} 8997 8996 
Monoplatinated D1-27 9076 9077 
Diplatinated D1-27 – {HPO3} 9226 9225 
Diplatinated D1-27 9306 9305 
Figure A 1.4:  MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination performed using 2 eq of monoaquated cisPt at 37 °C.  
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RNA species  Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – {HPO3} 8997 8997 
Monoplatinated D1-27 9076 9077 
Diplatinated D1-27 – {HPO3} 9226 9225 
Diplatinated D1-27 9306 9305 
Triplatinated D1-27 – {HPO3} 9438 9451 
Tetraplatinated D1-27 – 2{HPO3} 9570 9599 
Figure A 1.5: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination performed using 2 eq of monoaquated cisPt at 50 °C. 
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RNA species  Predicted mass (m/z) Experimental mass (m/z) 
D1-27 – {HPO3} 8768 8768 
Monoplatinated D1-27 – {HPO3} 8997 8993 
Monoplatinated D1-27 9076 9074 
Diplatinated D1-27 9306 9301 
Figure A 1.6: MALDI-MS spectrum of the platinated RNA species isolated from the "faster migrating" upper 
band of the gel corresponding to platination performed using 0.5 mM RNA and 1 eq of monoaquated cisPt.  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – {HPO3} 8997 8991 
Monoplatinated D1-27 9076 9074 
Diplatinated D1-27 – 2{HPO3} 9226 9221 
Diplatinated D1-27 9306 9301 
Figure A 1.7: MALDI-MS spectrum of the platinated RNA species isolated from the slower migrating upper band 
of the gel corresponding to platination performed using 0.5 mM RNA and 1 eq of monoaquated cisPt.  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – {HPO3} 8997 8996 
Monoplatinated D1-27 9076 9076 
Diplatinated D1-27 – 2{HPO3} 9226 9224 
Diplatinated D1-27 9306 9303 
Figure A 1.8: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination with monoaquated cisPt for 4 days. 
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RNA species  Predicted mass (m/z) Experimental mass (m/z) 
D1-27 – {HPO3} 8768 8768 
D1-27 8848 8850 
Monoplatinated D1-27 – {HPO3} 9077 9076 
Monoplatinated D1-27 9157 9156 
Diplatinated D1-27 9466 9465 
Figure A 1.9: MALDI-MS spectrum of the platinated RNA species isolated from the upper band of a gel 
corresponding to platination performed using 5 eq of oxaliPt, incubating for 2 days, at 25 °C. 
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RNA Predicted mass (m/z) Experimental mass (m/z) 
D1-27 – {HPO3} 8768 8766 
Monoplatinated D1-27 – 2{HPO3} 8997 8994 
Monoplatinated D1-27 – 1{HPO3} 9077 9074 
Monoplatinated D1-27 9157 9154 
Diplatinated D1-27 – 1{HPO3} 9386 9381 
Diplatinated D1-27 9466 9463 
Figure A 1.10: MALDI-MS spectrum of the platinated RNA species isolated from the upper band of the gel 
corresponding to platination performed using 5 eq of oxaliPt, incubating for 16 h, at 37 °C.  
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RNA species  Predicted mass (m/z) Experimental mass (m/z) 
D1-27 8848 8847 
Monoplatinated D1-27 – 2{HPO3} 8998 8999 
Monoplatinated D1-27 – 1{HPO3} 9077 9075 
Monoplatinated D1-27 9157 9156 
Diplatinated D1-27 – 1{HPO3} 9387 9380 
Diplatinated D1-27 9466 9462 
Figure A 1.11: MALDI-MS spectrum of the platinated RNA species isolated from the upper band of the gel 
corresponding to platination performed using 5 eq of oxaliPt and 0.25 mM of RNA for 1 day at 25 °C. 
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
D1-27 8848 8848 
Monoplatinated D1-27 – 1{HPO3} 9077 9075 
Monoplatinated D1-27 9157 9155 
Diplatinated D1-27 – 1{HPO3} 9386 9383 
Diplatinated D1-27 9466 9463 
Triplatinated D1-27 9775 9769 
Figure A 1.12: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination performed using 5 eq of oxaliPt incubating for 2 days at 25 °C in the presence of 
120 mM KClO4.  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – 1{HPO3} 9077 9075 
Monoplatinated D1-27 9157 9154 
Diplatinated D1-27 – 1{HPO3} 9386 9380 
Diplatinated D1-27 9466 9462 
Triplatinated D1-27 9775 9769 
Figure A 1.13: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination performed using 10 eq of oxaliPt incubating for 1 day at 25 °C in the presence of 
120 mM KClO4.  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – 1{HPO3} 9077 9073 
Monoplatinated D1-27 9157 9154 
Diplatinated D1-27 – 1{HPO3} 9386 9382 
Diplatinated D1-27 9466 9461 
Triplatinated D1-27– 1{HPO3} 9695 9688 
Triplatinated D1-27 9775 9769 
Tetraplatinated D1-27 10084 10075 
Figure A 1.14: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination performed using 10 eq of oxaliPt incubating for 2 days at 25 °C in the presence of 
120 mM KClO4.  
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RNA species  Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – 2{HPO3} 8997 8999 
Monoplatinated D1-27 – 1{HPO3} 9077 9078 
Monoplatinated D1-27 9157 9159 
Diplatinated D1-27 – 1{HPO3}3 9386 9386 
Diplatinated D1-27 9466 9466 
Figure A 1.15: MALDI-MS spectrum of the platinated RNA species isolated from the upper band (in water) in the 
blue frame in Figure 2.20.  
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RNA species Predicted mass (m/z) Experimental mass (m/z) * 
Monoplatinated D1-27 – 1{HPO3} 9077 9118 
Monoplatinated D1-27 9157 9201 
Diplatinated D1-27 9466 9517 
Figure A 1.16: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination performed in the presence of 80 mM KCl.  
*There was an acetonitrile moiety corresponding to +41 in the experimental mass  
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RNA species Predicted mass (m/z) Experimental mass (m/z)* 
Monoplatinated D1-27 – 1{HPO3} 9077 9118 
Monoplatinated D1-27 9157 9200 
Diplatinated D1-27 9466 9517 
Figure A 1.17: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination performed in the presence of 120 mM KCl.  
*There was an acetonitrile moiety corresponding to +41 in the experimental mass  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – 1{HPO3} 9077 9073 
Monoplatinated D1-27 9157 9156 
Diplatinated D1-27 9466 9464 
Figure A 1.18: MALDI-MS spectrum of the platinated RNA species isolated from the upper bands of the gel 
corresponding to platination performed in the presence of 200 mM KCl.  
 
 
229 
 
7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 11.0
0
200
400
600
800
8
6
9
4
8
5
4
2
8
7
6
6
In
te
n
si
ty
 [
a.
 u
.]
m/z (x 10
-3
)
8
8
4
8
 
RNA species Predicted mass (m/z) Experimental mass (m/z) 
D1-27 – CMP 8543 8542 
D1-27 – 2{HPO3} 8688 8694 
D1-27 – 1{HPO3} 8768 8766 
D1-27 8848 8848 
Figure A 1.19: MALDI-MS spectrum for the RNA sample used as control in the gel in Figure 2.26 (blue frame).  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – 2{HPO3} 8998 8999 
Monoplatinated D1-27 – 1{HPO3} 9077 9070 
Monoplatinated D1-27 9157 9151 
Diplatinated D1-27 – 1{HPO3} 9387 9379 
Diplatinated D1-27 9466 9459 
Figure A 1.20: MALDI-MS spectrum for the platinated RNA species isolated from the upper band of the gel in 
Figure 2.26 (red frame).  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
D1-27 - 1CMP – 1{HPO3} 8463 8462 
D1-27 – 1CMP 8453 8543 
D1-27 – 1{HPO3} 8768 8767 
D1-27 8848 8847 
Monoplatinated D1-27 – 1{HPO3} 9077 9073 
Monoplatinated D1-27 9157 9154 
Diplatinated D1-27 – 1{HPO3} 9387 9382 
Diplatinated D1-27 9466 9461 
Figure A 1.21: MALDI-MS spectrum for the platinated RNA species isolated from the lower band of the gel in 
Figure 2.26 (green frame). 
7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 11.0
0
50
100
150
200
8
5
1
8
8
8
2
7
8
7
4
7
In
te
n
si
ty
 [
a.
 u
. 
]
m/z (x 10
-3
)
8
4
3
9
 
RNA species Predicted mass (m/z) Experimental mass (m/z) 
RNA 26 – 1{HPO3} 8439 8439 
RNA 26 8519 8518 
Monoplatinated RNA 26 – 1{HPO3} 8748 8747 
Monoplatinated RNA 26 8827 8827 
Figure A 1.22: MALDI-MS spectrum for the platinated RNA species resulting from the platination of RNA 26 
with oxaliPt.  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – 1{HPO3} 9077 9075 
Monoplatinated D1-27 9157 9156 
Diplatinated D1-27 – 1{HPO3} 9387 9382 
Diplatinated D1-27 9466 9463 
Triplatinated D1-27 9775 9770 
Figure A 1.23: MALDI-MS spectrum for the platinated RNA species isolated from the upper band resulting from 
the reaction of 10 eq of oxaliPt with D1-27 for 2 days (diplatinated RNA).  
 
 
Figure A 1.24: Chromatograms corresponding to platinated RNA with the monoplatinated adducts as main 
species (black line) and of platinated RNA with increased amount of diplatinated RNA (peak at 21.2 min) (red 
line). 
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – 3{HPO3} 8917 8917 
Diplatinated D1-27 – 3{HPO3} 9227 9225 
Figure A 1.25: MALDI-MS spectrum for the platinated RNA species isolated from the upper band of the gel 
corresponding to platination of deph-D1-27 with oxaliPt (Figure 2.45, green line).  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
D1-27 – 3{HPO3} 8608 8612 
Monoplatinated D1-27 – 3{HPO3} 8917 8919 
Diplatinated D1-27 – 3{HPO3} 9227 9226 
Figure A 1.26: MALDI-MS spectrum for the platinated RNA species isolated from the middle band of the gel 
corresponding to platination of deph-D1-27 with oxaliPt (Figure 2.45, black line).  
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RNA species Predicted mass (m/z) Experimental mass (m/z) 
Monoplatinated D1-27 – 3{HPO3} 8917 8917 
Diplatinated D1-27 – 3{HPO3} 9227 9226 
Figure A 1.27: MALDI-MS spectrum for the platinated RNA species isolated from the lower band of the gel 
corresponding to platination of deph-D1-27 with oxaliPt (Figure 2.45, red line). 
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Appendix 2 – Chapters 3 - 4 
 
In appendix 2 additional NMR spectra, CD spectra of untreated and platinated RNA samples as well as 
HPLC chromatograms are reported. They all refer to experiments described in chapters 3 and 4.  
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Figure A 2.1: Time evolution NMR experiment for the platination of deph-RNA 26 with oxaliPt (left), Right Top: 
Secondary structure of RNA 26. (5 eq. of oxaliPt, 0.1 mM deph-RNA 26, 25 °C, 120 mM KCl, pH 6,  
600 MHz) 
 
 
 
Figure A 2.2: Comparison of the CD spectra of triph-D1-27 in the presence of 0 mM (black) and 120 mM (red) 
KClO4. CRNA = 1.3 μΜ, pH 6.5. 
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Figure A 2.3: Comparison of the CD spectra of triph-D1-27 (black) and the platinated triph-D1-27 (red). CRNA 
and CPt-RNA = 1.3 μΜ, in 120 mM KClO4, pH 6.5. 
 
 
 
 
Figure A 2.4: Comparison of 1H-NMR spectra (aromatic and imino proton regions) of the untreated  
deph-D1-27 (black line), Pt-deph-D1-27 sample (green line) and Pt-triph-D1-27 sample (red line). In the black 
dotted frame is indicated the down-field shifted peak corresponding to H8 of the platinated guanosines. The 
spectra were recorded in 90% H2O:10% D2O at 25 °C on 600 MHz.  
 
 
238 
 
 
Figure A 2.5: 1H-NMR spectra (aromatic and imino proton regions), including imino proton assignment, of the 
untreated D1-27 (blue line), Pt-triph-D1-27 sample isolated from the upper band (red line) and recorded at  
4 °C and Pt-triph-D1-27 sample isolated from the upper band (green line) and recorded at 25 °C. The spectra 
were recorded in 120 mM KClO4, pH 6, 600 MHz. The spectrum in green line corresponds to the one shown in 
Figure 4.22 (red line).  
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Figure A 2.6: Upper panel: Comparison of 1H-NMR spectra (aromatic region) of the untreated triph-D1-27 
(black line) and of the Pt-triph-D1-27 sample (red line). In the black dotted frame are indicated the down-field 
shifted peak(s) corresponding to H8 of the platinated guanosines. The spectra were recorded in 100 % D2O at  
25 °C on 600 MHz. Lower panel: Overlay of the aromatic region (C8-H8 and C2-H2 of purines and C6-H6 of 
pyrimidines) of [1H,13C]-HSQC spectra recorded on unreacted (green) and platinated (red) D1-27. The platinated 
sample was isolated from the upper band of a platination reaction performed using triph-D1-27. (0.69 mM RNA, 
120 mM KClO4, pD 6.9, 4 °C, 700 MHz for the unreacted RNA; 0.2 mM RNA, 120 mM KClO4, pD 7, 25 °C, 
600 MHz for the platinated sample).The labels refer to non-platinated D1-27. The cross-peak  
G23C8-H8 is very weak, and it is not visible at the contour level used in this Figure. Chemical shifts for both the 
species are reported in Table A 2.1.  
Red boxes indicate guanine cross-peaks, which significantly shift upon platination, while the blue boxes indicate 
cross-peaks of other residues that also move upon platination. In the less crowded C2-H2 regions, arrows have 
been added to better visualize the shift of the cross-peaks. The Figure has been prepared with MestReNova version 
10.0 (Mestrelab Research S.L.) and CorelDRAWX3. 
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Table A 2 1: 1H and 13C chemical shifts of guanine (C8H8), adenine (C8H8 and C2H2) as well as uracil and 
cytosine (C6H6) resonances of unreacted and platinated D1-27. The platinated sample was isolated from the 
upper band of a platination reaction performed using triph-D1-27. The following sample conditions were used: 
0.69 mM RNA, 120 mM KClO4, pD 6.9, 25 °C, 700 MHz for the unreacted RNA; 0.2 mM RNA, 120 mM KClO4, 
pD 7, 25 °C, 600 MHz for the platinated sample. Chemical shift differences (Δδ) between platinated and unreacted 
sample are indicated in the last column. 
 a C8 and C6 resonances of A4 and C26 significantly shift; however their assignment is unclear because they seem 
to overlap with other signals; w = weak; n.v. = not visible. 
 
Residue Atom 
D1-27  
δ [ppm] 
Platinated D1-27 
δ [ppm] 
Δδ [ppm] 
G1 C8 139.11 141.29 2.18 
 H8 8.14 9.00 0.86 
G2 C8 136.95 141.23 4.28 
 H8 7.53 8.97 1.44 
A3 C2 153.04 153.29 0.25 
 H2 7.22 7.41 0.19 
 C8 139.40 140.56 1.16 
 H8 7.72 8.18 0.46 
A4 C2 154.01 153.96 –0.05 
 H2 7.83 7.85 0.02 
 C8 138.95 141.36a 2.41 
 H8 7.55 8.14 0.59 
U5 C6 140.39 140.78 0.39 
 H6 7.40 7.48 0.08 
A6 C2 154.75 153.83 –0.92 
 H2 7.43 7.50 0.07 
 C8 141.18 141.45 0.27 
 H8 8.12 8.17 0.05 
U7 C6 142.98 142.85 –0.13 
 H6 7.85 7.83 –0.02 
G8 C8 137.02 136.95 –0.07 
 H8 7.61 7.66 0.05 
C9 C6 141.38 141.51 0.13 
 H6 7.64 7.68 0.04 
U10 C6 142.22 142.16 –0.06 
 H6 7.93 7.94 0.01 
C11 C6 141.40 141.38 –0.02 
 H6 7.76 7.79 0.03 
U12 C6 140.71 140.79 0.08 
 H6 7.77 7.81 0.04 
U13 C6 144.71 144.72 0.01 
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 H6 8.01 8.04 0.03 
C14 C6 142.83 142.90 0.07 
 H6 7.67 7.70 0.03 
G15 C8 142.98 142.99 0.01 
 H8 7.85 7.85 0.00 
G16 C8 138.99 139.00 0.01 
 H8 8.29 8.34 0.05 
A17 C2 153.37 153.41 0.04 
 H2 7.48 7.52 0.04 
 C8 139.43 139.48 0.05 
 H8 7.76 7.81 0.05 
G18 C8 135.67 135.69 0.02 
 H8 7.14 7.19 0.05 
C19 C6 140.71 140.73 0.02 
 H6 7.38 7.42 0.04 
U20 C6 141.38 141.52 0.14 
 H6 7.64 7.70 0.06 
A21 C2 154.05 153.46 –0.59 
 H2 7.05 7.15 0.10 
 C8 140.98 141.24 0.26 
 H8 8.02 8.08 0.06 
A22 C2 154.73 154.06 –0.67 
 H2 8.11 8.01 –0.10 
 C8 141.84 142.04 0.20 
 H8 8.28 8.24 –0.04 
G23 G8 138.18w n.v. - 
 H8 7.92 7.95 0.03 
U24 C6 141.59 142.04 0.45 
 H6 7.75 7.78 0.03 
U25 C6 142.65 142.81 0.16 
 H6 8.04 8.05 0.01 
C26 C6 141.94 142.07a 0.13 
 H6 7.89 7.94 0.05 
C27 C6 141.88 143.52 1.64 
 H6 7.64 7.87 0.23 
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Figure A 2.7: Zoom of a [1H,1H]-NOESY spectrum (sequential walk and aromatic staking regions) 
recorded on a platinated sample isolated from the upper band of a platination reaction performed using 
triph-D1-27 (0.2 mM RNA, 120 mM KClO4, pD 7, 25 °C, 600 MHz). The box indicates the cross-peak 
between A6H2 and A21H2, which suggests that the adenine stacking in the internal loop is not 
completely broken upon platination. The Figure has been prepared with MestReNova version 10.0 
(Mestrelab Research S.L.) and CorelDRAWX3. 
 
  
Figure A 2.8: Indicative thermal melting profiles for unreacted deph-D1-27 (black line), platinated deph-D1-27 
(blue line) and RNAUU (red line). They were monitored at 260 nm, data collected from 20 °C to 90 °C at a rate 
of 1 °C / min. CRNA = 1.3 μΜ, 120 mM KClO4, pH 6.5. 
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Figure A 2.9: HPLC chromatograms of the reactions of GpG dinucleotide (left), GpA dinucleotide (middle) and 
ApG dinucleotide (right) with oxaliplatin. After 1 day of interaction, new peak(s) appeared corresponding to 
platinated dinucleotides. Experimental conditions: Cdinucleotide=0.2 mM, CPt= 2 mM, at 37 °C, in ddH2O. 
 
 
 
 
 
 
 
 
 
Figure A 2.10: HPLC chromatograms of the reactions of GMP and AMP with oxaliplatin in 2 GMP:1 oxaliPt 
(left), 2 AMP:1 oxaliPt (middle) and 1 GMP:1 AMP:1 OxaliPt (right) ratio. The attribution of the peaks 
corresponding to GMP, AMP, A (adenosine) and G (guanosine) were performed upon injection of their standard 
solutions. On the left and middle chromatograms the new main peaks appeared were attributed to the platinated 
nucleotides based on literature data (see ref 35 in chapter 4) and the peaks of the chromatogram on the right was 
performed upon comparison with the other two. Experimental conditions: Cdinucleotide=0.5 mM, CPt= 5 mM, 
incubation for 5 days at 37 °C, in ddH2O. 
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Appendix 3 - Chapter 5 
 
In appendix 3 IR and 1H-NMR spectra of DACH, [Pt(DACH)Cl2], [Pt(DACH)Cl(H2O)]+ and 
[Pt(DACH)(H2O)2]2+ are reported. They all refer to experiments described in chapter 5.  
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Figure A 3.1: IR spectra of DACH (upper panel) and [Pt(DACH)Cl2] (lower panel). 
 
 
Figure A 3.2: 1H-NMR spectrum of DACH in DMSO at 25 °C recorded on 500 MHz, including proton 
attributions. 
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Figure A 3.3: 1H-NMR spectrum of [Pt(DACH)Cl2] in DMSO at 25 °C recorded on 500 MHz, including proton 
attributions. 
 
 
 
Figure A 3.4: 1H-NMR spectra of [Pt(DACH)Cl2] (blue line), [Pt(DACH)(H2O)Cl] (red line) and 
[Pt(DACH)(H2O)2] (green line) in 90 % H2O / 10 % D2O at 25 °C recorded on 500 MHz, including proton 
attribution. 
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Figure A 3.5: 1H-NMR spectra of [Pt(DACH)Cl2] dissolved in 90 % H2O / 10 % D2O with (blue line) and without 
heating (red line) the sample, respectively. Interestingly, the spectrum recorded on the sample that was previously 
heated at 40 °C for 20 - 30 min shows a few additional peaks, which may be due to degradation products formed 
upon heating (25 °C, 500 MHz).  
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1. Purpose of the STSM  
The aim of my 5 weeks stay in the group of Prof. Sofi Elmorth in Lund was to monitor the kinetics of 
two different platinum(II) complexes namely (cis-1,2- DACH)dichloridoplatinum ([Pt(DACH)Cl2]) 
and (cis-1,4- DACH)dichloridoplatinum (kiteplatin) with different RNA constructs and compare their 
behaviour with literature data on cisplatin previously reported from Elmroth’s group.  
 
2. Description of the work and the main results 
2.1: UV measurements 
I followed the kinetics of the reaction between the monoaquo form of [Pt(DACH)Cl2] 
([Pt(DACH)(H2O)Cl]+) and the two RNA constructs depicted in Figure 1, by measuring the change in 
absorbance at 260 nm at 38 °C for 24 hours. The reaction was followed in potassium phosphate buffer, 
K2HPO4/KH2PO4 pH 5.7 (KPi) and sodium phosphate buffer Na2HPO4 / NaH2PO4 pH 5.7 (NaPi) and 
four different platinum concentrations were used (7.5 μM, 15 μM, 30 μM, 45 μM). Preliminary 
experiments with both RNA constructs (Picture 1) in the two different phosphate buffers gave results 
difficult to interpret. The shape of the curve indicates that there is more than one event taking place 
during the reactions and in all cases the curve does not reach a 
plateau, suggesting that the reaction is not finished. In a try to 
understand this behaviour, several experiments were 
performed, including blank experiments to investigate the 
stability of our platinum complexes in phosphate buffer. 
Unfortunately, the UV machine did not work properly and we 
had several problems. Consequently, the measurements with 
[Pt(DACH)(H2O)Cl]+ could not be repeated neither the experiments with monoaquo kiteplatin could be 
run. Prof. Sofi K. C. Elmroth has ordered a new UV machine and all the kinetic measurements will be 
repeated in the future, to understand from where this unusual behaviour comes from.  
 
2.2: Fluorescence measurements  
Taking into consideration that I could not finish the initially planned project we decided to start another 
one based on a different method that Elmorth’s group has developed in order to follow kinetics. In this 
case we studies the kinetics of the RNA platination by using RNA1 (duplex that contains GG platination 
site) modified with a fluorescence label at the 5´-end (6-FAM) and a quencher at the 3´-end. The melting 
of the two strands induced by platination results in an increase of fluorescence. With a real time PCR 
(rt-PCR) we could monitor the desired product at any point during the platination reaction by measuring 
fluorescence over time. The following samples were prepared: RNA1 in Na / KPi buffer for four 
Picture 104: Secondary structure for 
RNA1(GG) and RNA2(GNG). 
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different platinum concentration (7.5 μM, 15 μM, 30 μM, 45 μM). Both monoaquated [Pt(DACH)Cl2] 
and monoaquated kiteplatin were used. All measurements were conducted in triplicates.  
The addition of platinum to RNA solution results to kinetic traces that can be described by single-
exponential function. Under pseudo-first order conditions with [CPt] >> [RNA], the observed rate 
constant (kobs) which was obtained by a fit of a single-exponential function to the experimentally 
obtained ΔE-values (E= emission) should be linearly dependent on platinum concentration [CPt]2,3. For 
that reason, the observed rate constants were plotted as a function of added CPt and a linear dependence 
was observed. From the slope of the plot of the kobs vs CPt the apparent second-order rate constant (k2,app) 
was directly obtained. The data shows that both complexes have slower reactivity compared to cisplatin 
with k2app ca. 2.8 M-1s-1 while for cisplatin2 k2app is 7.72 M-1s-1. The monoaquated [Pt(DACH)Cl2] 
behaves the same in both phosphate buffers, while the monoaquated kiteplatin has higher reactivity in 
KPi buffer (k2app 4.26 M-1s-1 in KPi, 2.89 M-1s-1 in NaPi). Similar behaviour had reported for the 
monoaquated cisplatin3 (Table 1). 
 
Experimental details: CRNA= 3 μM (1.5 μM per strand), CPt = 7.5 - 45 μM, in 122 mM KPi / NaPi buffer, 
pH 5.7, Vf = 40 μL, 37 °C for 600 min. 
 
Table 1: Summary of the reaction rate constants (kobs and k2app) for the RNA1. 
 
 
2.3: Plasmid binding studies 
Given that the UV measurements for the study of the kinetics of the platination reaction were not 
conclusive, we decided to start another small side project. This was based on a previous study published 
from the Elmroth group4. Utilizing the ability of the platinum (II) anticancer drugs as DNA unwinding 
agents we studied the DNA binding affinity of the monoaquated complexes of cisplatin, kiteplatin and 
 kobs x104 (s-1)     
CPt 7.5 μM 15 μM 30 μM 45 μM k2app (M-1 s-1) 
[Pt( DACH )Cl2] Na+ 0.78±0.14 1.11±0.02 1.73±0.05 1.67±0.03 2.49±0.84 
[Pt( DACH )Cl2] K+ 1.07±0.01 1.09±0.02 1.45±0.03 2.11±0.03 2.82±0.53 
Kiteplatin Na+ 0.79±0.12 0.77±0.14 - 1.79±0.04 2.89±0.59 
Kiteplatin K+ 0.61±0.08 0.83±0.12 - 2.17±0.05 4.26±0.27 
Cisplatin Na+ 0.54 1.60 2.70 3.50 7.72±0.45 
Cisplatin K+ 1.3 ± 0.3 2.2 ± 0.3 3.8 ± 0.3 4.7 ± 0.2 9.2±0.6 
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[Pt(DACH)Cl2] with the negatively supercoiled pUC18 plasmid. Additionally, we compared their 
behaviour in two different phosphate buffers (NaPi, KPi). Upon platination supercoiled and relaxed 
forms can be visualized by agarose gel electrophoresis. By increasing the amount of platinum 
complexes bound to DNA it could be detected the appearance of a slower migrating supercoiled plasmid 
band. The point at which the supercoiled and relaxed forms coincide is called coalescence point. For 
these studies we used the conditions that were previously reported from the Elmroth’s group4. The ratio 
of nucleotide concentration (CDNA) and concentration of platinum compounds (CPt) (rf=CPt/CDNA) was 
varied from 0 to 0.5. Each platinum complex have its coalescence point at the same rf in NaPi and KPi 
buffer meaning that they exhibit similar behaviour in both buffers. Cisplatin is the one that reacts the 
fastest, as expected, having the coalescence point much earlier compared to the other two complexes. 
Amongst the other two kiteplatin is faster considering that we have the appearance of the slower 
migrating supercoiled band earlier (picture 2).   
Experimental conditions: 2 % agarose gel, 70 V for 1.5 h, incubation for 24 h, 37 °C with rf varying 
from 0 to 0.5, 200 mM Na2HPO4 / NaH2PO4, 200mM K2HPO4 / KH2PO4, pH 5.8, [pUC18] = 0.03 μM 
 
 
 
 
 
 
 
 
 
 
Picture 2: Gel mobility shift assay of platinum complex with supercoiled and relaxed forms of the 
pUC18 plasmid.  
2.4: References 
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3. Conclusion and outlook 
Due to technical problems, we were not able to perform the kinetic measurements. Preliminary 
experiments on the interaction of [Pt(DACH)(H2O)Cl]+ with the RNA1 and RNA2 were not conclusive 
and fully understood. The measurements will be performed once the new UV machine will arrive. The 
fluorescence measurements took place as an alternative way to follow the kinetics of the platination 
reactions. The monoaquated [Pt(DACH)Cl2] and monoaquated kiteplatin were used. Both complexes 
exhibit lower reactivity compared to cisplatin. Kiteplatin is reacting faster in KPi buffer, behaviour that 
is in accordance with was is reported to the literature for the cisplatin. From the plasmid binding studies 
we conclude that monoaquated cisplatin binds faster than the monoaquated [Pt(DACH)Cl2] and 
monoaquated kiteplatin. From the comparison of the last two, we can conclude that monoaquated 
kiteplatin reacts faster considering that we have the appearance of the slower migrating supercoiled 
band earlier. 
 
4. Personal feedback 
The opportunity of working for few weeks in another lab abroad has been very useful. From the 
scientific point of view, the discussions with the members of Elmroth’s group were very helpful. Despite 
the technical problems that we enfaced during my stay, we were able to find alternatives and continue. 
The alternatives that we tried gave me the opportunity to learn new techniques. Additionally, the 
discussions with Prof. Sofi K. C. Elmroth were very advantageous for the continuation of my project in 
Zurich.   
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